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ABSTRACT 
Using label free proteomics and RNA sequencing to investigate the 
human respiratory syncytial virus and the effects of the antiviral 
ribavirin 
 
Waleed A. Aljabr 
 
Human respiratory syncytial virus (HRSV) is a known cause of severe lower 
respiratory tract infection (LRTI) in infants and young children worldwide. 
HRSV can cause illness in all ages especially those people at high risk 
including the immunocompromised and the elderly. Globally, HRSV infection 
leads to a significant healthcare and economic burden due to the lack of an 
approved vaccine and costly antiviral therapies that are potentially ineffective 
in some cases. Ribavirin is the only therapeutic licensed for the treatment of 
severe HRSV infection. It is a synthetic nucleoside with broad spectrum of 
antiviral activity encompassing both DNA and RNA viruses.  The mechanism 
of action of ribavirin is unclear.  It is thought to inhibit the replication of HRSV 
and lead to a reduction in viral load. How it does this is unknown and the 
subject of this thesis.  This study focused on investigating the effect of the 
anti-viral ribavirin on cells in general and then infected with HRSV using both 
label free quantitative proteomics and transcriptomics.  This allowed the 
investigation of the mutation frequency in HRSV and cellular protein 
abundance, which encompass several mechanisms by which ribavirin is 
postulated to work.  This study was demonstrated that treatment of cells with 
ribavirin resulted in the increased transcription of selected cellular mRNAs 
including those involved in mediating anti-viral signalling. Additionally, 
ribavirin treatment caused a decrease in viral mRNA and proteins.  In the 
absence of ribavirin, HRSV specific transcripts accounted for up to one third 
of total RNA reads from the infected cell RNA population. Ribavirin treatment 
resulted in a greater than 90% reduction in reads mapping to viral mRNA, 
while at the same time no such drastic reduction was detected for the 
abundance of cellular transcripts. The presented data revealed that ribavirin 
significantly increased the frequency of HRSV-specific RNA mutations in the 
viral genome, suggesting direct influence on the fidelity of the HRSV 
polymerase. The presented data shows transition and transversion 
substitutions occur during HRSV replication, and that these changes 
occurred in ‘hot spots’ along the HRSV genome. Examination of nucleotide 
substitution rates in the viral genome indicated an increase in the frequency 
of transition but not transversion mutations in the presence of ribavirin. In 
addition, the data indicated that in the continuous cell types used, and at the 
time points analyzed, the abundance of some HRSV mRNAs did not reflect 
the order in which the mRNAs were transcribed.  Overall, the work describes 
a mechanism of action for ribavirin in the context of viral infection, that has 
not previously been elucidated for HRSV. 
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CHAPTER 1: INTRODUCTION 
1.1. CLASSIFICATION, DISCOVERY AND EPIDEMIOLOGY  
1.1.1 CLASSIFICATION  
Human respiratory syncytial virus (HRSV) is a negative strand RNA virus 
belong to the genus Pneumovirus, of the subfamily Pneumovirinae, of the 
family Paramyxoviridae, of the order Mononegavirales according to the 
International Committee on Taxonomy of Viruses (ICTV) (Table 1.1). 
Paramyxoviridae has two subfamilies: Paramyxovirinae, which includes 
several important human pathogens, e.g. human parainfluenza viruses 
(HPIVs), mumps, and measles; and the subfamily of Pneumovirinae has two 
genera: Pneumovirus which includes HRSV, bovine respiratory syncytial 
virus (BRSV); and the Metapneumovirus genus which includes human 
metapneumovirus (HMPV) and avian metapneumovirus (AMPV). Moreover, 
The Mononegavirales are classified under group V according to Baltimore 
classification system based on the method of viral mRNA synthesis. This 
class are all single-stranded negative sense RNA viruses (Baltimore, 1971).   
 
The properties of the Paramyxoviridae family are enveloped non-segmented 
negative-stranded RNA (-ssRNA) viruses and are defined as having a protein 
(F) that causes viral cell membrane fusion. Members of the Paramyxoviridae 
causes disease in humans and animals; e.g. measles virus (which is one of 
the most infectious viruses), parainfluenza viruses (PIVs), mumps virus, 
respiratory syncytial virus (RSV) (are the most prevalent viruses). The 
Paramyxoviridae included Hendra and Nipah viruses, which causes deadly 
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diseases (Collins, 2013). Moreover, other unique features of the 
Paramyxoviridae family is that all viruses are transmitted through the 
respiratory route and that virus replication occurs in the cytoplasm (Enders, 
1996).   
 
Table 1.1. Classification of HRSV from the virus Taxonomy of the 
International Committee on Taxonomy of Viruses (ICTV) released in 2012. 
http://ictvonline.org/virusTaxonomy.asp?version=2012 
Order Family Subfamily Genus  Type Species 
M
o
n
o
n
e
g
a
v
ir
a
le
s
 
Bornavirid
ae 
 Bornavirus  Borna disease 
virus 
Filoviridae  Ebolavirus  Zaire Ebolavirus 
Marburgvirus  Marburg 
marburgvirus 
P
a
ra
m
y
x
o
v
ir
id
a
e
 P
a
ra
m
y
x
o
v
ir
in
a
e
 
Aquaparamyxovirus  Atlantic salmon 
paramyxovirus 
Avulavirus  Newcastle 
disease virus 
Ferlavirus  Fer-de-Lance 
paramyxovirus 
Henipavirus  Hendra virus 
Morbillivirus  Measles virus 
Respirovirus  Sendai virus 
Rubulavirus  Mumps virus  
P
n
e
u
m
o
v
ir
in
a
e
 
Metapneumovirus  Avian 
Metapneumovirus 
Pneumovirus  Human 
respiratory 
syncytial virus 
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1.1.2. DISCOVERY AND EPIDEMIOLOGY  
HRSV was first isolated from chimpanzees in 1956 and a year later was 
recovered from infants who had severe lower respiratory tract disease 
(Blount Jr et al., 1956). Most children are infected with HRSV by the age two 
years and re-infection occurs throughout life. HRSV can cause acute upper 
respiratory tract infection in people of all ages; but can also cause severe 
lower respiratory tract infection (such as acute bronchiolitis and pneumonia) 
R
h
a
b
d
o
v
ir
id
a
e
 
 Cytorhabdovirus  Lettuce necrotic 
yellow virus 
Ephemerovirus  Bovine ephemeral 
fever virus 
Lyssavirus  Rabies virus 
Novrirhabdovirus  Infectious 
hematopoietic 
necrosis virus 
Nucleorhabdovirus  Potato yellow 
dwarf virus 
Perhabdovirus Perch rhabdovirus 
Sigmavirus Drosophila 
melanogaster 
sigmavirus 
Tibrovirus Tibrogargan virus 
Vesiculovirus  Vesicular 
stomatitis Indiana 
virus 
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in young children (Borchers et al., 2013). Generally, mortality from HRSV is 
very low in developed countries, whereas, in developing countries it can be 
quite high. The highest case fatality rate is found among those who have 
chronic lung disease, immune deficiency or congenital heart disease and 
elderly patients (Navas et al., 1992; Stensballe et al., 2003).  
 
HRSV has a single serotype with two major antigenic subgroups; A and B 
and although both subtypes usually co-circulate, one of the subtypes 
predominates (Gilca et al., 2006; Imaz et al., 2000). In temperate countries, 
HRSV infections demonstrates a distinct seasonality with onset in late 
autumn or early winter and a peak between mid-December and early 
February, before a fall in cases around late spring. The seasons of HRSV 
epidemics are difficult to predict because they typically depend on 
geographic location and the climate (Borchers et al., 2013).  
 
According to the World Health Organization, HRSV infects approximately 60 
million people and causes an estimated 160,000 deaths every year 
(MacLellan et al., 2007). Also, from a recent study, it has been estimated that 
HRSV caused about 34 million cases of acute lower respiratory tract infection 
(ALRI) in children younger than 5 years old in 2005 and 10% of those cases 
requiring hospitalization (Nair et al., 2010).  
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1.2. HRSV STRUCTURE, GENOME ORGANISATION AND GENOMIC RNA 
1.2.1 HRSV STRUCTURE 
The HRSV ribonucleocapsid is found inside the virion, surrounded by a lipid 
bilayer derived from the host cell plasma membrane through virus budding 
(Figure 1.1) and comprises of virally encoded transmembrane surface 
glycoproteins (Collins, 2013).  The viral genome of HRSV has 10 genes and 
encodes 11 different proteins. The genomic RNA of HRSV has five structural 
proteins which consist of the viral nucleoprotein (N), phosphoprotein (P), the 
large polymerase protein (L), matrix (M), and M2-1 and two non-structural 
proteins (NS1 and NS2). The characteristic spikes of HRSV virions are 
formed by the glycoprotein (G), the fusion protein (F) and the small 
hydrophobic (SH) protein. Syncytia formed during viral infection, are 
necessary for cell-to-cell viral transmission and are the hallmark of the HRSV 
cytopathic effect (McNamara & Smyth, 2002). 
 
The structure of the virions of HRSV are heterogeneous, both in shape and 
size, which can be observed using electron microscopy (EM) (Figure 1.2). 
Two types of viral particles can be identified: virus filaments that are 
membrane-bound progeny viruses up to 10  m in length and round- or 
kidney shaped viruses which are around 150 to 250 nm thick (Bachi & Howe, 
1973). Using sucrose gradient centrifugation, these two particles can be 
separated (Gower et al., 2005).  
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Figure 1.1 Schematic diagram of HRSV virion structure. The inset shows 
viral genomic RNA that composes the nucleocapsid with the 
ribonucleoprotein (RNP)s complex, including N, P, L and M2-1 proteins. The 
nucleocapsid is encapsuled into the viral envelope structure; external which 
is made of the glycosylated G, F and SH protein and internal non-
glycosylated M protein. 
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Figure 1.2 Electron micrograph showing an RSV budding virion through the 
plasma membrane of an infected cell, RNA genome and encoded proteins. 
The viral protein functions in the virion and their locations are indicated. This 
electron micrograph image was adapted from Garofalo et al., 2013.  
 
1.2.2. PARAMYXOVIRIDAE GENOMIC ORGANISATION 
Both sub-families Paramyxoviridae and Pneumovirinae in the family 
Paramyxoviridae encode N, P, M, F and L genes (Figure 1.3), however, they 
have limited sequence relatedness (Collins, 2013). Members of 
Pneumovirinae subfamily express a G protein, which has an attachment 
function, to facilitate cell entry, whereas members of Paramyxoviridae 
subfamily express the attachment proteins hemagglutinin (H) or 
hemagglutinin-neuraminidase (HN) for a similar function. Moreover, the M2 
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gene encodes M2-1 and M2-2, which is unique to the Pneumovirinae 
subfamily. The NS1 and NS2 non-structural (NS) proteins are only expressed 
by HRSV. 
 
Figure 1.3 A genetic map of the genomic organization of viruses in 
Paramyxoviridae family. The gene encodes viral proteins matching their 
function. Genes highlighted in green colour encode proteins that are 
essential for viral replication. Genes shown in orange colour encode proteins 
that form the viral envelops. Genes in blue colour encode proteins that are 
unique to HRSV.   
 
1.2.3. THE HRSV GENOME 
HRSV genome is a negative-sense, single strand and non-segmented RNA 
of approximately 15.2 kb in length. The HRSV genome has ten non-
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segmented genes that follow a linear order from 3’ (leader region) to 5’ 
(trailer region) along the genome (Collins, 2013). These genes encode 
eleven viral proteins (Figure 1.4). The 3’ end of the genome contains the 44-
nt leader (Le) promoter region which is responsible for directing initiation of 
mRNA transcription and anti-genome synthesis. Also, at the 3’ end of the 
anti-genome contains a 155-nt trailer complement (TrC) promoter that directs 
genome RNA synthesis. To perform transcription and genome replication, the 
RNA dependent RNA polymerase RdRp engages with the promoter 
sequences that lie at the 3’ ends of the genome and anti-genome RNAs 
(Collins et al., 1991). The ten viral genes are arranged sequentially, NS1, 
NS2, N, P, M, SH, G, F, M2 and L, and each (except the overlapping L and 
M2-1 genes) is flanked by conserved gene-start (GS) and gene-end (GE) 
sequences, which control the polymerase during transcription. Each gene is 
separated from the preceding one by an intergenic region of variable length. 
The polymerase initiates RNA synthesis at the leader promoter and then 
progresses along the length of the genome. When it reaches a GE signal, the 
polymerase polyadenylates and releases the nascent mRNA. It then 
reinitiates RNA synthesis at the next GS signal. By responding to the GE and 
GS signals in this fashion, the polymerase is able to transcribe viral mRNAs 
(Barik, 1992).  
 
 
 
 
 
Chapter 1: Introduction 
 10   
 
 
 
 
Figure 1.4 Schematic of the HRSV negative-sense, single strand and non-
segmented enveloped RNA virus ∼15 kb. From the 3’-end, HRSV genomic 
RNA is transcribed into 10 mRNAs genes, however, the M2 gene encodes 
two proteins, M2-1 and M2-2, which have slightly overlapping open reading 
frames (ORFs).   
 
1.3 PROTEINS 
1.3.1 ENVELOPE PROTEINS: G, F, SH AND M 
The HRSV virion consists of a RNP that is packaged in a lipid bilayer 
envelope derived from the host cell plasma membrane through budding 
(Collins, 2013). HRSV particles are surrounded by a lipid layer where three 
transmembrane surface (outside the virion) glycoproteins are integrated; the 
attachment (G) protein that functions in binding the virus to the host cell 
surface (Lamb, 2013), fusion (F) protein which mediates fusion of the viral 
and cell membranes (Collins, 2013), and small hydrophobic (SH) protein. All 
of these glycoproteins form the characteristic spikes of HRSV virions. Also, 
the non-glycosylated matrix (M) protein is thought to form a layer on the inner 
surface of the envelope (Collins & Mottet, 1993).     
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 1.3.1.1 G PROTEIN 
The G protein is a major attachment glycoprotein that is expressed in two 
different forms in the infected cells; soluble protein (Gs) that is excreted by 
the infected cells and trans-membrane protein (Gm) that is incorporated into 
virions (Hendricks et al., 1987; Hendricks et al., 1988). The length of this 
protein is 282-319 amino acids but this depends on the strain of HRSV 
(Johnson et al., 1987). The HRSV has the ability to re-infect individuals 
repeatedly may be due to immunological pressure changing certain areas of 
the G protein (Cane et al., 1991). The G protein is important for viral 
replication and was initially expected to play a role in viral attachment, 
however, it was later found that even when deleted from recombinant HRSV, 
there was no significant reduction in replication in HEp-2 cells or mice (Tengt 
& Collins, 2002). The ectodomain of the G protein comprises a CX3C motif 
that has sequence relatedness with the CX3C domain of the chemokine 
fractalkine (Tripp et al., 2001). Also this ectodomain of the G protein has 
been shown to have activity in modulating host defence and inhibiting the 
host innate immune response to HRSV by inhibiting activation of the NF-kB 
transcription factor and secretion of inflammatory cytokines by monocytes 
(Polack et al., 2005).  
 
1.3.1.2 F PROTEIN 
The F glycoprotein mediates viral penetration by fusion between the virion 
envelope and the infected cell plasma membrane. This protein, through 
infection, passed on the cell surface can mediate fusion with neighbouring 
cells to make syncytia (giant cell formation) (Lamb, 2013; Techaarpornkul et 
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al., 2001). The F protein is a transmembrane protein that is synthesized as 
an inactive precursor (F0) and then cleaved by cellular proteases during 
maturation to yield two disulfide-linked polypeptides, F1 from the C-terminus 
and F2 from N-terminus, and a small p24 fragment (Collins & Mottet, 1991). 
The HRSV F protein can efficiently mediate fusion independent of the other 
viral glycoproteins, however, unlike for most members of Paramyxovirinae, 
they promote fusion require for interaction between both (G) and (F) proteins, 
however, in vivo HRSV which is lacking the G protein is highly attenuated, 
and results in formation of small sized of syncytia (Techaarpornkul et al., 
2001; Teng et al., 2001). The F protein has been demonstrated to initiate an 
innate immune response by two cellular pattern recognition receptors, a 
cluster of differentiation 14 (CD14) and the Toll-like receptor (TLR) (Kurt-
Jones et al., 2000). The F protein can also induce caspase-dependent cell 
apoptosis and activation protein 53 (p53) in epithelial cells (Eckardt-Michel et 
al., 2008).  
 
1.3.1.3 SH PROTEIN 
The function of the SH protein in the HRSV infectious cycles is unknown 
(Carter et al., 2010), which is only the viral gene that still remains without an 
allocated activity for viral replication in cell culture, or within the human host 
(Melero, 2007). However, the SH viral protein was slightly attenuated in mice 
and chimpanzees (Bukreyev et al., 1997) and deletion of SH from a highly 
attenuated vaccine candidate did not increase the level of attenuation in 
small infants (Karron et al., 2005). Earlier studies demonstrated that SH 
could enhance cell-to-cell fusion (Heminway et al., 1994) or act as a channel-
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forming viroporin (Carter et al., 2010; Techaarpornkul et al., 2001), however, 
the function as an ion channel activity in HRSV biology is uncertain.   
    
1.3.1.4 M PROTEIN 
The HRSV M matrix protein is a non-glycosylated protein which accumulates 
at the inner surface of envelope face (Figure 1.2) and interacts with the F 
protein and other factors during the process of virion morphogenesis 
(Henderson et al., 2002; Teng & Collins, 1998). It has been reported that the 
M protein interacts with cell membranes during the later phase of the HRSV 
replication cycle (Marty et al., 2004). The M protein also plays a major role in 
coordinating the assembly, budding process and release of new HRSV 
virions particles by; the interacting of nucleocapsids proteins N, P and M2-1 
protein and the viral envelope proteins G and P at specific sites of the cell 
membrane (Förster et al., 2015; Liljeroos et al., 2013; Melero, 2007).  It was 
demonstrated that at an early phase of HRSV infection, the M protein is 
localized in the nucleus of infected cells and may have the ability to inhibit 
host cell transcription (Ghildyal et al., 2003). Since the HRSV M protein is 
essential for virion morphogenesis and can bind RNA, it has been predicted 
that its activity may shut off RNA synthesis by the viral nucleocapsid 
(Rodríguez et al., 2004).     
 
1.3.2 NUCLEOCAPSID PROTEINS: N, P, L AND M2 PROTEINS 
HRSV has four proteins N, P, L and M2-1 associated with RNP formulation 
which are involved in RNA synthesis (Melero, 2007). The N protein tightly 
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binds the genomic RNA and forms a helical nucleocapsid for viral RNA 
(MacLellan et al., 2007; Tawar et al., 2009). The P protein is the major 
phosphorylated HRSV protein and is a part of the polymerase complex 
(Collins, 2013). The L protein is the viral RdRp (Stec et al., 1991). The M2-1 
protein is known as a transcription factor important for viral viability and 
allowing the synthesis of full-length mRNAs (Collins et al., 1995; Collins et 
al., 1996; Hardy & Wertz, 1998).  
 
The N, P and L proteins are essential for sufficient direct RNA replication 
(Collins et al., 1996; Melero, 2007; Turner et al., 2014). Moreover, the N, P 
and L proteins have transcription functions, however, complete transcription 
requires the M2-1 protein (Collins, 2007; Collins, 2013; Melero, 2007) (Figure 
1.2). The N protein interact with the P protein in the nucleocapsid (Collins, 
2013), the P protein also binds to the L (Khattar et al., 2001) and M2-1 
(Asenjo et al., 2006) proteins and can mediate the interactions of these with 
the nuclopcapsid. Thus, the P protein has some roles in the viral genome; it 
is important for promoter clearance (Dupuy et al., 1999) and chain elongation 
by the viral polymerase, and in separating the M protein from the 
nucleocapsid during the un-coating stage to initiate the infection (Asenjo et 
al., 2008).  
 
Although the HRSV M2-1 protein is necessary for sufficient viral transcription, 
without this protein, the viral polymerase terminates prematurely and non-
specifically within several hundred nucleotides and downstream genes are 
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not transcribed (Collins et al., 1999; Collins et al., 1996; Fearns & Collins, 
1999). In addition, the HRSV M2-1 has the ability to decline the termination 
efficiency at the gene-end signals (GE) transcription signals causing 
increased production of read-through mRNA’s (Burke et al., 1998). The M2-1 
protein binds RNA and it has been indicated that the P protein deliver to the 
RNA template (Cartee & Wertz, 2001; Tran et al., 2009).  The M2-2 protein 
has been indicated to play a function in shifting RNA synthesis from the 
transcription stage to the RNA replication stage. Also, the M2-2 protein can 
inhibit RNA synthesis, however, the inhibition activity can happen when 
protein M2-2 expression is increased (Collins, 2013).    
 
1.3.3 ACCESSORY PROTEINS: NS1 AND NS2 
NS1 and NS2 proteins (139 and 124 amino acid, respectively) were 
characterized as non-structural proteins due to the difficulty to detect them in 
the purified HRSV virion (Huang et al., 1985). Hence, they are not essential 
for viral growth in cell culture (Melero, 2007). HRSV NS1 and NS2 are non-
structural proteins that suppress the induction of interferon IFN-    in HRSV 
infection (Ramaswamy et al., 2004). This occurs by inhibiting the 
phosphorylation and nuclear translocation of interferon regulatory factor 3 
(IRF3) (Spann et al., 2005). In addition, it has been reported that there was 
inhibition of the interferon-induced JAK/STAT signalling pathway and 
targeting STAT2 for proteasome-mediated degradation (Bakre et al., 2015), 
however, thus can be mediated primarily by both NS1 and NS2 together 
(Ramaswamy et al., 2004). It has been suggested that both NS1 and NS2 
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play a vital function in inhibition of premature apoptosis and thus enhances 
viral replication in the HRSV infected cell (Bitko et al., 2007; Wu et al., 2012). 
 
1. 4. INFECTIOUS CYCLE  
1.4.1. BINDING AND ENTRY 
HRSV can infect cells and replicate in vitro in both human and animal cells, 
however, it has been identified that in vivo, the respiratory ciliated epithelial 
cells of the respiratory tract are the main sites of virus replication. There are 
extensive ranges of epithelial cultured cells that are permissible to growth of 
HRSV, for example; human larynx carcinoma cell (HEp-2), human lung 
alveolar basal epithelial cells (A549), and African green monkey kidney 
epithelial cell (Vero). However, the efficient infection and viral propagation 
are different on these cell lines. Moreover, efficient HRSV binding 
(attachment) occurs through interaction between the G and F proteins and 
cellular glycosaminoglycans (GAGs), mainly heparin sulphate and 
chondroitin sulphate B (Hallak et al., 2000; Techaarpornkul et al., 2002). 
There are also some cellular surface proteins receptors which have been 
reported to assist binding, including, RhoA (Pastey et al., 1999), annexin II 
(Malhotra et al., 2003), intracellular adhesion molecule (ICAM)-1(Behera et 
al., 2001), and the CX3CR1 chemokine receptor (Tripp et al., 2001).  
However, it has been reported that the same virus might use different 
receptor combinations based on the cell type being infected (Melero, 2007). 
The HRSV replication cycle occurs in the cytoplasm and requires clathrin-
mediated endocytosis at neutral pH (Kolokoltsov et al., 2007) (Figure 1.5). 
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The viral entry route starts by fusion of the virion and the cell plasma 
membrane (Srinivasakumar et al., 1991) and insertion of the RNP complex 
into the host cell (Figure 1.5 a and b). Some elements are required for HRSV 
replication including cytoskeletal proteins, whereas, efficient RNA synthesis 
requires actin that is packaged in the virion and profilin (Burke et al., 1998; 
Burke et al., 2000). 
 
 
Figure 1.5 Overview of the HRSV replication cycle. (a) Shows the interaction 
of the virus with the host cell. The virus interaction is localised in a lipid 
bilayer (green) with the host-cell receptor (red) and is mediated by the G 
protein (dark blue). (b) Fusion step, the lipid bilayer derived from the virus 
enveloped and the cell membrane, mixed on cell surface, the virus 
glycoproteins are embedded in the cell membrane. (c) The RNP complex 
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was transported in the host cell to the site of mRNA transcription and 
replication. (d) The vRNA transcription step, the virus polymerase generates 
mRNA species (orange) from each virus gene and then subsequently 
translated into the various virus proteins. (e)The vRNA replication step which 
is linked with the viral genes expression which is subsequently used as a 
template to produce more vRNA by the virus polymerase. (f) Accumulation of 
viral particles. (g) Virus assembly where new virus glycoproteins are 
synthesised and RNP complexes are targeted to specific sites on the cell 
surface membrane. (h) The virus maturation where the virus are release from 
the cell, to go infect another cell where the process begins again.       
 
1.4.2.TRANSCRIPTION AND REPLICATION OF THE VIRAL GENOME 
HRSV mRNAs transcription and protein synthesis can be detected in the cell 
cytoplasm 4-6 hr post-infection (and reach a peak at approximately 15 to 20 
hr post-infection) (Collins, 2013). Because the Group V viruses in the 
Baltimore classification system, (Paramyxoviruses, including HRSV) have –
ssRNA genomes which are not directly readable by the host cell ribosomes, 
therefore, they encode their own RdRp (present in the virion) which 
transcribe the –ssRNA genome into a readable, monocistronic positive sense 
mRNAs form (Figure 1.5). HRSV transcription proceeds from the 3’ to 5’ end 
of the viral gene (vRNA) in a sequential stop-start manner (Dickens et al., 
1984). However, there are several factors that affect the relative levels of 
HRSV gene expression, thus genes closer to the 3’ end of genome are 
expressed more efficiently because the polymerase (RdRP) falls-off at the 
sequential transcription (intergenic) regions (Collins & Wertz, 1983; Krempl et 
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al., 2002). Another factor that has effects on the relative levels of gene 
expression are alterations in the efficiency of transcription at the gene end 
(GE) signals in a specific site in the L polymerase (Harmon & Wertz, 2002; 
Moudy et al., 2004). When the polymerase has reached a GE signal, 
polyadenylation of the RNA occurs, releasing the nascent mRNA and allows 
reinitiation of the transcription from the next GS single promoter at 3’ end, 
capping and cap methylation. The transcription process is repeated for each 
gene to generate different mRNAs (Melero, 2007).  
 
There are four proteins required for the transcription step; (1) the L 
polymerase protein which stimulates the polymerization stages of RNA 
synthesis as well as the capping and polyadenylation process of the mRNAs, 
(2) the N protein that forms the nucleocapsid template recognised by the 
polymerase, (3) the P protein known to be a co-factor of the L polymerase 
and (4) the M2-2 protein, an anti-termination factor that promotes completion 
of mRNA synthesis. Also, the M2-2 protein has been reported to be 
responsible for shifting RNA synthesis from transcription to RNA replication 
and ensuring a balance during the infection (Bermingham & Collins, 1999).  
 
1.4.3 ASSEMBLY AND BUDDING  
The mature HRSV virions begins to be released by 10-12 hr post-infection 
and reaches a peak after 24 hr and continues until the cells are destroyed by 
30-48 hr post-infection (Collins, 2013). The mature viruses bud only from the 
apical surface in polarized epithelial cells during the infection (Lamb, 2013). 
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The assembly and budding of HRSV virions involves the viral components, 
including the viral surface (enveloped proteins) and the M protein and the 
RNP complexes at the cell plasma membrane. Two steps are required for 
assembly: first, free N protein and the P-L protein complex associates with 
the viral genome or template RNA to form the helical RNP structure in the 
cytoplasm (Collins, 2013), secondly the assembly of the RNP complex within 
the envelope occurs at the regions of the host cell surface enriched by 
caveolin-1 (CAV-1) (Brown et al., 2002). Moreover, it has been reported that 
the M protein plays a major role in the assembly of new virions by bridging 
the interaction with specific sites on the cell membrane (Marty et al., 2004; 
Teng & Collins, 1998).     
 
1.5. DISEASE PATHOGENESIS AND HOST-CELL INTERACTIONS 
1.5.2 DISEASE PATHOGENESIS 
HRSV is the most common human pathogen that causes illnesses with 
symptoms similar to the common cold in most healthy adults and children. It 
causes lower respiratory tract infection (LRTI), pneumonia and bronchiolitis in 
infants and young children (Van Drunen Littel-Van Den Hurk & Watkiss, 
2012) HRSV also can cause many diseases such as asthma (Mailaparambil 
et al., 2009) and otitis media (middle ear infection) (Gomaa et al., 2012). 
HRSV is the most common respiratory virus and can be isolated from 
patients hospitalized for bronchiolitis during the HRSV season (Hall et al., 
2009). The peak season of HRSV infections in temperate climates of the 
Northern hemisphere are the months of November to April, while HRSV 
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outbreaks occur regularly during the rainy season in tropical climates. In 
2005, around 34 million cases of LRTI in children were caused by HRSV, the 
10% required hospitalization. The mortality in the same year was 66000-
199000 worldwide, of which 99% occurred in developing countries (Nair et 
al., 2010). Humans are the only host for HRSV infection and it spreads 
rapidly through close contact with infected individuals or through contact with 
hands contaminated with nasal or conjunctival mucosa. Viral replication 
starts in the nasopharynx and the incubation period from infection time to 
symptoms onset is 4 to 5 days (Collins, 2013). Common clinical signs of 
HRSV include rhinorrhea, cough and low grade fever. HRSV can cause 
morbidity and mortality in infants, immunocompromised and elderly people, 
and this required a better understanding of the mechanisms of HRSV 
pathogenesis to allow for effective treatments (Collins & Graham, 2008). 
 
1.5.2.1 FACTORS PLAYING A ROLE IN HRSV PATHOGENESIS AND DISEASE 
OUTCOME 
It is thought that there are many factors which drives the pathogenesis of 
HRSV; genetic polymorphisms, viral, environmental and host factors which 
contribute to severe disease especially in infants (Figure 1.6).  
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Figure 1.6 Factors influencing the pathogenesis and clinical disease caused 
by HRSV infection in infants and young children. adapted from HRSV 
pathogenesis van Drunen Littel-van den Hurk and Watkiss (2012) 
 
1.5.2.1.1 ENVIRONMENTAL AND SOCIAL FACTORS 
Several factors may play a role and increase the risk of serious infection with 
HRSV such as the presence of members of the household who smoke or 
young siblings, day care attendance, stay in a nursing home or hospital 
(Bocchini Jr et al., 2009). In general, exposure to smoke from cigarettes has 
a detrimental impact on respiratory health. There is a significant link 
illustrated between smoking in the household, and the incidence and severity 
of HRSV infection (Bradley et al., 2005). 
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1.5.2.1.2 VIRAL FACTORS 
HRSV is not a very cytopathic virus, but targeting nonbasilar airway epithelial 
cells and type I alveolar (Johnson et al., 2007). This results in damage to the 
ciliary function and removal of infected epithelial cells (Wright et al., 2005). In 
general, HRSV does not stop cell transcription; nevertheless, there was a 
change in abundance of cell cycle regulatory proteins investigated in A549 
and human primary HBEpC cells, and this leads to enrichment of cells in the 
G0/G1 population and doubled the number of progeny virus (Wu et al., 
2011). Viral load is not the only factor determining disease severity and the 
correlation remains controversial. In spite of HRSV low cytopathicity, there is 
clear evidence that the level of HRSV replication relates to the severity of 
disease (El Saleeby et al., 2011). Consequently, HRSV in clinical isolations 
was found to induce variable pathogenesis (Van Drunen Littel-Van Den Hurk 
& Watkiss, 2012).  
 
There are many HRSV proteins that play a role in alteration of the host 
response to infection. NS1 and NS2 proteins stop IFN regulatory factor 3 
activation and prevent the type I IFN induced signalling during the JAK/STAT 
pathway. Therefore, this leads to an effective block of IFN /  production by 
the infected host allowing increased virus replication without killing. HRSV 
also down regulates the production and function of IFN by inhibiting toll-like 
receptor (TLR) signalling during mitochondrial antiviral signalling protein 
(Bhoj et al., 2008). Moreover, a reduced apoptosis and enhanced survival of 
the infected cells results from activation of the phosphoinositidide 3-kinase 
pathway by NS1 and NS2 (Bitko et al., 2007).  
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The transmembrane attachment glycoprotein G plays an important function in 
immune evasion in HRSV. Firstly, the G protein is a highly glycosylated 
protein, which may impede immune recognition. Secondly, it is highly 
variable, with only 53% amino acid identity and 1–7% antigenic relatedness 
between subgroups, and, as a result, leads to easy escape from specific 
neutralizing antibodies. Thirdly, the G protein also has limited sequence 
homology to fraktalkine (CX3CL1), therefore, decreasing the action of host 
fraktalkine and the influx of CXCR1 leukocytes, for instance CD4, CD8 T and 
cells natural killer (NK) cells (Tripp et al., 2001).  
 
1.5.2.1.3 HOST FACTORS 
Host risk factors for more severe LRTI HRSV infections and hospitalization 
are correlated to premature birth, immunodeficiency, chronic lung disease 
(CLD) of prematurity and hemodynamically congenital heart disease (CHD). 
In addition, immunodeficiency, immunosuppression or old age may lead to 
prolonged viral replication and more severe illness. Further risk factors for 
children include male gender, low birth weight, multiple births and low titer of 
HRSV-specific maternal antibodies (Groothuis et al., 2011; Kristensen et al., 
2012; Resch et al., 2002). 
 
1.5.2.1.4 GENETIC FACTORS 
Many genetic polymorphisms, including innate defence genes, host cell 
receptor genes, neutrophil response genes surfactant protein genes, 
Th1/Th2 response genes and gene effectors of adaptive immunity (Figure 
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1.6) have been reported as significant factors in the severity of human RSV 
disease (Miyairi & DeVincenzo, 2008). 
 
Macrophages and epithelial cells were predictably involved in the innate 
immune response to HRSV. Therefore, many cytokines and chemokines 
including IL-8/ CXCL8, IP-10/CXCL10, MCP-1/CCL2, MIP-1 , CCL3, MIP-
1b/CCL4, RANTES/CCL5, IL-6, TNF- , IL-1 / , and IFN- /  are produced 
by macrophages and epithelial cells in response to HRSV infection, and can 
be detected in enhanced amounts in respiratory secretions of children, 
hospitalized for HRSV infection (McNamara et al., 2005). 
 
1.6 TREATMENTS AND PREVENTION 
While there has been a lot of research into the clinical manifestation, 
diagnostic approaches and animal models of HRSV, there is currently no 
vaccine or general anti-viral therapy and the infection causes large 
economical and health care burdens every year.  
 
1.6.1. TREATMENT 
1.6.1.1 RIBAVIRIN  
Ribavirin (1-b-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide) is the only 
antiviral drug licensed by the FDA for the treatment of severe HRSV 
infection. It is a synthetic nucleoside with a broad spectrum of antiviral activity 
that affects a diverse range of DNA and RNA viruses in vivo and in vitro 
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(Sidwell et al., 1972). Ribavirin has become a standard therapy for the 
treatment of hepatitis C virus infection in combination with pegylated 
interferon (Pawlotsky, 2003) and has been used experimentally against 
Lassa fever virus infection (McCormick et al., 1986) and other haemorrhagic 
virus infections, for instance, ebola (Alfson KJ, 2015; Bronze & Greenfield, 
2003). Moreover, the doses of ribavirin for HRSV patients are administered 
as a little-particle aerosol for two to five days and usually for 12 or more 
hours per day. However, ribavirin is not in routine use for management of 
infants/children with HRSV infection because the drug is expensive, difficult 
to administrating and produced conflicting results for long-term treatments 
(Wright & Piedimonte, 2011). For these reasons, the drug is used for those 
patients at high risk of developing severe disease and the decision depends 
on the individual stations (Lieberthal et al., 2006).  
 
Since ribavirin was discovered, its mechanism of action in vivo is still 
unknown (Crotty et al., 2002). However, it is thought to inhibit the replication 
of HRSV throughout the active replication phase (Jafri, 2003). There are 
many mechanisms thought to be responsible for the antiviral activity of 
ribavirin (Figure 1.7), depending on the particular virus being studied 
(Paeshuyse et al., 2011). And there are five primary mechanisms of action 
suggested for ribavirin, three direct mechanisms contain direct inhibition of 
the viral polymerase, inhibition of RNA capping activity and reproduced 
mutation frequency throughout incorporation of ribavirin into newly 
synthesized genomes resulting to error catastrophe. Two indirect 
mechanisms compose an immunomodulatory effect in which a T-helper type 
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1 (antiviral) immune response is maintained and a decrease in cellular 
guanosine triphosphate (GTP) pools through inosine monophosphate 
dehydrogenase (IMPDH) inhibition (Crotty et al., 2001; Graci & Cameron, 
2006; Hofmann et al., 2008). However, the predominant mechanism of 
antiviral activity of ribavirin against Paramyxoviruses such as HRSV and 
parainfluenza in vitro is based on inhibition of IMPDH activity (Leyssen et al., 
2005).   
 
Figure 1.7 A. structural formula of ribavirin. B. The five mechanisms of 
action: (1) modulation of Th1 and Th2 immune response, (2) Inhibition of 
IMPDH, (3) Direct inhibition of translation initiation factor eIF4E, (4) Direct 
inhibition of viral polymerase, (5) Viral lethal mutagenesis. However, the 
precise mechanism of action of ribavirin is still unknown for HRSV.   Adapted 
from (Chung et al., 2008; Paeshuyse et al., 2011).  
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1.6.1.2 MECHANISM OF ACTION (FIVE MECHANISMS) 
The mechanism of action of ribavirin in many cases is unknown. Several 
hypotheses for a mode of action have been suggested and are discussed 
below:  
 
1.6.1.2.1 IMMUNOMODULATORY EFFECT    
Immunomodulation of antiviral cellular responses are an indirect mechanism 
of action of ribavirin, for instance the ability to induce a Th2 to Th1 shift in the 
immune response (Shah et al., 2010) (Figure 1.7 B). It has been suggested 
that the cytokine profile of CD4 cells may determine whether HCV infection 
results in a chronic, failure of the immune system to amount an active cellular 
response needed to clear the virus from the liver (Rehermann, 2009; 
Rehermann & Nascimbeni, 2005), or clearance to clear HCV following an 
acute infection which is associated with production of Th1 cytokine, 
interleukin 2 and interferon gamma (Rehermann & Nascimbeni, 2005). 
Therefore, ribavirin is thought to preserve or enhance the Th1 responses that 
are needed to clear HCV infection, Th2 responses that associated with 
tolerance and chronic infection (Fang et al., 2000) and for HRSV 
(DeVincenzo, 2000).    
 
1.6.1.2.2 INHIBITION OF IMPDH 
Intracellular pools of GTP are depleted in ribavirin treated cells through 
inhibition of cellular inosine monophosphate dehydrogenase (IMPDH) (Figure 
1.7 B). This has been suggested to be correlated with the inhibition of 
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flavivirus (including yellow fever virus) and paramyxovirus replication. 
Inhibition of IMPDH is an indirect mechanism of action of ribavirin, which is a 
host enzyme that specific for the de novo synthesis of guanosine 
triphosphate (GTP) and has a key role in guanine nucleotide biosynthesis 
(Leyssen et al., 2005; Leyssen et al., 2006; Malinoski & Stollar, 1981; Shu & 
Nair, 2008; Streeter et al., 1973). Also, IMPDH has been reported to 
modulate intracellular guanine (deoxy)nucleotide pools and thus has a vital 
impact on many of cellular processes, composing the control of cell 
proliferation. Intracellular pools of GTP are an essential building block for 
viral RNA synthesis and have been reported to be reduced by up to 60% in 
cells infected with influenza or those which are treated with ribavirin (Wray et 
al., 1985). Moreover, inhibition of IMPDH by ribavirin results in inhibition of 
the replication of many RNA viruses, including HCV and flavivirus (Leyssen 
et al., 2005; Leyssen et al., 2006).  
 
1.6.1.2.3 INHIBITION OF RNA CAPPING ACTIVITY       
Inefficient translation of viral transcripts occurs as a result of ribavirin which 
prevent the capping of mRNA (Figure 1.7 B). Ribavirin can also affect the 
translation of eukaryotic mRNAs and has been proposed as a therapeutic for 
acute myeloid leukemia (Tamburini et al., 2009). It has also been shown to 
act as a competitive inhibitor of the methyl 7-guanosine (m(7)G) cap, the 
natural ligand of the translation initiation factor eIF4E (Volpon et al., 2013). 
Moreover, ribavirin has been reported to have an effect on HCV replication 
by inhibition of eIF4E (Paeshuyse et al., 2011).  
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1.6.1.2.4 INHIBITION OF VIRAL POLYMERASE 
It has been reported that ribavirin can lead to a direct inhibition of viral RdRp 
(Figure 1.7 B), which is responsible for the replication of the viral genome, 
such as in influenza virus (Eriksson et al., 1977) and vesicular stomatitis virus 
(Toltzis et al., 1988). This leads to inhibition of viral transcription and 
replication. For HCV infection, ribavirin 5’-triphosphate (RTP) can function as 
a substrate for the HCV RdRP, interacting with the viral polymerase and 
inhibiting nucleic acid synthesis (Graci & Cameron, 2006). Ribavirin was 
demonstrated to act as a competitive inhibitor of either GTP or ATP (i.e act 
as an analoge) suggesting that ribavirin might be an RNA virus mutagen in 
vivo. However, RTP has been suggested to inhibit predominantly the RNA 
transcription of reovirus (Rankin Jr et al., 1989). In addition, ribavirin was 
investigated to act as inhibitor to HIV-1 reverse transcription (Fernandez-
Larsson & Patterson, 1990). 
 
1.6.1.2.5 LOSS OF FITNESS OF RNA VIRUS GENOMES  
RNA virus error catastrophe is a direct mechanism of action of ribavirin 
(Figure 1.7 B). Ribavirin is a base analogue of either adenine or guanine and 
thus can base pair with cytosine or uracil. For RNA viruses, ribavirin might be 
incorporated into genomic RNA by the RdRp during replication. The result is 
termed hyper-mutation that can cause ‘’lethal mutagenesis’’ to virus biology 
through error catastrophe.  This mechanism of action has been proposed and 
supported by experimental data in vitro for poliovirus (Crotty et al., 2001) and 
HCV and in vivo for HCV (Dietz et al., 2013). 
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Multiple mechanisms of action, GTP depletion by ribavirin may act in concert 
to increase its incorporation into viral genomes, thus increasing error prone 
replication as has been suggested for West Nile virus (Day et al., 2005). 
Furthermore, up-regulation of anti-viral gene products, micro-array analysis 
suggested that ribavirin can directly up-regulate antiviral gene expression 
including STAT-1  and STAT-1  in HRSV-infected cells (Zhang et al., 2003). 
In summary, all mechanisms of action of ribavirin discussed above were 
different from virus one to other, whether the virus causes an acute or 
chronic infection and the accumulation of ribavirin, in vivo, in some tissues 
(such as liver when administered orally or an aerosol) (Crotty et al., 2002).  
  
1.6.2. PREVENTATIVE THERAPY 
Palivizumab (Syngis: Medlmmune) prophylaxis is a monoclonal antibody 
(MAB) that was developed against the F protein of HRSV. It is the main drug 
approved by the FDA for the prevention of serious LRTI caused by HRSV in 
young children and infants at high-risk. Also, it has been proven to be safe, 
effective and reduces the risk of hospitalization for HRSV LRTI in high-risk 
infants (Connor, 1998). Palivizumab can be used in hematopoietic stem cell 
recipients making it useful for immunocompromised people (Boeckh et al., 
2001). Therefore, the FDA approval was based on the reduction in HRSV 
hospitalization by 45% (Feltes et al., 2003). Palivizumab was recommended 
at 5 monthly doses of 15mg/kg body weight in the start of the HRSV season, 
which occurs differently from country to country (Bocchini Jr et al., 2009). 
However, many studies have unsuccessfully attempted to develop modules 
that predict which infants at high risk would benefit most from using 
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palivizuamb prophylaxis (Sampalis et al., 2008; Simões et al., 2008). Overall, 
no drug will completely prevent HRSV infection, but they can limit replication 
sufficiently to reduce disease (Zhu et al., 2011).  
 
Vaccination is the most effective way to prevent virus infection. However, 
there are currently no licensed HRSV vaccine available (Gomez et al., 2014). 
Vaccines and new antiviral drugs are in pre-clinical and clinical development, 
however, until these are complete controlling HRSV still remains a formidable 
challenge (Collins & Melero, 2011; Zhu et al., 2011).  Therefore, the major 
challenges to develop improved antivirals and vaccines include; elucidating 
the basis of the pathology associated with HRSV infection and understanding 
the effects that HRSV has on the host immune response (Collins & Melero, 
2011; Dapat & Oshitani, 2016).   
  
1.7. HIGH THROUGHPUT APPROACHES 
1.7.1 AN INTRODUCTION TO LABEL FREE PROTEOMICS  
Label- free quantitative proteomics approaches have become highly popular 
in mass spectrometer-based proteomics. It is a technique in MS that have 
two main concepts to compare two or more samples. This method is 
providing an excellent resource for studying host cell proteomes and can be 
applied for the study of virus infection (Cox & Mann, 2011; Otto et al., 2014). 
In order to have successful quantitative proteomics, its important to perform 
excellent experimental design and appropriate sample preparation. Also, 
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having statistical analysis and validation of the MS data through the use of 
independent techniques and functional analysis (Podwojski et al., 2012). 
 
Label-free quantification aim to compare two or more different experiments 
by (i) associating the direct mass spectrometric signal intensity for any given 
peptide or (ii) comparing the number of fragment spectra matching to a 
peptide/protein as an indicator for their respective amounts in a given protein 
(Otto et al., 2014). However, there are three important experimental 
parameters affect the analytical accuracy of quantification by ion intensities 
for proteomic analysis of very complex peptide mixture; (i) It is useful to 
employ a high mass accuracy mass spectrometer because the influence of 
interfering signals of similar but distinct mass can be minimized. (ii) The 
peptide chromatographic profile should be optimized for reproducibility in 
order to ease finding corresponding peptides between different experiments. 
(iii) The good balance between acquisition of survey and fragment spectra 
has to be found. MS has no longer cycles between MS and MS/MS mode but 
aims to detect and fragment all peptides in a chromatographic window 
simultaneously by rapidly alternating between high-and low-energy 
conditions in the MS (Bantscheff et al., 2007; Cox & Mann, 2011). Label-free 
approaches are the least accurate technique among the MS quantification 
techniques when considering the overall experimental process since all the 
systemic and non-systemic variations between experiments are reflected in 
the obtained data. Also, in term of simple practical, the time-consuming steps 
of introducing a label into proteins or peptides can be neglected and there 
are no costs for labelling reagents (Bantscheff et al., 2007). 
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Advantages of label-free quantification over stable isotope labelling by amino 
acids in cell culture (SILAC): In terms of analytical strategy, there are some 
important advantages over SILAC: (a) label free has no principle limit to the 
number of experiments that can be compared whereas SILAC are typically 
limited to 2-8 experiments. (b) Label-free methods give higher dynamic range 
of quantification than SILAC. (C) Label-free different for SILAC techniques, 
mass spectral complexity is not increased that might provide for more 
analytical depth as the MS is not occupied with fragmenting all forms of the 
labelled peptide (Bantscheff et al., 2007; Cox et al., 2014; Cox & Mann, 
2011). Previous studies of HRSV infection have been studied using SILAC 
technique (Munday et al., 2010a; Munday et al., 2012a).    
 
Another high throughout quantitative proteomic approach utilises isobaric 
tagging, where chemical isotope incorporation is based on tags with an 
identical chemical labelling structure and same total mass (Dayon & 
Sanchez, 2012). The two key platforms are isobaric tags for absolute and 
relative quantitation (iTRAQ) and Tandem mass tags (TMT). Both platforms 
represent a method for differentiating between multiple conditions and 
determining relative protein levels in 4 or 8 samples (iTRAQ) or 6 or 10 
samples (TMT) simultaneously (Amaya et al., 2014). This approach lends 
itself to the labelling of in vivo samples and/or primary cells (Wiese et al., 
2007) as such labels are applied post-sample preparation. For example, 
iTRAQ has been used to investigate influenza virus infection in primary 
human macrophages (Lietzén et al., 2011). However, the disadvantages of 
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such techniques include; incomplete labelling, complex sample preparation 
and the requirement for high sample concentration (Munday et al., 2012b).  
 
One of label free proteomics applications in this thesis is to study the effect of 
ribavirin on the host cell in the absence and presence of HRSV using high 
throughput quantitative proteomic techniques but focused on label free rather 
than SILAC.  This includes using antiviral drugs such as ribavirin, and 
determining the viral and cellular proteome changes that occur during virus 
infection. 
 
1.7.2 AN INTRODUCTION TO RNA-SEQ 
RNA-seq is high-throughput technique, also known whole transcription of 
RNA molecules including the messenger RNA (mRNA), provides a complete 
set and precise measurement of the changing expression levels of each 
transcript in cells and tissues during development and under different 
conditions (McGettigan, 2013). Transcriptomics also focused on the gene 
expression at the RNA level and provides the genome information of gene 
structure and function in specific biological processes (Dong & Chen, 2013; 
Ozsolak & Milos, 2011). Understanding the transcriptome is necessary for 
interpreting the functional elements of the viral genome and exposing the 
molecular constituents of cells and understanding diseases (Wang et al., 
2009).  
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RNA-seq has generally replaced traditional approach such as microarray 
techniques by providing the ability to visualise gene expression in sequence 
form (Grada & Weinbrecht, 2013; Liu et al., 2014). Previous studies of host 
cell gene expression, after HRSV infection, have been studied using 
microarray analysis (Dapat & Oshitani, 2016; Martínez et al., 2007; Zhang et 
al., 2003). However, the RNA-seq approach allows sequencing and 
quantification of mRNA expression levels on a small or large scale (Wang et 
al., 2009). Moreover, RNA-seq has advantages over microarray, for instance, 
RNA-seq can identify novel transcripts because it is not limited to detecting 
transcripts that correspond to existing gene sequences (Marioni et al., 2008; 
Wang et al., 2009). Another advantage is that RNA-seq has a larger dynamic 
range to quantify gene expression level accurately (Wang et al., 2009). 
Finally, RNA-seq has a much lower cost than microarrays for gene 
expression profiling in model organisms (Mantione et al., 2014). 
 
RNA-seq approach is now common use in biology and in detecting cellular 
pathway changes during viral infection, for example, on West Nile virus (Qian 
et al., 2013), human adenovirus (Evans et al., 2012) and Hendra virus 
(Wynne et al., 2014). However, RNA-seq has not been used for HRSV in the 
published literature, thus using such this high-resolution approach making a 
novelty in this thesis. Therefore, this will allow determination of the genetic 
sequence of the virus to great depth of coverage and to better understanding 
the mechanism of action of the antiviral ribavirin.   
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1.8. RESEARCH OBJECTIVES  
The main aims of this study were to investigate the potential mechanism of 
ribavirin and study its effect on the host cell in the absence and presence of 
HRSV by using high throughput techniques; quantitative proteomics and 
RNA-seq. The findings of this study will provide a better understanding of the 
mechanism of action on HRSV and the host cell. This thesis is composed 
three parts: the first part focuses on establishing appropriate experimental 
and assay conditions to study the effect of ribavirin in the following chapters. 
HEp-2 and A549 cell lines, derived from human lung carcinomas, were used 
in this study. The results generated from this work were presented in Chapter 
3 and have contributed to a publication (Aljabr et al., 2015) (see appendix). 
 
The second part of this study aimed to investigate the action of ribavirin on 
the host cell and HRSV biology in general, using a combined high-resolution 
RNA-seq and deep discovery label free quantitative proteomics. The results 
based on this work are presented in Chapter 4. Some of this work (mainly the 
chaperone proteins which were detected in mock verses HRSV infected 
cells) contributed to another publication (Munday et al., 2015) (see 
appendix). A manuscript is currently in preparation using the most data in 
Chapter 4. 
 
The third part of this study investigates the effect of ribavirin on HRSV 
infected cells and identifying a potential direct mutagenic effect of ribavirin on 
HRSV. The results based on this work were presented in Chapter 5, and has 
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contributed to several publications (Aljabr et al., 2015; Noton et al., 2014) 
(see appendix).  
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CHAPTER 2: MATERIALS AND METHODS 
2.1. TISSUE CELL CULTURE METHODS 
2.1.1. CONTINUOUS CELL CULTURE 
HEp-2 and A549 cells were purchased from the European Collection of 
Authenticated Cell Cultures (ECACC) (held by Public Health England) and 
were maintained at 37°C with 5% CO2. Both continuous cell lines, HEp-2 and 
A549, were grown in Dulbecco's modified Eagle's medium (DMEM) (Sigma 
[D6429]) and supplemented with 10% foetal bovine serum (FBS) (Sigma 
[F9665]) and 100% penicillin and streptomycin antibiotics (Sigma [P4333]). 
All cell lines were passaged using trypsin EDTA ([Sigma [T3924]) for normal 
cell maintenance, or using a phosphate-buffer saline (PBS) (Sigma). For 
different infection experiments, cells were seeded at the following densities 
24 hr prior to infection to achieve a 60-70% confluent cell layer (Table 2.1). 
The cell monolayers were washed with PBS and 2 ml of (1X) Trypsin/EDTA 
was added release adherent cells from culture surfaces for 2 min at 37°C. 
Following detachment, 10 ml growth medium were added to the flask 
containing cells to prevent further tryptic activity. The cell suspension was 
transferred to a 50 ml conical tube and centrifuged at 220 x g for 5 min at 
room temperature. Without disturbing the cell pellet, the supernatant was 
aspirated from the tube and the tip of the conical tube was flicked by finger to 
loosen the cell pellet. Then the cells were re-suspended in 2 ml of growth 
medium by pipetting the cells up and down to break up cell collections. For 
quick growth in a 75 cm2 flask, 7.5 x103 cells per cm2 were seeded, however, 
for regular sub-culturing 5 x103 cells per cm2 were seeded. For IF 
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experiments, 19 mm glass coverslips were dipped in methanol and left to dry 
before the coverslips were washed in sterile PBS (137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 pH adjusted to 7.4) then transferred 
to dishes or 6 well plates prior to seeding using methanol sterilised forceps. 
 
Table 2.1 The seeding density of HEp-2 and A549 cells. 24 hr post-seeding 
required growing cells at a layer 60-70% confluent. The amount of diluted 
virus per ml during the virus incubation.  
 
Cell Culture 
Vessels 
Seeding Density 
Diluted virus in 
Serum Free 
Media 
(ml) 
Growth Medium 
(ml) 
Dishes    
60 mm 8x105 1-1.5 3 
Cluster Plates    
6-well 2X105 0.5-1 2 
12-well 2X105 0.5-1 1-2 
24-well 2X105 0.5 1 
96-well 1X104 0.05 0. 2 
Flasks    
T-25 5.2X106 2.5 5 
T-75 1.5X106 4-5 10 
T-175 3X106 5-7 25 
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2.1.2. FREEZING AND THAWING CELLS 
In order to have a continual supply of cells, cells were frozen in liquid 
nitrogen; 106 cells/per vial were washed three times in ice-cold PBS and 
centrifuged at 1000 x g for 3 min at 4°C. To prevent ice crystal formation, the 
cell pellet was re-suspended in pre-prepared ice cold FBS supplemented with 
10% (v/v) DMSO and 1 ml/vial of cell suspension was transferred to labelled 
cryovials. The cryovial tubes were stored at least 24 hr at -80°C in an 
isopropanol chamber or a rate freezing chamber before being transferred to 
liquid nitrogen storage. Frozen cells were rapidly thawed at 37°C (in 
incubator or water bath) and transferred to a conical tube containing growth 
media and centrifuged at 1000 x g for 3 min at room temperature. The cell 
pellet was washed three times in room temperature with PBS to remove all 
traces of DMSO and was re-suspended in an appropriate volume of complete 
cell culture media and transferred to a 25     flask. Another way to eliminate 
DMSO from frozen cells was to transfer the cells directly to a 25 cm2 flask 
that has culture media with a dilution 1:10. Once cells were 80% confluent, 
cell cultures were expanded and sub-cultured in 75 cm2 flasks. 
 
2.1.3 INHIBITOR STUDY 
2.1.3.1 RIBAVIRIN  
The antiviral ribavirin was obtained from Sigma (R9644). A 1 mM stock was 
pre-prepared in dimethyl sulfoxide (DMSO) and added at either 6 hr or 24 hr 
post-infection. From the stock, aliquots were made (in order to avoid thaw 
and freeze cycles) and stored at -20°C. 
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2.1.3.2 17-AAG & 17-DMAG 
17-N-Allylamino-17-demethoxygeldamycin (17-AAG) was obtained from 
Calbiochem/EMD Millipore (100068) and was diluted in DMSO and a 10 mM 
stock solution was made. 17-Dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG) was obtained from Santa Cruz (CAS 
467214-20-6), diluted in water and a 10 mM stock solution was made. Both 
were aliquoted and stored at -20°C. 
 
2.1.3.3 ETOPOSIDE  
Etoposide was purchased from Sigma (E1383) and dissolved in DMSO. A 1 
M stock solution was made, aliquoted, covered with foil and stored at  -20°C.    
 
2.1.4 MTT ASSAY 
Cell viability was determined by using a colorimetric 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay (MTT) from Sigma (MKBH9792V). 
A549 and HEp-2 cells were seeded in triplicate in 96-well plates at a density 
of 1x    cells/well to ensure 70% confluency 24 hr later. After which, all wells 
were washed twice with 1x phosphate buffered saline (PBS). Ribavirin (or 
other inhibitors e.g. 17-AAG or 17-DMAG) were then added to wells at 
different concentrations (low to high concentration) and incubated for 24 hr at 
37°C. 24 hr later, wells were washed twice with 1x PBS. Then 0.024 g of 
MTT was prepared in 10 ml of media (DMEM plus 10% FBS) and warmed at 
37°C for 15 min. The MTT was dissolved and filtered and 100  l added to 
each well and the plate incubated for 45 min at 37°C. The MTT was then 
Chapter 2: Materials and methods  
43 
 
removed and 100  l of DMSO added and mixed. The optical density was 
measured by spectrophotometer at 570 nm on a Tecan (Infinite® 
F50/Robotic-Absorbance microplate reader). A curve was then created to 
assess cell viability. 
 
2.1.5 HRSV STRAINS 
In this study the HRSV-A2 strain was used and it was kindly provided by Dr 
Patricia Cane and Dr Brian Dove (Public Health England, UK). HRSV-A2 
undergoes productive infection in A549 and HEp-2 cells, and was passaged 
and propagated through the latter. The full-length cDNA sequence of the A2 
strain has been published on GenBank: 
http://www.ncbi.nlm.nih.gov/nuccore/M74568. 
 
2.1.6 VIRUS PROPAGATION: SUPERNATANT  
HRSV was propagated in HEp-2 cells and seeded in four 175 cm2 flasks at a 
density of 3x106 cells/flask, 24 hr prior to infection. HRSV at low MOI (MOI 
0.1) was diluted in 10 ml serum-free media, applied to the cells and 
incubated for 2 hr at 37°C with shaking every 10 min to ensure coverage of 
the whole flask. New culture media (supplemented with 10% [v/v] FBS) was 
added to each flask (20 ml) before further incubation at 37°C. After five days 
post-infection, virus was harvested by cell disruption with autoclaved glass 
beads and the supernatant (80 ml) was collected and clarified by 
centrifugation at 3200 x g for 10 min at 4°C. The supernatant was either 
passed through a 0.45 μm filter, aliquotted, snap-frozen in an ethanol/dry ice 
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bath or liquid nitrogen and stored at -80°C, or additional virus concentrated 
by using a sucrose density gradient. 
 
2.1.7 VIRUS PURIFICATION BY SUCROSE GRADIENT 
Sucrose gradient centrifugation was performed to purify HRSV supernatant in 
order to remove the culture media and the majority of cellular components, 
that can act as contaminants and effect follow on experiments (Wu et al., 
2012). Two sucrose gradients; discontinuous and continuous were prepared 
24 hr prior to use: the discontinuous gradient was prepared by three 
sequential layers of 2.5 ml of 60%, 45% and 30% (w/v) sucrose (dissolved in 
autoclaved NT buffer [50 mM Tris-HCl (pH 7.5), 100 mM MgSO4, 1mM 
EDTA, 150 mM NaCl] and filter sterilised) into each of two, 14x89 mm 
centrifuge tubes (Sefton). Between each layer step, the gradient was frozen 
at -20°C. After adding the final layer the gradient was left overnight at -20°C 
and thawed immediately before use. The continuous gradient was prepared 
by two sequential layers of 3 ml of 60% and 30% sucrose into each of two, 
14x89 mm centrifuge tubes. Also, between each layer step, the sucrose 
gradient was frozen at -20°C. After the application of the final layer, the 
continuous gradient was kept overnight at 4°C to let the layers to disperse 
into one another. Polyethylene glycol (PEG)-6000 powder was dissolved in 
NT buffer to make a 50% (w/v) solution and 20 ml was added to the clarified 
virus suspension to dilute the final PEG concentration to 10%. Virus was 
precipitated for 90 min at 4°C (inside a cold room) with moderate stirring, 
transferred into 50 ml conical tubes and centrifuged at 3200 x g for 10 min at 
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4°C. The pelleted virus was re-suspended in 5 ml of cold NT buffer and 
added equally to the tops of the discontinuous sucrose gradients prior to 
centrifugation at 35,000 rpm for 90 min at 4°C in a TH-641 swinging rotor. 
The middle opalescent band observed at the 30-45% sucrose interface (~2 
ml) gently was removed from each centrifuge tube by using a 5 ml syringe 
and carefully a 25 gauge needle, and diluted with 2 ml of cold NT buffer. 
Diluted virus was added equally to the top of the two continuous sucrose 
gradients tubes before centrifugation at 35,000 rpm for 90 min at 4°C in a 
TH-641 swinging rotor. The white opalescent band observed at ~45% 
sucrose density was carefully removed using a 5 ml syringe and a 25 gauge 
needle (~1.5 ml), mixed gently, aliquoted and snap-frozen in an ethanol-dry 
ice bath for long term storage at -80°C.  If needed, a sample of the undiluted 
middle band from the discontinuous gradient was kept for a concentration 
comparison to the final continuous gradient band by TCID50 or plaque assay. 
Furthermore, the bottom bands observed at the 45-60% interface of the 
discontinuous gradient were extracted for TCID50 or plaque assay 
comparison to the middle band. 
 
2.1.8 HRSV TITRE DETERMINATION 
2.1.8.1 PLAQUE ASSAY 
HRSV titre was calculated for HEp-2 and A549 cells by using an antibody 
based methylcellulose plaque assay procedure based on previous studies 
(McKimm-Breschkin, 2004; Murphy et al., 1990). Before using this technique, 
1.6% (w/v) high viscosity carboxymethyl-cellulose (Sigma [M0555]) was 
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made in ddH2O. In separate bottles ddH2O and the carboxymethyl-cellulose 
powder (plus a stir bar) were autoclaved before adding hot water to the 
powder immediately after autoclaving and allowing the powder to dissolve 
with stirring. Cells were seeded at density 1 x 105 / well in a 24-well plate 24 
hr before infection to achieve 70-80% confluency. 50 μl of HRSV stock (that 
need to titrated) was serial diluted in 450 μl of DMEM ranging from 10-1 to 10-
8 in duplicate for each dilution. Growth culture media was removed and the 
monolayers were washed with sterile 1x PBS before adding 400 μl of each 
virus dilution to the cells. Additionally, in duplicate wells, 400 μl serum- and 
antibiotic-free DMEM was added and acted as a mock-infected control. 24 
well plates were incubated for 2 hr at 37°C with intermittent 10-15 min 
rocking periods to ensure coverage of the entire wells. 2 hr later, the virus 
inoculum was aspirated and the cell monolayer washed with sterile 1x PBS 
three times to ensure that unbound virus was removed. High viscosity 
carboxymethyl-cellulose (1.6%) (already prepared) and DMEM (plus 10% 
FBS and 1% penicillin-streptomycin) were mixed 1:1 and 1 ml of this mixture 
was applied to each well. With a minimal movement, plates were incubated 
at 37°C from 3 to 6 days or until syncytia were observed. The carboxymethyl-
cellulose overlay was aspirated using an aspirator and the wells were 
washed four times with 1x PBS in order to remove the overlay. Cells were 
fixed in 80% (v/v) of cold methanol (already prepared and stored at -20°C) 
and the plates stored at -20°C for 1 hr. Alternative fixative applications were 
used including, 4% (v/v) ice cold formalin fixative was incubated at room 
temperature for 10 min or cold 100% acetone (-20°C storage) for 30 sec. 
Cells were then washed with PBS-0.1% tween (PBST) three times and 200 
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μl in each well of blocking buffer solution (5% [w/v] dried skimmed milk in 
PBS). The plates were incubated with rocking overnight at 4°C or for 1 hr at 
room temperature. Goat anti-HRSV primary antibody (Abcam [ab20745]) was 
diluted 1:200 in blocking buffer (~100 to 200 μl/well) and kept overnight at 
4°C (inside the cold room) on a rocker. To visualized the plaques, a 
horseradish peroxidise (HRP) conjugated anti-goat secondary antibody 
(Abcam [ab6741]) diluted 1:1000 in blocking buffer (~100 to 200 μl/well) was 
applied and incubated overnight at 4°C or 1 hr at room temperature with 
rocking. The secondary antibody was detected using the peroxidise 
substrate, 4-Chloro-1-naphthol (4-CN) (Pierce [Thermo Scientific-34010]) 
prepared in either ethanol or methanol and diluted 1/10 in 10 ml PBS. Before 
using the diluted 4-CN directly, it was supplement with 30% (v/v) hydrogen 
peroxide (H2O2) (10 μl H2O2 /10 ml PBS) and added to the wells. Plates were 
incubated with rocking for 10 min at room temperature or shaking every 2 
min, after which time the grey/purple colour development was detected and 
the reaction was stopped with water. Duplicate wells containing between 10 
and 100 colour stained plaques were only counted and using this formula to 
calculate the titration of virus: 
 
HRSV titre (PFU/ml) was calculated by (number of plaques) / (dilution factor 
x volume of diluted virus added to the well). For making virus stocks, cells 
were infected at MOI 0.1. For all the experiments discussed in Chapter 3, 4 
and 5 (unless otherwise specified) cells were infected with HRSV-A2 at MOI 
0.5.  
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2.1.8.2 TISSUE CULTURE INFECTIOUS DOSE 50 (TCID50) 
HEp-2 cells were trypsinized as explained above and the cell suspensions 
were counted. The density for the TCID50 in 24-well plates was 5 x 10
4 of 
HEp-2 cells per well in 1 ml growth medium in order to achieve a ~80% 
confluence following overnight incubation. Then 900 μl of HEp-2 infection 
medium (2% FBS, 1% PIS) were added to 5 ml tubes, using eight tubes to 
test each viral stock. The virus stocks were quickly thawed in a 37°C water 
bath and put immediately on ice.  100 μl of virus stock were added on the 
first dilution tube and 7-fold serial dilutions were undertaken for each sample 
by sequentially adding 100 μl of virus sample to the 5 ml tubes, vortexing 
before continuing to the next dilution. Therefore, virus stock was diluted to 10-
8 and all dilutions were kept on ice until they were used to infect the cell 
cultures in 6 well plates. However, before infecting the cells, most of the 
medium was removed from wells and the cells were washed twice with 500 
μl of PBS. 200 μl of each sample dilution was added to four wells in the same 
order that were washed in order to avoid the possibility of the well drying out.  
The plates were incubated at 37°C for 1.5 – 2 hr with shaking every 15 min. 
Virus dilution were removed and the cells were washed three time with 1x 
PBS and 1 ml of maintenance medium added and kept all plates at 37°C for 
seven days. In days five and seven post-infection, the plates were tested and 
the number of wells of each dilution which were positive for typical HRSV 
cytopathic effects CPE (syncytia formation) was counted. Virus titres were 
calculated using the method of Kärber algorithm in units noted as (TCID
50
), 
as described below: 
Log10 TCID50 = D + d(S-0.5) 
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Where: 
D, Log10 of the last dilution demonstrating 100 % CPE, i.e., all wells of the 
dilution are positive for viral CPE. d, Log10 of the dilution factor (in this case 
the dilution factor is 10). S, the sum of the fraction of all the wells inoculated 
for each dilution, including and beyond the last dilution with 100 % CPE, that 
are positive for viral CPE (as 4 wells are inoculated, the fraction beyond the 
100 % CPE row will be 0.25, 0.5, 0.75 or 1.0). 
 
The titre was calculated according to the above formula and corresponds to a 
volume of 0.2 ml (the volume added per well). To adjust this titre to log
10
 
TCID
50 per ml, 0.7 was added to the Log10 value calculated. This 
corresponds to log
10 5, with 5 being the multiplication factor necessary to 
adjust 0.2 ml to 1 ml.  To have the titre as PFU/ml, the value needs to 
multiply the TCID50 by 0.7. 
 
2.2 MOLECULAR BIOLOGICAL TECHNIQUES 
2.2.1 RNA EXTRACTION 
Total RNA from HEp-2 cells (different conditions) was extracted using the 
RNeasy Mini Kit (Qiagen) based on the manufacturer’s instructions. The 
reagents were provided by Qiagen and the components of the buffers 
supplied were not disclosed, however, these kit components are marked with 
an asterisk (*) in the text. All centrifugation steps in this technique were done 
at room temperature for 15 sec at 8000 x g (           . Cell pellets 
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(<5x106 cells) were thawed (if they were in -80°C) and re-suspended by 
vortexing in 350 μl RLT buffer* (plus 1.43 mM β-mercaptoethanol [BME]) for 
1 min. 1 volume of 70% ethanol was added to each sample (700 μl in total) 
and mixed by pipetting. The samples were then transferred to an RNeasy 
mini column, placed in a 2 ml collection tube, centrifuged and discard the flow 
through (RLT buffer). Then another centrifugation after 350 μl buffer RW1* 
was added to each column. Following centrifugation, genomic DNA 
contamination was removed by using the RNase-Free DNase Set. Once 
placed in a clean collection tube, master mix pre-prepared depends on 
number of samples (each sample has 10 μl DNase I solution was added to 
70 μl buffer RDD* mixed gently) and the mixture was transferred to the 
column prior to incubation at room temperature for 15 min. After incubation, 
350 μl buffer RW1* was added followed by centrifugation. Once centrifuged 
the flow through (buffer RW1) was discarded before adding 500 μl buffer 
RPE* to each column sample, followed by centrifugation. The last step was 
repeated by thoroughly washing the column, followed by centrifugation for 2 
min, ensuring that no ethanol is carried over for RNA elution. Prior to the 
RNA elution step, a new 1.5 ml collection tube* was used, 30-50 μl RNase-
free water was added and centrifuged for 1 min. If required at a high 
concentration, RNA elution was repeated and followed by centrifugation for 1 
min. The concentration of RNA was then quantified by Qubit®RNA BR Assay 
Kit (from Life technologies). Standards and samples were vortexed for 2-3 
sec and incubated at room temperature for 2 min. The RNA broad range 
assay was selected on Qubit ®fluorometer to calibrate with standards. 
Alternatively, the RNA concentration was determined using a NanoDrop 1000 
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spectrophotometry and the purity was estimated to meet this criteria 
(OD260/280 ~2.0, OD260/230 > 2.0). To ascertain RNA integrity and observe 
and distinguished the 28S and 18S rRNA bands, 0.5 μg RNA was run on a 
1% agarose gel for 45 min at 100V. A good indication of purified total cellular 
RNA is that the 28S rRNA band should be approximately twice as intense as 
the 18S rRNA band (with a ratio of band intensity ~2:1). RNA samples were 
stored at -80°C. 
 
2.2.2 FIRST-STRAND CDNA SYNTHESIS AND REVERSE TRANSCRIPTION 
cDNA was synthesised from 1 μg of total RNA using the ThermoScript RT-
PCR System (Invitrogen) according to the manufacturer’s instructions: using 
an RNase-free 0.2 or 0.5 ml tube, 1 μg of total RNA, 500 ng oligo (dT)20 and 
2 μl of 10 mM deoxyribonucleotide triphosphate dNTP were mixed and 
DEPC-treated water or RNase-free diH2O were used to adjust the final 
volume to 12 μl.  RNA and primer was denatured by incubating at 65°C for 5 
min and placed on ice for 1 min. Following incubation, a master reaction mix 
was prepared on ice (depending on the number of samples) from 4 μl 5X 
cDNA Synthesis Buffer, 1 μl 0.1 M DTT and 1 μl RNaseOUT (40 units/μl), 1 
μl DEPC-treated water and 1 μl ThermoScript RT (15 U/μl) and added into 
each reaction tube on ice. Then this was incubated at 50°C for 1 hr. To 
terminate the reaction, samples were incubated at 85°C for 5 min and 1 μl of 
RNase H was added. This was incubated at 37°C for 20 min. Following 
incubation, 20 μl of cDNA product was diluted in 80 μl of nuclease-free water 
to produce 100 μl in total. Successful reverse transcription was confirmed by 
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PCR amplifying the HRSV G gene (923 bp) and a human GAPDH gene 
fragment (240 bp). 
  
2.2.3 OLIGONUCLEOTIDES 
All of the DNA primers in Table 2.2 were designed and purchased from MWG 
Biotech (Germany) with HPLC purification, whereas, the human GAPDH 
gene primers were purchased from Enzo Life Sciences. The lyophilised 
primers were resuspended in nuclease-free water to a final concentration of 
100 μM (stock solution) and aliquoted and further diluted to 10 μM (working 
solution) and all of them were stored at -20°C. 
 
Table 2.2  Primers used for PCR and qRT-PCR 
Oligo Name Sequence (5’  3’) 
HRSV-A2 G-fwd 
CTCGAGCCATGTCCAAAAACAAGGACC 
HRSV-A2 G-rev 
GGATCCCTACTGGCGTGGTGTGTTGGG 
HRSV-A2 G-fwd 
ATGTCCAAA AACAAG GACCAACG 
HRSV-A2 G-rev 
CTACTGGCGTGGTGTGTTGGGTG 
HRSV-A2 NS1-fwd 
TTGGCTAAGGCAGTGATA 
HRSV-A2 NS1-rev 
AGGTTGAGAGCAATGTGT 
HRSV-A2 NS2-fwd 
CCCTCGAGATGGACACAACCCACAATGATAATA 
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HRSV-A2 NS2-rev 
CCGGATCCCGTGGATTGAGATCATACTTGTAT 
ATTATG 
HRSV A2 N-fwd 
CTCGAGCCATGGCTCTTAGCAAAGTCAAG 
HRSV-A2 N-rev 
GGATCCTCAAAGCTCTACATCATTATC 
HRSV-A2 P-fwd 
CTCGAGCCATGGAAAAGTTTGCTCCTG 
HRSV-A2 P-rev 
GGATCCTCAGAAATCTTCAAGTGATG 
HRSV-A2 M-fwd 
CTCGAGCCATGGAAACATACGTGAACAAG 
HRSV-A2 M-rev 
GGATCCATCTTCCATGGGTTTGATTGC 
HRSV-A2 F-fwd 
CTCGAGCCATGGAGTTGCTAATCCTCAAAG 
HRSV-A2 F-rev 
GGATCCTTAGTTACTAAATGGAATATTATTTAT 
HRSV-A2 SH-fwd 
CTCGAGCCATGGAAAATACATCCATAAC 
HRSV-A2 SH-rev 
GGATCCCTATGTGTTGACTCGAGCTC 
HRSV-A2 M21-fwd 
CTCGAGCCAGTGGAGCTGCAGAGTTGGAC 
HRSV-A2 M21-rev 
GGATCCTCAGGTAGTATCATTATTTTTG 
HRSV-A2 L- fwd 
CTCGAGCCATGACCATGCCAAAAATAATG 
HRSV-A2 L-rev 
GGATCCTTATGACACTAATATATATATTG 
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2.2.4 MEASUREMENT OF DNA CONCENTRAION 
The concentration of DNA were measured using a Qubit® dsDNA BR Assay 
Kit (Life technologies). Standards and samples were vortexed for 2-3 sec and 
incubated at room temperature for 2 min. A DNA broad range assay was 
selected on Qubit ®fluorometer to calibrate with standards. Alternatively the 
DNA concentration was determined using a NanoDrop, and the purity was 
estimated to meet this criteria (OD260/280 ~1.8, OD260/230   2.0).  
 
2.2.5 POLYMERASE CHAIN REACHTION (PCR) FOR HRSV-G AND GAPDH 
DETECTION 
PCR (referred to general PCR not ‘qRT-PCR’ which is described below) was 
used to detect HRSV infection by amplifying the HRSV G gene. PCR was 
performed in thin-walled 0.2 ml PCR tubes and reaction volumes of 25 μl 
typically comprised the following; 2.5 μl of 10X PCR buffer minus Mg, 1 of 
10mM (dNTP) mix (Invitrogen [18427013]), 0.5 μl of 10 μM of appropriate 
forward and reverse primers, 1 μl of template cDNA (created as described in 
section 2.2.2), 0.5 μl unit of Taq DNA polymerase and DEPC-treated water 
bringing 25 μl in total. PCR cycling was carried out in a thermocycler (Primus, 
MWG Biotech) typically using the conditions shown in Table 2.3. PCR 
products (5 μl) then were analysed by agarose gel electrophoresis as 
described in section 2.2.7. 
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Table 2.3. PCR conditions used for detection of HRSV genes 
No. of cycles Duration Temperature 
1 2 min 94°C 
 
30 
30 sec 94°C 
30 sec 60°C (55°C GAPDH)  
1.5 min (30 sec 
GAPDH) 
72°C 
1 2 min 72°C 
 
2.2.6 QUANTITATIVE REAL-TIME RT-PCR 
Following confirmation of successful RT via PCR reactions with primers of 
human GAPDH or HRSV G gene from a 100 μl of cDNA that made according 
to section 2.2.2. Using iTaq TM Universal SYBR® Green Supermix (BIO-RAD), 
a PCR master mix was made up with each primer set for each reaction 
according to the manufacture’s instructions; for each reaction, 1 μl of diluted 
cDNA and 10 μl iTaq TM Universal SYBR® Green Supermix mixed with 1 l of 
the appropriate primer pairs (0.5 μl of each forward primer and reverse 
primer) and made up the final reaction volume to 20 μl with nuclease-free 
water. The mixture was equally loaded into each well (20 μl /well) of the 96-
well array plate. Quantitative Real-Time PCR (qRT_PCR) arrays were 
performed on DNA Engine Opticon 2 Real-Time Cycler (BioRad) with the 
following program settings (Table 2.4). The data results from three 
independent experiments were averaged and normalized using a human 
GAPDH gene as control.  
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Table 2.4 qPCR program setting using DNA Engine Opticon 2 Real-Time 
Cycler 
No. of cycles Duration Temperature 
1 10 min 95°C 
 
40 
15 sec 95°C 
30 sec 55°C  
30 sec  72°C 
1 Melt Curve (Default Setting) 
   
2.2.7 AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis with ethidium bromide (EtBr) staining was used 
to visualize DNA or RNA, digestion analysis and purification. Electrophoresis 
grade agarose (AGTC Bioproducts) (1% [w/v]) was melted in 1X TAE buffer 
(40 mM Tris-acetate, 1 mM EDTA, pH 8.0) or 1x TBE (89 mM Tris-borate, 0.5 
M EDTA, pH 8.0) by heating, and EtBr was added to molten agarose to a 
final concentration of 0.5 μg/ml. Molten agarose was then added into a gel-
casting tray containing an appropriate comb, and allowed to set. Once the gel 
had set the tray was transferred to a gel running tank and submerged with 
sufficient 1X TAE or 1x TBE buffer. An appropriate volume of DNA was 
diluted in 5x DNA loading buffer (Bioline) and 5 μl of Hyperladder I DNA 
ladder (Bioline) were loaded in the wells of gel. The electrophoresis was then 
run until the indicator dye migrated to about the three quarters length of the 
gel.  
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2.2.8 PURIFICATION OF DNA FROM GEL 
The bands were separated on a 2% agarose gel corresponding to correct 
DNA fragments were excised by visualization with a UV transilluminator. 
Purification of DNA from agarose gel was performed using the QIAquick® Gel 
Extraction Kit (Qiagen) according to the manufacture’s instruction. All 
centrifugation steps in this technique were done at room temperature for 1 
min at 17,900 x g (           . The DNA fragments were excised from the 
agarose gel with a clean and sharp scalpel. DNA gel slices were weighed in 
a 1.5 ml (Eppendorf tubes) and 3 volumes buffer QG were added to 1 volume 
gel. Tubes were incubated at 50°C until the gel slice had completely 
dissolved with vortex steps every 2-3 min to help dissolve gels. Once the gel 
slices had dissolved, the colour of the mixture was checked and compared to 
Buffer QG. If the colour was not yellow, 10 μl of 3 M sodium acetate were 
added and mixture turned yellow. One gel volume of isopropanol 100% was 
added to the samples and mixed. The mixtures were transferred in a 
QIAquick spin column and centrifuged. After centrifugation, the flow through 
was discarded before 0.5 ml of buffer QG was added and centrifuge. 
Following centrifugation, the flow through was discarded; 0.75 ml Buffer PE 
(prepared in 100% of ethanol) was added and centrifuged. A new 1.5 ml 
tubes were placed after centrifugation, purified DNA was eluted in 30-50 μl of 
buffer EB or free water and centrifuged. The concentration of DNA was then 
determined according to section 2.2.4.  
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2.2.9 TOTAL RNA-SEQ 
After assessing the quality extracted total RNA from the RNA integrity 
number RIN values, the samples were subjected to poly A selection using the 
Dynabead mRNA purification kit (Life Technologies). In this case, 15 μl of 
beads per sample were washed with binding buffer (2X) and re-suspended in 
30 μl of 2x bead buffer. RNA samples were made up to 30 μl and heated to 
65°C for 5 min to remove any secondary structure. Samples were then mixed 
with the beads on a rotator for 5 min at room temperature. After collecting the 
beads on a Magnetic Particle Concentrator (MPC), the beads were washed 
2x with wash buffer, removing all traces after each washing step. 12 μl of 
water was added to the beads for elution, which was achieved by heating at 
70 degrees for 2 min and immediately placing on the MPC to retrieve the 
supernatant containing the RNA. This was assessed for rRNA on a RNA pico 
chip.  The twice poly A-selected material was all used as input for Scriptseq 
(Epicentre). Samples were treated as the protocol indicated. Samples were 
mixed with primer and fragmentation buffer, and heated at 85°C for 5 min 
and placed on ice. Samples were converted to cDNA and purified with 
Ampure XP. Samples were mixed with barcoded primers and amplified with 
15 cycles PCR. The libraries were purified with Ampure XP and assessed by 
bioanalyser using HS DNA kit and the quantity was determined by Qubit DNA 
HS kit. Samples were pooled on an equimolar basis for a single lane. 
 
The quantity and quality of the final pool were assessed using Qubit 
(Invitrogen) and Bioanalyzer (Agilent) and subsequently qPCR using the 
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Illumina Library Quantification Kit from Kapa on a Roche Light Cycler LC480II 
according to manufacturer's instructions. The template DNA was denatured 
according to the protocol described in the Illumina cBot User guide and 
loaded at 9 pM concentration. To improve sequencing quality control, 1% 
PhiX was spiked-in. The sequencing was carried out on one lane of an 
Illumina HiSeq 2500 with version 3 chemistry generating 2 × 100 bp paired 
end reads.  For each time point, the sequence reads were mapped to the 
HRSV A2 genome using Bowtie2. For each alignment to the HRSV genome, 
the output BAM files were further analysed using QuasiRecomb. Where 
Bowtie2 aligned more than 1 million reads to the HRSV genome, 1 million 
alignments were selected at random. The coverage option for QuasiRecomb 
was used (command line: java -XX:NewRatio=9 -Xms2G -Xmx10G -jar 
QuasiRecomb.jar –i reads.sam -coverage) and then parsed the output files 
with in house software written in PERL that determined the most abundant 
nucleotide for each position (i.e. the consensus nucleotide) and reported the 
frequency of use for the other three nucleotides. The RNA-seq was carried 
out by the Centre for Genomic Research CGR, University of Liverpool.   
 
2.3 PROTEIN METHODS 
2.3.1 PREPARATION OF WHOLE CELL LYSATES 
For different applications; Coomassie stain, silver-stain or western blot 
analysis of whole cell lysate, RIPA buffer (50 mM Tris, [pH 7.5], 150 mM 
NaCl, 1% (v/v) NP40 alternative, 0.5% (w/v) sodium deoxycholate, 0.1% 
sodium dodecyl-sulphate [SDS], supplemented with 1 EDTA-free complete 
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protease inhibitor mixture [Roche Applied Science] per 50 ml buffer) was 
applied directly to the washed cell monolayer and incubated for 20 min at 
4°C before cell scraping. Alternatively, cell pellets were re-suspended in 
RIPA buffer and incubated for 30 min at 4°C. Both procedures of lysis were 
followed by 3 min incubation in a sonicating water bath at 4°C to complete 
lysis. The whole cell lysate was centrifugated at 13,000 x g for 20 min at 4°C, 
the supernatant containing total protein was collected and stored at -80°C. 
 
2.3.2 DETERMINING PROTEIN CONCENTRATION BY BCA ASSAY 
DETERMINING PROTEIN CONCENTRATION BY BCA ASSAY 
The whole cell lysates were obtained as explained above (section 2.3.1) and 
total protein concentrations were determined using the Micro BCA 
(bicinchoninic acid) protein assay system (Pierce [23227]) according to the 
manufacture’s 96-well plate instructions. Bovine serum albumin (BSA) 
standards were used in order to create a standard curve. Protein lysates 
were first diluted in either distal water or their respective buffer to give a 100 
μl volume. Whole cell lysate was diluted 1/20. In duplicate or triplicate, 10 μl 
of each sample and standard were then mixed with 200 μl assay standard 
reagent (prepared by diluting reagent B 1:50 into reagent A) and transferred 
to a 96 well plate (200 μl / well) and incubated at 37°C for 30 min. 
Absorbance was then measured at 570 nm on a Tecan microplate reader 
(Infinite F50/Robotic-Absorbance). The mean was calculated and a standard 
curve was created using the BCA standards to which the test samples could 
be compared. The protein concentration was determined at the same time as 
taking the dilution factor into account. 
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2.3.3. SODIUM-DODECYL SULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) 
Protein samples (size 5-10 μg) were resolved using a Bio-Rad Mini-Protein 
system and appropriate concentration of SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) was made. Resolving (7.5%, 10% or 12%) and 
stacking gel (5%) were made as described in (Table 2.5). The resolving gel 
solution was placed between two clean glass plates and a small volume of 
distilled water or water -saturated butanol was added to provide a smooth gel 
interface. After the resolving gel was set and the water removed, the stacking 
gel solution was added on top of the resolving gel and a comb was added. 
Following stacking gel polymerisation the comb was removed, the glass plate 
and wells were placed inside the tank with 1x SDS-PAGE running buffer (25 
mM Tris-HCl [pH 8.3], 250 mM glycine, 0.1 % [w/v] SDS). Protein samples 
were then prepared using 4x LDS sample buffer (Invitrogen) and 
supplemented with 50 mM DTT reducing agent and denatured at 80°C for 10 
min (when using 5x LDS no DTT was added and the denaturation 
temperature was 95°C and incubated for 10 min). 5 μl SeeBlue plus 2 pre-
stained standard (Invitrogen: 250-4 kDa [LC5925]) or ColorPlus prestained 
protein ladder (NEB: 11-245 kDa [P7712S]) was loaded as a reference for a 
molecular weight ladder. The SDS-PAGE gel was run at 15V/cm in 1x SDS-
PAGE running buffer and the gel run at 100-150V, the current 200-400mA for 
~30-45 min) until the optimum separation of marker proteins was achieved. 
Gels were analyzed by staining with coomassie blue or continued to western 
blot analysis. 
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Table 2.5. SDS-PAGE resolving and stacking gel reagents with different 
concentrations. The acrylamide materials were used to cast 2 mini-gels for 
the Bio-Rad Mini-Protein II system, and the volume doubled if a 26 thick gel 
casting set was used. 
Resolving Gel (10 ml) Stacking Gel (5 ml) 
% Gel 15% 12% 10% 7.5% % Gel 5% 
30% 
Acrylamide  
5 ml 4 ml 3.3 ml 2.5 30 % 
Acrylamide  
830 μl  
1.5M Tris-HCl 
pH8.8 
2.5 ml 1M Tris-HCl 
pH6.8 
630 μl 
H2O 2.3 
ml 
3.3 ml 4 ml 4.8 ml H2O 3.4 ml 
10% (w/v) 
SDS 
100 μl 10% (w/v) SDS 50 μl 
10% (w/v) 
APS 
100 μl 10% (w/v) APS 50 μl 
TEMED 10 μl TEMED 5 μl 
Resolution 
(Protein kDa) 
10-40 20-100 30-100 25-
200 
 
 
2.3.4.WESTERN IMMUNOBLOT 
Once SDS-PAGE was completed, poly-vinylidine fluoride (PVDF) 
membranes (Millipore [IPVH00010]) were kept in 100% methanol for 30 sec 
and placed on the bottom of the gel using Towbin transfer buffer (25 mM 
Tris-HCl [pH8.3], 192 mM glycine, 20% [v/v] methanol). Also, two thick pieces 
of filter paper were soaked in the transfer buffer and placed with this order 
(from bottom to the top); one of filter paper was placed on the surface of a 
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Bio-Rad semi-dry transfer instrument, the soaked PVDF membrane, the 
complete gel, finally, the second piece of soaked filter paper was placed on 
top of the gel. Transfers were carried out according to the manufacturer’s 
instructions, at 15 V for 1.5 hr. After the transfer, the membranes were 
blocked in 5%-10% (w/v) fat free skimmed milk powder (Sigma) dissolved in 
Tris-buffered saline (50 mM Tris-HCl [pH 8.3], 150 mM NaCl) containing 
0.5% (v/v) Tween-20 (TBST) at room temperature on a rocker for 1 hr at 4°C 
(cold room) overnight. Blocking buffer was then discarded and membranes 
were washed three times in TBST. Primary antibodies (listed in Table 2.6) 
were diluted in blocking buffer and 4-8 ml applied for either overnight at 4°C 
(cold room) or 1 hr at room temperature on rocker.  Unbound antibody was 
then washed from PVDF membranes by three washes in 1X TBST for 5 min 
for each wash. The primary antibodies were detected with the horse radish 
peroxidase HRP-conjugated secondary antibodies listed in (Table 2.7) which 
were diluted in blocking buffer and 4-8 ml added onto the membranes for 1 hr 
at room temperature with rocking. Unbound antibody was removed with three 
washes in 1X TBST for 5 min of each wash. The target protein(s) bound to 
antibodies were visualised by using either enhanced chemiluminescence 
(ECL) or SuperSignal West Femto Substrate (Thermo Scientific). The blots 
were reused by striping and restoring a maximum of three times using a blot 
restore membrane rejuvenation kit (Millipore [2520]) according to the 
manufacturer’s instructions. 
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2.4 IMMUNOFLUORESCENCE-BASED TECHNIQUES 
2.4.1 CELL FIXATION 
Prior to fixation, cells grown on coverslips were washed three times with PBS 
to remove traces of growth media and fixed using either 4% (V/V) 
paraformaldehyde [37% of formaldehyde stock solution [BDH Chemicals] 
diluted in 1x PBS) and incubated for 10 min at room temperature or 100% 
cold acetone (stored in -20°C before used) and incubated for 20 min at 4°C. 
The fixation solution was removed and the monolayer was washed three 
times with PBS. PBS containing 0.1% (v/v) sodium azide could be used for 
fixed coverslip-adhered monolayers as long-term storage at 4°C.  
 
2.4.2 CELL PERMEABILISATION AND IMMUNOFLUORESCENCE STAINING 
Following fixation, cells were permeabilised in order to take the antibodies 
into cells using 0.1% (v/v) Triton X-100 made up in PBS for 10 min at room 
temperature. The permeabilisation buffer was then removed and the 
monolayer was washed three times with PBS. Primary antibodies diluted in 
PBS containing 2% (v/v) FBS (Table 2.6), 50-100 μl were added onto 
coverslips and incubated either 1 hr at room temperature or overnight at 4°C 
(cold room). Unbound primary antibody was washed off using three rinses in 
PBS-0.5% Tween-20 (PBST) for 5 min per wash on a rocker. The 
fluorescently-conjugated secondary antibody (Table 2.8) was diluted in PBS 
containing 2% FBS and incubated in the dark either 1 h at room temperature 
or overnight at 4°C. Coverslips were washed three times in PBST to remove 
the unbound secondary antibody. 
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2.4.3 MOUNTING OF FIXED CELLS SAMPLES 
Coverslips were removed from dishes by clean forceps, inverted and placed 
on glass microscope slides spotted with Prolong Gold mounting media either 
contain DAPI (Invitrogen) counter stain to allow visualisation of cell nuclei or 
not and incubated overnight in the dark at room temperature. Mounted 
coverslips were sealed with clear nail varnish and stored at 4°C with 
protection from light. 
 
2.4.4 MICROSCOPY 
Immunofluorescence images were captured on an Axio imager M2 
microscope (Carl Zeiss). 
 
2.5 MASS SPECTROMETRY 
2.5.1 PREPARATION OF WHOLE CELL LYSATE FOR LABEL FREE QUANTITATIVE 
PROTEOMICS 
HEp-2 cells at 70% confluency were infected with HRSV A2 at a MOI of 0.5 
while uninfected cells were used as controls (mock). At 6 hr post-infection 
uninfected and infected cells were treated with Ribavirin (RBV), the (DMSO) 
or left untreated. At 24 hr post-infection, cells that were uninfected-untreated 
(mock), uninfected-treated (DMSO or RBV), infected-untreated (HRSV) and 
infected-treated (HRSV + DMSO or HRSV + RBV) were harvested in 
triplicates and re-suspended in an equal volume of 0.1% RapiGest diluted in 
fresh 25 mM ammonium bicarbonate (pH 7.8). Three freeze-thaw cycles (10 
sec in liquid nitrogen), including 5 min vortexing between each cycle were 
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carried out followed by two cycles of 15 min sonication to allow for maximum 
solubilization efficiency. Samples were then heated at 80  for 10 min before 
the soluble fraction was transferred to low adhesion micro-centrifuge 
(Eppendorf) tubes. Finally, total protein concentration was measured by BCA 
assay (Pierce). 
 
2.5.2 SAMPLE PREPARATION FOR PROTEOMICS 
Sample protein content and volume was normalised with 25 mM ammonium 
bicarbonate. Samples were then heated at 80⁰C for 10 minutes, reduced with 
3 mM dithiothreitol (Sigma) at 60⁰C for 10 minutes then alkylated with 9 mM 
iodoacetimde (Sigma) at room temperature for 30 min in the dark. Proteomic 
grade trypsin (Sigma) was added at a protein: trypsin ratio of 50:1 and 
samples incubated at 37⁰C for 12 hr. Rapigest (Waters) was removed by 
adding TFA to a final concentration of 1% (v/v) and incubating at 37⁰C for 2 
hr. Peptide samples were centrifuged at 12,000 g for 60 min (at 4⁰C) to 
remove the precipitated Rapigest.  
 
2.5.3 NANOLC MS ESI MS/MS ANALYSIS 
Peptide mixtures (2 µl) were analyzed by on-line nanoflow liquid 
chromatography (LC) using the nanoACQUITY-nLC system (Waters MS 
technologies, Manchester, UK) coupled to an LTQ-Orbitrap Velos 
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(ThermoFisher Scientific, Bremen, Germany) mass spectrometer equipped 
with the manufacturer’s nanospray ion source. The analytical column 
(nanoACQUITY UPLCTM BEH130 C18 15 cm x 75 µm, 1.7 µm capillary 
column) was maintained at 35⁰C and a flow-rate of 300 nl/min. The gradient 
consisted of 3-40% acetonitrile in 0.1% formic acid for 150 min then a ramp 
of 40-85% acetonitrile in 0.1% formic acid for 5 min. Full scan MS spectra 
(m/z range 300-2000) were acquired by the Orbitrap at a resolution of 
30,000. Analysis was performed in data dependant mode. The top 20 most 
intense ions from MS1 scan (full MS) were selected for tandem MS by 
collision induced dissociation (CID) and all product spectra were acquired in 
the LTQ ion trap.  
 
Thermo RAW files were imported into Progenesis LC–MS (version 4.1, 
Nonlinear Dynamics). Runs were time aligned using default settings and 
using an auto selected run as reference. Peaks were picked by the software 
and filtered to include only peaks with a charge state of between +2 and +6. 
Peptide intensities were normalised against the reference run by Progenesis 
LC-MS and these intensities are used to highlight differences in protein 
expression between control and treated samples with supporting statistical 
analysis (ANOVA p-values) calculated by the Progenesis LC-MS software. 
Spectral data were transformed to .mgf files with Progenesis LC–MS and 
exported for peptide identification using the Mascot (version 2.3.02, Matrix 
Science) search engine. Tandem MS data were searched against the human 
(20,253 sequences; 11,332,942 residues) and human respiratory syncytial 
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virus HRSV A (strain A2) predicted proteomes (Uniprot release 2013_04). 
Mascot search parameters were as follows; precursor mass tolerance set to 
10ppm and fragment mass tolerance set to 0.5 Da. One missed tryptic 
cleavage was permitted. Carbamidomethylation (cysteine) was set as a fixed 
modification and oxidation (methionine) set as a variable modification. 
Mascot search results were further processed using the machine learning 
algorithm Percolator. The false discovery rate was < 1%. Individual ion 
scores > 13 indicated identity or extensive homology (p < 0.05).  Protein 
identification results were imported into Progenesis LC–MS as .xml files. 
 
2.6 DATA PROCESS 
2.6.1 STATISTICAL ANALYSIS 
Prism 5 was used to compare two independent dataset of different time 
points with different conditions for growth curves. Student’s t-test was used to 
analysis the cell viability with different concentrations of ribavirin. Statistical 
analysis of three datasets of data (MOCK, DMSO, RBV, HRSV, HRSV plus 
DMSO and HRSV plus RBV) when harvesting in two different time points 
were performed using the (ANOVA p-values) test. For all tests, a p-
value<0.05 was considered statistically significant.  
 
2.6.2 BIOINFORMATICS ANALYSIS USING STRING AND INGENUITY PATHWAY 
ANALYSIS (IPA) 
The String 9.05 programme was used to identify protein-protein interaction 
networks and the pathways, however, only proteins were uploaded which 
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were identified and quantified with two or more peptides and a cut-off   2 
fold change. Also, data were analyzed by the use of Ingenuity Pathway 
Analysis software (Ingenuity® Systems, www.ingenuity.com). Networks were 
generated using data sets containing gene identifiers and corresponding 
expression values, which were uploaded into the application. Each gene 
identifier was mapped to its corresponding gene object in the Ingenuity 
Pathways Knowledge Base. A cut-off of  2.0 or greater was set to identify 
the genes whose expression in abundance may have different functional 
relevance. These genes, named focus genes, were overlaid onto a global 
molecular network developed from information contained in the Ingenuity 
Pathways Knowledge Base. Focus genes networks were then algorithmically 
generated based on their connectivity. Graphical representations of the 
molecular relationships between genes/gene products were generated. 
Genes or gene products are represented as nodes, and the biological 
relationship between two nodes is represented as an edge (line). All edges 
are supported by at least one published reference from the literature, from a 
textbook, or from canonical information stored in the Ingenuity Pathways 
Knowledge Base. Human, mouse, and rat orthologs of a gene are stored as 
separate objects in the Ingenuity Pathways Knowledge Base but are 
represented as a single node in the network. The intensity of the node color 
indicates the relative change in expression level; the increased (red) or 
decreased (green) abundance, whereas, grey nodes represent no change in 
abundance. Nodes are displayed using numerous shapes that represent the 
functional class of the gene product. Canonical pathway analysis utilizes well 
characterized metabolic and cell signaling pathways which are generated 
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prior to data input and on which identified proteins are overlaid. From various 
datasets, some of interesting cellular proteins and genes, that identified and 
quantified by mass spectrometry and RNA-seq, were searched in Uniprot 
identification database (http://www.uniprot.org) in order to ascertain their 
functions and gain further information. Some analysis on RNA-seq and label 
free proteomics has already been described above in Sections, 2.2.9 and 
2.5.3, respectively.     
  
2.7 LIST OF ANTIBODIES 
2.7.1 PRIMARY ANTIBODIES 
Table 2.6 Primary antibodies used in this study for western blot and/or 
immunofluorescence staining. 
Target 
antigen 
Vendor Product 
No. 
Species WB 
dilution 
IF dilution 
HRSV Abcam Ab20745 Goat 
polyclonal 
1:1000 1:50 
GAPDH Abcam Ab8245 Mouse 
Monoclonal 
1:5000 NA 
OAS3 Santa 
Cruz 
Sc-99100 NA 1:200-
1:1000 
1:50 
ISG15 Santa 
Cruz 
Sc-50366 NA 1:200-
1:1000 
1:50 
HRSV 
FITC 
Abcam Ab20391 Goat 
ployclonal 
NA 1:50 
FBL Abcam Ab153862 Rabbit 
polyclonal 
NA NA 
UTP14A Abcam Ab138278 Rabbit NA  NA 
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polyclonal 
RRM2 Abcam Ab154964 Rabbit 
ployclonal 
NA NA 
TRIM25 Abcam Ab167154 Rabbit 
monoclonal 
NA NA 
Stat1 Santa 
Cruz 
Sc-346 NA NA NA 
SOD2 Abcam Ab13533 NA 1:5000 NA 
Actin Abcam Ab3280 NA 1:1000 NA 
VDAC2 Abcam Ab77160 NA NA NA 
Cdc2 Abcam Ab18 Mouse 
monoclonal 
1:1000 1:50 
 
2.7.2 SECONDARY ANTIBODIES FOR WESTERN BLOT 
Table 2.7 Secondary HRP-conjugated antibodies used for western blot were 
diluted at 1:2500 in 5% milk TBST. 
Target 
antigen 
Vendor Product No. Species 
Rabbit Sigma A6154 Goat  
Goat Abcam Ab6741 Rabbit 
Mouse Sigma A4116 Goat 
Rat Sigma A5795 Rabbit 
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2.7.3 SECONDARY ANTIBODIES FOR IMMUNOFLUORESCENCE 
Table 2.8 Secondary fluorochrome-conjugated antibodies used for 
immunofluorescence were diluted at 1:200 in 1x PBS. 
Target 
antigen 
Vendor Fluorophore Product No  Species 
Goat Abcam FITC Ab6881 Donkey 
Mouse Invitrogen Alexa Fluor 
568 
A10037 Donkey 
Rabbit Invitrogen Alexa Fluor 
546 
A10040 Donkey 
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CHAPTER 3: OPTIMISING THE APPLICATION OF RIBAVIRIN 
AND VIRAL INFECTION 
3.1 INTRODUCTION 
Acute infection with HRSV is treated therapeutically with ribavirin, i.e. the 
drug is applied post-infection (Shah et al., 2010; Zhang et al., 2003).  In order 
to characterize the effect of ribavirin on the host cell, and dissect the potential 
anti-viral activity, in more detail, a high-resolution approach was used to 
elucidate the interaction between ribavirin, the host cell and HRSV in a cell 
culture system. Two independent but over lapping methods, RNA-seq and 
quantitative label free proteomics, were used to assess whether both cellular 
and viral gene expression were changed in the presence of ribavirin in 
uninfected and HRSV-infected cells. RNA-seq was used to quantify changes 
in the abundance of cellular and viral transcripts, and to evaluate whether the 
mutational frequency during HRSV RNA synthesis was increased. 
Quantitative label free proteomics was used to quantify changes in the 
abundance of cellular and viral proteins. Both approaches had the potential 
to identify the same gene product to study regulation and generally 
transcriptomic approaches provide the greater coverage, and thus if the 
proteomic approach did not identify or quantify a gene product, then RNA-
seq may have done. However, before these approaches were used, the 
optimal experimental conditions were defined including; the concentration of 
ribavirin, MOI and the time points to be assayed post-infection. This has to be 
balanced with maximising data output with a realistic cost of the proteomics 
and transcriptomic assays. 
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The objective of the current study was to establish appropriate experimental 
and assay conditions to study the effect of ribavirin in the following chapters. 
HEp-2 and A549 cell lines, derived from human lung carcinomas, were used 
in this study. Both cell lines are permissive for HRSV (Hughes et al., 1988; 
Xatzipsalti & Papadopoulos, 2007) and have been used extensively in the 
study of this virus and other respiratory pathogens using high-resolution 
approaches (Coombs et al., 2010; Dove et al., 2012; Evans et al., 2012; Lam 
et al., 2010; Munday et al., 2010a; van Diepen et al., 2010). In general, the 
HEp-2 cells line was used in this analysis to study the effect of ribavirin and 
in some cases the A549 cell line was used to validate the results and 
investigate whether data was cell line specific. It is worth noting that 
previously, the A549 cell line, was reported to show some resistances to 
ribavirin (Morfin et al., 2005). For this reason the HEp-2 cell line was used 
predominately in this study.   
 
The A2 strain of HRSV was used as researchers in the laboratory had 
previously characterised the biology of this virus in cell culture using 
proteomics and other assays (Munday et al., 2010a; Wu et al., 2011) and 
therefore would provide a basis of comparison to historical data sets, and 
validate the approaches used in this thesis. It is important to study the 
viability of the cells in the presence of any compound without the virus 
(Mosmann, 1983) as many inhibitors can also be toxic to the cell at certain 
concentrations. In order to assess cell viability; different concentrations of the 
drug can be added in a dose dependent manner. Previous studies have also 
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investigated optimising the addition of ribavirin in cell culture to disrupt virus 
replication and these can be used as a starting point (Hruska et al., 1980; 
Shah et al., 2010). The data in this chapter defining the affect of ribavirin on 
cell viability and optimisation of HRSV were used as a starting point for the 
high-resolution approaches described in subsequent chapters.  
 
Some of the work described in this chapter has recently been published in 
the Journal of Virology.  Waleed Aljabr, Olivier Touzelet, Georgios Pollakis, 
Weining Wu, Diane C. Munday, Margaret Hughes, Christiane Hertz-Fowler, 
John Kenny, Rachel Fearns, John N. Barr, David A. Matthews and Julian A. 
Hiscox, (2015). Investigating the influence of ribavirin on human respiratory 
syncytial virus RNA synthesis using a high-resolution RNA-seq approach 
10.1128/JVI.02349-15. (See appendix). 
 
The candidate confirms that the work submitted is his own, except where 
work which has formed part of jointly-authored publications has been 
included. The contribution of the candidate and the other authors to this work 
has been explicitly indicated below. The candidate confirms that appropriate 
credit has been given within the thesis where reference has been made to 
the work of others. 
 
Chapter 3 of this thesis was based on the work from jointly-authored 
publication: 
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 Waleed Aljabr planned and performed all experiments, prepared 
samples for RNA-seq, western blot, immunofluorescence, data 
analyses, and jointly wrote the manuscript. 
 Rachel Fearns and John Barr provided advice regarding manuscript 
structure. 
 Oliver Touzelet, Weining Wu and Diane Munday provided technical 
support. 
 Georgios Pollakis provided minor variant analysis. 
 John Kenny, Margaret Hughes and Christiane Hertz-Fowler run RNA-
seq. 
 David Matthews provided viral transcriptomic analysis. 
 Julian Hiscox provided supervision and jointly wrote the manuscript. 
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3.2. RESULTS 
3.2.1 DETERMINING THE CELL VIABILITY IN THE PRESENCE OF RIBAVIRIN 
To establish an optimal therapeutic regime for ribavirin in cell culture, the 
toxicity of ribavirin was first established in HEp-2 cells (Figure 3.1). An MTT 
assay was used to determine the proportion of viable cells in the presence of 
different concentrations of ribavirin, ranging from 100 μM to 30 mM, based on 
an analysis of published concentrations of ribavirin used in vitro (Player et al., 
1998; Shah et al., 2010; Zhang et al., 2003). Untreated cells were used to 
measure the total viable cell population and this was fixed at 100%, for 
comparison of the ribavirin treatments. Etoposide, which promotes apoptosis, 
was used as a positive control for cell death, and hence loss of cell viability 
(Barry et al., 1993; Day et al., 2009). The data indicated that at 
concentrations above 500 μM of ribavirin less than 50% of cells were viable. 
However, at concentrations less than 500 μM more viable cells were 
observed.   
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Figure 3.1 Cell viability at 48h post treatment with different concentrations of 
ribavirin on HEp-2 cells using 3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) colorimetric assay on 96-well microplate 
(in triplicates). MTT a yellow tetrazole is reduced by mitochondrial 
dehydrogenases in living cells to purple formazan. Absorbance at 570 nm 
was measured by spectrophotometer on Tecan reader to calculate cell 
viability in order to determine the half maximal effective concentration (EC50) 
of ribavirin. 500 μM of ribavirin becomes the EC50. Etoposide, at 20 μM, was 
used as positive control for defining minimum cell viability. 
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3.2.2 ASSESSING RIBAVIRIN ON DIFFERENT MULTPLICITIES OF 
INFECTION (MOI) 
The optimum multiplicity of infection (MOI – the theoretical number of viruses 
that will infect each cell) of HRSV was then established in either untreated 
cells or cells treated with 500 μM ribavirin. Both the RNA-seq and 
quantitative label free proteomic approaches are comparative, i.e. the 
abundances of mRNA/protein prepared from mock-infected cells can be 
compared to the abundance of the same mRNA/protein from HRSV-infected 
cells. Therefore the proportion of infected cells was maximised relative to the 
control cell layer. Also, this had to be balanced with the effective 
concentration of ribavirin (500 μM) being able to reduce infection.  Based on 
previous experience (Jairath et al., 1997; Munday et al., 2015; Zhang et al., 
2002), four different MOIs were used, 0.005, 0.05, 0.5 and 5.  Cells were 
then treated with 500 μM ribavirin and infected cells were visualized using 
indirect immunofluorescence (Figure 3.2).  
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Figure 3.2 Indirect immunofluorescence was used to determine the 
proportion of cells infected. Shown are Mock, HRSV and different MOIs with 
500 μM of ribavirin (RBV). Mock cells without HRSV/RBV, HRSV infected 
cells only at different MOI (MOI 5, 0.5, 0.05 and 0.005 respectively) at 48 hr 
post-infection.  HRSV+RBV infected cells at different MOI (MOI 5, 0.5, 0.05 
and 0.005 respectively) at 48 hr post-infection and treated with 500 μM of 
ribavirin at 24 hr post-infection. HRSV viral proteins were labeled with goat 
anti-HRSV antibody and conjugated with donkey anti-goat FITC fluorescent 
antibody (Green). For each of the IF picture the scale bar is shown. 
MOI 5 
MOI 0.5 
MOI 0.05 
MOI 0.005 
MOCK		 HRSV +500µM RBV MOCK+DMSO		
200µm  200µm  200µm  200µm  
200µm  200µm  
200µm  200µm  
200µm  200µm  
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The data indicated that using an MOI of 0.005 and 0.05, the number of 
infected cells was significantly decreased with 500 μM ribavirin, however, 
very few cells were infected. While using an MOI of 5, the majority of cells 
were infected, but there was no apparent difference at the number of infected 
cells between ribavirin treated and untreated cells.  In contrast, at an MOI of 
0.5, the majority of cells were positive for fluorescence, but 500 μM ribavirin 
resulted in a decrease in the proportion of stained cells. Taken together, this 
study suggested that infection cells with MOI 0.5 would be a good 
distinguishable MOI to study the infected cells with and without ribavirin 
treatment (Figure 3.2). Further, more quantitative assays were used to 
investigate this. 
 
3.2.3 TIME COURSE OF INFECTION VERSUS TREATMENT WITH 
RIBAVIRIN  
After identifying the appropriate concentration of ribavirin (Figure 3.1) and the 
optimum MOI (Figure 3.2) it was important to know which time points to 
perform the antiviral ribavirin in this study. To determine assay points for 
high- resolution analysis, the affect of ribavirin on HRSV infection was 
investigated at different time points post-infection (Figure 3.3). The virus was 
added at time zero and 500 μM ribavirin added at; -6hpi, 0hpi, +6hpi, +12hpi 
and +18hpi. 
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Figure 3.3 Scale of adding ribavirin at different time points post-infection. 
This scale shows the time course of adding ribavirin drug before the infection 
as prophylaxis (-6hpi), at the same time of infection (0hpi) and after the 
infection as a therapeutic (6, 12, 18hpi) and harvest after 24 hr post-infection. 
Also, adding the drug after 24 hr post-infection and harvest after 48 hr post- 
infection. Cells infected with HRSV-A2 at MOI 0.5 and the concentration of 
ribavirin was 500 μM. 
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For these time points virus biology was assayed at +24 hr post-infection by 
extracting either total RNA for RNA-seq and qRT-PCR or whole cell lysate for 
quantitative proteomics described in subsequent chapters.  Ribavirin (500 
μM) was also added at +24 hr post-infection and virus biology assayed at 
+48 hr post-infection by extracting either total RNA for RNA-seq or cell lysate 
for quantitative proteomics described in subsequent chapters. Virus biology 
and progeny virus production was determined by indirect 
immunofluorescence (Figure 3.4), viral proteins abundance was measured 
using western blot (Figure 3.5), and TCID50 was used to determine progeny 
virus production (Figure 3.6). All these approaches were used to evaluate 
virus-infected cells. These factors were compared in untreated infected cells 
at +24 hr post-infection and +48 hr post-infection. 
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Figure 3.4 Indirect Immunofluorescence showing the time points tested in 
HEp-2 cells. Mock (cells only), -6 hr post-infection (treated 6 h before 
infection), 0 hr post-infection (treated and infected at the same time), +6 hr 
post-infection (treated after 6 hr of infection), +12 hr post-infection (treated 
after 12 hr of infection), +18 hr post-infection (treated after 18 hr of infection), 
HRSV (positive control harvested at 24 hr post-infection), +24 hr post-
infection (treated after 24 hr post infection) and HRSV 48 hr (positive control 
harvested at 48 hr post- infection). Ribavirin, at 500 μM, was used in all 
treated time points and HRSV-A2 at MOI 0.5 in all infected time points. The 
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IF analysis demonstrated that no virus was able to grow at -6 and 0 hr post-
infection, hence ribavirin stoppeded replication. At +6, +12, +18 and 24 hr 
post-infection virus grew with varying degrees. HRSV viral proteins were 
labeled with goat ant-HRSV antibody and conjugated with donkey anti-goat 
FITC fluorescent antibody. For each of the IF picture the scale bar is shown. 
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Indirect immunofluorescence was demonstrated (Figure 3.4) at all time points 
which were explained in Figure 3.3. Mock (cells only), -6hpi (treated 6 hr 
before infection) as a model for prophylaxis, 0 hr post-infection (treated and 
infected at the same), +6 hr post-infection (treated after 6 h of infection), +12 
hr post-infection (treated after 12 h of infection), +18 hr post-infection (treated 
after 18 hr of infection), HRSV (positive control harvested at 24 hr post-
infection), +24 hr post-infection (treated after 24 hr post infection) and HRSV 
48 hr (positive control harvested at 48 hr post infection). As can be seen from 
(Figure 3.4) adding ribavirin 6 hr before infections prevented the infection; 
also adding the ribavirin and infection at the same time (0 hr post-infection) 
appeared to prevent viral growth (as determined by fluorescence). However, 
there was a small amount of fluorescence when ribavirin was added 6 hr 
post-infection and it appeared that some cells stained with green were 
infected with the virus. Whereas, at later time points; 12, 18, 24 hr post-
infection, most of the cells were infected and these indicated that the addition 
of ribavirin 500 μM at late times points did not appear to inhibit the virus – as 
determined by fluorescence. Therefore, an alternative technique, western 
blot (Figure 3.5) was used to investigate this inhibition in more depth to 
compare viral proteins in the presence and absence of ribavirin.  
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Figure 3.5 Western blot with the selected assay time points in HEp-2 cells. 
Mock (cells only), -6 hr post-infection (treated 6 hr before infection), 0 hr post-
infection (treated and infected at the same time), +6 hr post-infection (treated 
after 6 hr of infection), +12 hr post-infection (treated after 12 hr of infection), 
+18 hr post-infection (treated after 18 hr of infection), HRSV (positive control 
harvested at 24 hr post-infection), +24 hr post-infection (treated after 24 hr 
post infection) and HRSV 48 hr (positive control harvested at 48 hr post-
infection). The HRSV infection was at MOI 0.5 and 500 μM of ribavirin 
treated. Primary antibody diluted was 1:1000 goat anti-HRSV antibody and 
1:2500 rabbit anti-goat antibody and the products corresponding to the HRSV 
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proteins are labelled. GAPDH was probed after striping the membrane to 
confirm equal protein loading. 
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All time points (in triplicates) that were tested by western blot (Figure 3.5); 
Mock (cells only), -6 hr post-infection (treated 6 hr before infection) as 
prophylaxis, 0 hr post-infection (treated and infected at the same), +6 hr post-
infection (treated after 6 hr of infection), +12 hr post-infection (treated after 12 
hr of infection), +18 hr post-infection (treated after 18 hr of infection), HRSV 
(positive control harvested at 24 hr post-infection), +24 hr post-infection 
(treated after 24 hr post-infection) and HRSV 48 hr (positive control 
harvested at 48 hr post-infection). 500 μM of ribavirin was used in all treated 
time points. As can be seen from Figure 3.5 adding ribavirin 6 hr before 
infection and at the same time of infection (0 hr post-infection) no viral 
proteins were observed indicating that growth of the virus was inhibited. 
Moreover, adding ribavirin 6 hr post-infection only the N protein could be 
visualised, suggesting an impairment of replication compared to the controls. 
However, at later time points; 12, 18, 24 hr post-infection, the G, F, N, P and 
M proteins were present. These results indicated that 500 μM ribavirin has an 
inhibitory affect when applied early in infection.  
 
Progeny virus production was also assayed.  TCID50 (Figures 3.6 A and B) 
have demonstrated the average of viral progeny production from all time 
points in HEp-2 cells in triplicates. The data from both intra-cellular and extra-
cellular virus indicated that 500 μM ribavirin significantly reduced progeny 
virus production by 24 hr post-infection when added at -6 hr post-infection, 0 
hr post-infection, +6 hr post-infection and +12 hr post-infection when 
compared to progeny virus production in untreated infected cells.  In infected 
Chapter 3: Optimising the application of ribavirin and viral infection 
90 
 
cells treated with 500 μM ribavirin at +24 hr post-infection and virus biology 
and progeny virus production determined at +48 hr post-infection, there was 
no significant difference in progeny virus, compared to untreated infected 
cells.  Indicating that to be effective, ribavirin should be applied early in 
infection. 
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Figure 3.6 Tissue culture Infectious dose, TCID50, in both (A) intra-cellular 
and (B) extra-cellular showing all time points in HEp-2 cells; -6 hr post-
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infection (treated 6 hr before infection), 0 hr post-infection (treated and 
infected at the same time), +6 hr post-infection (treated after 6 hr of 
infection), +12 hr post-infection (treated after 12 hr of infection), +18 hr post-
infection (treated after 18 hr of infection), HRSV (positive control harvested at 
24 hr post-infection), +24 hr post-infection (treated after 24 hr post-infection) 
and HRSV 48 hr (positive control harvested at 48 hr post-infection). 500 μM 
of ribavirin was used in all treated time points. 
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All data by immunofluorescence, western blot and TCID50 indicated that 500 
μM ribavirin significantly reduced virus biology and progeny virus production 
by 24 hr post-infection when added at -6, 0, +6 and +12 hr post-infection 
when compared to progeny virus production in untreated infected cells.  In 
infected cells treated with 500 μM ribavirin at +24 hr post-infection and virus 
biology and progeny virus production determined at +48 hr post-infection, 
there was no significant difference in progeny virus, compared to untreated 
infected cells (Figures 3.4, 3.5 and 3.6). Therefore application of ribavirin at 
+24 hr post-infection will be predicted to affect viral RNA and protein 
synthesis after this time point, and impinge on a second round of infection. 
This is indicated by a reduction in the abundance of viral proteins, reflected 
by both immunofluorescence and western blot analysis (Figures 3.4 and 3.5). 
From this analysis, two time points were selected for the investigation using 
high-resolution approaches; 500 μM ribavirin added at +6 and +24 hr post-
infection, with an assay point of purifying cellular RNA and proteins at +24 hr 
post-infection and +48 hr post-infection, respectively. 
 
3.2.4 THE EFFECT OF DMSO, AND RIBAVIRIN ON INFECTED CELLS  
DMSO was added to dissolve the ribavirin stock. It is important to assess the 
potential effect of DMSO on the cells and also on the infected cells with 
HRSV, as this may impinge on the interpretation of the data. To assess the 
effect of DMSO: different experiments were performed to assess virus 
biology; TCID50 – measuring and comparing the titre of progeny virus (Figure 
3.7), western blot to compare viral protein abundance (Figure 3.8) and 
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immunofluorescence to provide an overall visual guide of the number of 
infected cells (Figure 3.9). The data indicated that there was no significant 
effect of DMSO on virus biology by measuring these three parameters, with 
the optimal MOI of 0.5 (Figures 3.7, 3.8, 3.9).  
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Figure 3.7 Progeny virus production was compared in the presence and 
absence of RBV and DMSO only control. Tissue culture Infectious dose 
TCID50 analysis of extra-cellular virus production been diluted on samples 
HRSV, HRSV+DMSO and HRSV+RBV in HEp-2 cells and syncytia counted 
in the day seven of the infection. All samples were infected with HRSV-A2, 
MOI 0.5. Ribavirin and DMSO were added after 6 hr post-infection and all 
samples have harvested after 24 hr post-infection and performed in serial 
dilution and added to 96 well plates that have cells already confluent. This 
graph indicates a statistically significant difference P<0.05 of log10 TCID50 
titer mean between HRSV+RBV vs HRSV. However, there was no significant 
difference between HRSV+DMSO vs HRSV P>0.05. Statistical analysis was 
performed using Kruskal-Wallis test. 
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There was no significant effect of DMSO on infected cells compared to cells 
infected only (p value=0.5284) on extra-cellular (progeny virus in the 
supernatant) by TCID50. However, the data indicated that the amount of 
progeny HRSV, from cells infected with MOI of 0.5, was significantly reduced 
by approximately 5 logs in the presence of 500 μM ribavirin compared to 
either infected cells untreated or treated with the DMSO only. 
 
Western blot (a semi-quantitative method) and immunofluorescence were 
used to study the effect of DMSO on the abundance of viral proteins and 
general infectivity (Figures 3.8 and 3.9, respectively) with the following 
conditions: Mock (cells only), DMSO (added to cells), +6hpi (treated after 6 h 
of infection), RBV (500 μM ribavirin added to cells), HRSV (positive control 
harvested at 24 hr post-infection), HRSV+DMSO (DMSO was added to 
infected cells at 6 hr post-infection), HRSV+RBV (500 μM ribavirin was 
added to infected cells at 6 hr post-infection). Taken together, these results 
indicated that adding DMSO on cells and on infected cells with HRSV MOI 
0.5 resulted in stable affect compared to mock-untreated and infection with 
HRSV, respectively.    
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Figure 3.8 Western blot analysis on 24 hr post-infection in continuous HEp-2 
cells that infected with HRSV-A2 at an MOI 0.5. Cells lysates were examined 
by SDS-PAGE followed by western blot. The infections were confirmed using 
a (primary antibody) anti-HRSV 1:1000 goat anti-HRSV antibody (Abcam 
20745) and (secondary antibody) 1:2500 rabbit anti-goat antibody and the 
bands corresponding to the HRSV proteins. Antibody specific for GAPDH (as 
indicator for equal protein load) mouse anti-GAPDH (primary antibody) 
1:5000 (Abcam 8245) and (secondary antibody) 1:2500 mouse (Abcam 
4116) was used after striping the membrane to test loading samples. 
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Figure 3.9 Direct Immunofluorescence analysis in continuous cell culture 
HEp-2 in response to infection with HRSV-A2 at 24 hr post-infection. Mock 
(cells only), DMSO (added to cells), +6hpi (treated after 6 hr of infection), 
RBV (500 μM ribavirin added to cells), HRSV (positive control harvested at 
24 hr post-infection), HRSV+DMSO (DMSO was added to infected cells at 6 
hr post-infection), HRSV+RBV (500 μM ribavirin was added to infected cells 
at 6 hr post-infection). All samples after 24 hr post-infection were washed by 
PBS, fix by %4 PFA and permeabilised. FITC conjugated HRSV primary 
antibody (Abcam 20391) diluted 1:50 (v/v) and added on the top of coverslips 
(where cells there) for 1 hr at dark in the room temperature and mounted on 
slides microscopy. For each of the IF picture the scale bar is shown. 
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Taken together these results suggested that there was no effect of DMSO on 
virus biology. Hence, DMSO was used to dissolve ribavirin; it is necessary to 
analyse any effect that might occurred.   
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3.3. DISCUSSION 
The results of this chapter provided analysis data for the optimisation of the 
RNA-seq and proteomic to study the effect of ribavirin on the abundance of 
host and viral gene products and also the viral genome.  The optimisation 
considered both infection of the virus and toxicity of ribavirin and the DMSO.  
HEp-2, a lung cell line, was used as a model system to study the effect of 
ribavirin in the presence and absence of infection. The continuous cell type 
HEp-2 has previously been used to study cell viability with anti-viral drugs 
and HRSV infection (Currie et al., 2013; Donalisio et al., 2012; Hughes et al., 
1988; Shah et al., 2010). This study employed both quantitative and 
qualitative techniques to assess the concentrations of ribavirin, HRSV MOI 
and time points that could be used. The qualitative methods used involved 
direct immunofluorescence assay and western blot and TCID50. These 
demonstrated the infection of cells by HRSV-A2 with/without ribavirin antiviral 
treatment, while no cells were infected in mock-infected/treated, thus 
providing a clear discriminator for the comparative techniques and 
demonstrating virological methodologies that have no cross contamination. 
The findings of these independent analyses also showed a significant 
reduction of infection when ribavirin was added, in line with previous literature 
and expected results (Debing et al., 2014; Wyde et al., 2003). The 
measurement of progeny virus using TCID50, as a quantitative approach, 
provides a direct measure of output virus and allows the comparison of 
ribavirin treatment on viral load.   
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As well as a quantitative methods, the MTT assay was also used with 
different concentrations of ribavirin for 24 hr post-treated on HEp-2 cells 
(Figure 3.1) in order to assess the viability of cells and optimise ribavirin 
treatment from the perspective of cell viability. The result indicated that at 
concentrations below 500 μM of ribavirin cells were more viable; however, 
any concentrations above 500 μM of ribavirin cells were less viable. 
Therefore, 500 μM of ribavirin was selected as the EC50. This concentration 
of ribavirin has been used with other viruses to investigate its effects in cell 
culture models e.g. Vesicular Stomatitis virus and Sendai virus (Shah et al., 
2010). For comparison of the ribavirin treatments, untreated cells were used 
to measure the total viable cell population, whereas, etoposide, which 
promotes apoptosis was used as a positive control for cell death, and hence 
for loss of cell viability. Multiplicity of infection (MOI) on the other hand, was 
used to determine the proportion of cells infected by immunofluorescence 
assay. Different MOIs (MOI 5, 0.5, 0.05 and 0.005) at 48 hr post-infection 
(Figure 3.2) were used to maximize cells infection. Moreover, the same MOIs 
were used and treated with 500 μM of ribavirin at 24 hr post-infection in order 
to confirm that this concentration of ribavirin was effective on disrupting virus 
biology in a measurable way. The data indicated that at MOI of 0.005 and 
0.05, ribavirin 500 μM were effective in reducing the amount of HRSV, but 
only few cells were infected. Immunofluorescence analysis indicated that at 
MOI 5 majority of the cells were infected, but there was little apparent 
difference in infection with HRSV between the ribavirin treated or untreated 
cells.  In contrast, at MOI of 0.5, majority of the cells were infected, but 500 
μM ribavirin resulted in a decrease in the proportion of stained cells. 
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A time course assay was used to determine which time point was best to 
perform the 500 μM anti-viral ribavirin administration into infected cells with at 
an MOI of 0.5, in order to investigate the influence of ribavirin on infected 
cells. Several methods were established to investigate virus biology; namely 
indirect immunofluorescence, western blot and TCID50 (Figures 3.4, 3.5, 3.6).  
Considering that ribavirin could be added before the infection as prophylaxis 
or after the infection as treatment (Zhang et al., 2003), several different 
treatment options were used; -6 hr prior to infection and +6, +12, +18, and 
+24 hr post-infection. Also, in this study, two times points; 24 and 48 hr post-
infection without treatment were included as a positive control. The findings 
of these independent analyses demonstrated that adding ribavirin 6 hr before 
infection was effective at preventing viral growth. However, there was a slight 
increase in viral growth when adding ribavirin at 6 hr post-infection. Only N 
protein of HRSV at 6 hr post-infection was detected by western blot, 
whereas, other late time points; 12, 18, 24 hr post-infection, viral proteins G, 
F, N, P and M were detected, indicating that 500 μM ribavirin was unable to 
prevent the infection and no significant difference in progeny virus, compared 
with untreated infected cells. 
 
Therefore, taken together the following study design (Figure 3.10) was used 
to investigate the effects of ribavirin on cell and virus biology using the high- 
resolution approaches described in the subsequent chapters.  Six condition 
samples; Mock (non-infected and non-treated cells), DMSO (uninfected cells 
but treated with DMSO only), ribavirin (uninfected cells but treated with 500 
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μM ribavirin), HRSV (infected but un-treated cells), HRSV+DMSO (infected 
but cells treated with DMSO) and HRSV+RBV (infected but cells treated with 
500 μM ribavirin). The MOI was 0.5. The experiments were conducted in 
triplicate.  
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Figure 3.10 Study design of the main experiments for label free quantitative 
proteomics and RNA-seq. This design shows all control samples (negative 
and positive) in all experiments; immunofluorescence, Western Blot, 
Proteomics and deep sequences. Mock (cells only, and no virus and no 
drug), DMSO only, RBV only 500 μM concentration, HRSV only, 
HRSV+DMSO, and HRSV+RBV adding 500 μM of ribavirin after 6 hr post-
infection (early time point) and after 24 hr post-infection (late time point). 
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CHAPTER 4: INVESTIGATING THE EFFECT OF THE ANTI-VIRAL 
RIBAVIRIN ON CELLS INFECTED AND UNINFECTED WITH HRSV 
USING LABEL FREE PROTEOMICS AND TRANSCRIPTOMICS  
4.1 INTRODUCTION 
Human respiratory syncytial virus (HRSV) is one of the major lower respiratory 
tract pathogens and infants are infected at least once within the first two years of 
life (Collins & Graham, 2008). There is no vaccine for HRSV or general anti-viral 
therapy. In acute cases, HRSV infection is treated therapeutically with ribavirin, a 
broad spectrum anti-viral, whose mechanism of action is not clearly understood. 
Ribavirin is the only therapeutic approved by the Food and Drug Administration 
(FDA) for the treatment of HRSV (Chu et al., 2013). Clinically ribavirin tends not 
to be used due to several factors including evidence of marginal efficacy and no 
difference in the length of stay in hospital for treated versus untreated patients.  
However, ribavirin may also be used in immune-compromised and/or transplant 
and acute high-risk groups infected with HRSV for example see (Waghmare et 
al., 2013).  Ribavirin has broad-spectrum antiviral properties and apart from 
HRSV is also used clinically in the treatment of hepatitis E virus (Kamar et al., 
2014) and hepatitis C virus (HCV), where the treatment has been shown to have 
mutagenic effect on the viral genome (Dietz et al., 2013). Ribavirin is also used 
in the treatment of disease caused by hemorrhagic fever viruses (for example 
see (Soares-Weiser et al., 2010). The drug has been described as a being active 
against a number of viruses with RNA and DNA genomes, and can be 
considered a broad-spectrum anti-viral inhibitor. 
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The mechanism of action of ribavirin in many cases is unknown. Several 
hypotheses for a mode of action have been advanced. Ribavirin treatment may 
cause loss of fitness in RNA virus genomes. Ribavirin is a base analog of either 
adenine or guanine and thus can base pair with cytosine or uracil.  For RNA 
viruses, ribavirin might be incorporated into genomic RNA by the RNA-
dependent RNA polymerase during replication. In terms of base, G A mutations 
were predicated to be induced by incorporation of ribavirin triphosphate as a 
GTP nucleoside analog during positive strand RNA synthesis, however C T 
mutations were predicated to be the result of ribavirin incorporation during 
negative strand synthesis. The result is termed hyper-mutation that can be lethal 
to virus biology through error catastrophe. This mechanism of action has been 
proposed and supported by experimental data in vitro for poliovirus (Crotty et al., 
2001) and HCV and in vivo for HCV (Dietz et al., 2013).  There are two types of 
DNA substitution mutations; transitions are a point mutation that changes 
purine/purine nucleotides (A G) or pyrimidine/pyrimidine nucleotides (C T) and 
transversions are interchanges of purine/ pyrimidine (A T, A C, C G, G T) 
(Figure 4.1) (Collins & Jukes, 1994).    
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Figure 4.1 Definition of transition and transversion mutations. Shows the 
purine/pyrimidine transversions, the purine/purine and pyrimidine/pyrimidine 
transitions.  
 
Ribavirin may cause up-regulation of anti-viral gene products inside the cell in 
the absence of infection. Micro-array analysis suggested that ribavirin can 
directly up-regulate antiviral gene expression including STAT-1 and STAT-1 in 
HRSV-infected cells (Zhang et al., 2003). Intracellular pools of GTP have been 
shown to be depleted in ribavirin treated cells through inhibition of cellular 
inosine monophosphate dehydrogenase IMPDH. This has been suggested to be 
correlated with the inhibition of flavivirus (including yellow fever virus) and 
paramyxovirus replication (Leyssen et al., 2005; Leyssen et al., 2006). Ribavirin 
can also affect the translation of eukaryotic mRNAs and has been proposed as a 
therapeutic for acute myeloid leukemia (Tamburini et al., 2009) and has been 
shown to act as a competitive inhibitor of the methyl 7-guanosine (m(7)G) cap, 
the natural ligand of the translation initiation factor eIF4E (Volpon et al., 2013). 
G A	
C T 
Transitions 
Transitions 
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GTP depletion by ribavirin may act in concert to increase its incorporation into 
viral genomes thus increasing error prone replication as has been suggested for 
West Nile virus (Day et al., 2005).  
 
The objective of this chapter was to investigate the action of ribavirin on the host 
cell and HRSV biology in general, a combined high-resolution RNA-seq and 
deep discovery label free quantitative proteomics approach was used to analyze 
infected cells. The potential direct mutagenic effect of ribavirin on the HRSV 
genome is described in Chapter 5. Quantitative label free proteomics and RNA- 
seq were used to quantify changes in the abundance of cellular and viral 
proteins and genes, respectively. From the analysis in Chapter 3, two time points 
were selected for investigation using label free proteomics approaches; based 
upon the time course analysis several experimental conditions to assess the 
effects of 500 M ribavirin on virus were set up at +6 hr post-infection (assay 
point +24 hr post-infection) and +24 hr post-infection (assay point +48 hr post-
infection) (Figure 3.7). 
 
The data indicated that the abundance of cellular mRNAs and proteins altered in 
the presence of ribavirin; antiviral response was the top pathway significantly 
increased in infected-cells and untreated with ribavirin. Whereas cell death and 
survival were the top molecular and cellular functions in infected and cells-
treated. Also, the proteomics and transcriptomics data demonstrated the viral 
proteins and genes significantly decreased in the presence of ribavirin, 
confirming its antiviral mode of action.  
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 Some of the work (mainly the chaperone proteins which were detected in 
mock vs HRSV infected cells) described in this chapter has recently been 
published in the Journal of Virology. Diane C. Munday, Weining Wu, Nikki 
Smith, Jenna Fix, Sarah Louise Noton, Marie Galloux, Olivier Touzelet, 
Stuart D. Armstrong, Jenna M. Dawson, Waleed Aljabr, Andrew J. Easton, 
Marie-Anne Rameix Welti, Andressa Peres de Oliveira, Fernando M. 
Simabuco, Armando M. Ventura, David J. Hughes, John N. Barr, Rachel 
Fearns, Paul Digard, Jean-François Eléouët, Julian A. Hiscox (2015) 
Interactome Analysis of the Human Respiratory Syncytial Virus RNA 
Polymerase Complex Identifies Protein Chaperones as Important Cofactors 
That Promote L-Protein Stability and RNA Synthesis J. Virol. vol. 89 (2): 917-
930. (See appendix). Also, A manuscript is currently in preparation using the 
most data in this chapter. 
The candidate confirms that the work submitted is his own, except where 
work which has formed part of jointly-authored publications has been 
included. The contribution of the candidate and the other authors to this work 
has been explicitly indicated below. The candidate confirms that appropriate 
credit has been given within the thesis where reference has been made to 
the work of others. 
Chapter 4 of this thesis was based on the work from jointly-authored 
publication: 
 
 Diane Munday and Weining Wu planned the experiments, optimised 
and performed data analyses and subsequent immunoblot and 
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immunofluorescence confocal analyses, prepared tables and figures 
and jointly wrote the manuscript. 
 Olivier Touzelet expertise regarding mice experiments. 
 Stuart Armstrong run samples and helped on MS-proteomic analysis.  
 Jenna M. Dawson helped on western blot.  
 Waleed Aljabr prepared samples for MS-proteomics and performed 
data analysis the chaperone proteins which were detected in mock vs 
HRSV infected cells. 
 Jenna Fix, Sarah Noton, Marie Galloux, Andrew Easton, Marie-Anne 
Welti, Andressa Peres de Oliveira, Fernando Simabuco, Armando 
Ventura and David Hughes provided expertise and advice. 
 Nikki Smith and Paul Digard carried out pluse chase experiments with 
the mini genome system. 
 Jean-François Eléouët provided the EGFP-L constructs, support 
plasmid and expertise.  
 John N. Barr, Rachel Fearns and Julian A. Hiscox jointly wrote the 
manuscript. 
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4.2. RESULTS  
Both RNA-seq and label free quantitative proteomics were used to identify 
and quantify cellular and viral RNA and proteins, respectively. These were in 
several experimental conditions; mock-infected and mock-treated cells; 
mock-infected cells treated with (DMSO) only; mock-infected cells treated 
with 500 M ribavirin; HRSV-infected cells; HRSV-infected cells treated with 
the DMSO only; HRSV-infected cells treated with 500 M ribavirin. These 
conditions were investigated in triplicate using the high-resolution 
approaches. Quantitative label free proteomics was used to identify and 
quantify proteins in whole cell lystates and this returned an average of 2616 
proteins. Several selection criteria were used to improve the confidence in 
the identification of proteins. Individual ion scores > 13 indicated identity or 
extensive homology (p < 0.05) and using a criterion of two or more peptides 
pre-selected 1721 proteins and the abundance of these proteins was then 
compared across the six different treatment conditions. For the proteomic 
analysis, the data was presented as volcano plots, which allow the 
visualization of proteins that are significantly increased and decreased in 
abundance and points are plotted against abundance and p-value. For RNA- 
seq analysis, total RNA was prepared from cells with the different 
experimental conditions. It is important to mention that the p-value was used 
to standardize the analysis of RNA-seq data and proteomics data. Also, data 
presented in this chapter is based on the 24 hr post-infection assay point. 
This is because the effect of ribavirin at 48 hr post-infection, when the drug 
was added after 24 hr of virus replication, was limited and no apparent 
decrease in progeny virus production was noted. 
Chapter 4: Investigation the effect of the anti-viral ribavirin on cells infected and un 
 112 
4.2.1 THE EFFECT OF DMSO AND RIBAVIRIN ONLY ON THE HOST CELL 
Ribavirin was added to cells in a DMSO. To assess the potential effect of 
DMSO on host cell biology, the proteomics datasets for mock-infected cells 
on both untreated and treated with DMSO were compared (Figure 4.1 A). 
Supplementary tables I and II (see appendix) respectively show the identified 
proteins that were decreased or increased significantly. The transcriptomics 
datasets for mock-infected cells of both untreated and treated with DMSO 
were also compared (Figure 4.2 B). Supplementary tables III and IV (see 
appendix) list the genes that were significantly decreased or increased in 
abundance. This data indicated, for the +6hpi (assay point +24hpi), that out 
of a total of 1720 proteins identified and quantified by 2 or more unique 
peptides, 6 cellular proteins increased in abundance and 2 cellular proteins 
decreased in abundance in the presence of DMSO ( 0.4%). 
 
There was a good correlation between the abundance of both proteins and 
mRNAs (Figure 4.2 B). RNA-seq comparison between untreated and cells 
treated with DMSO for the +6hpi (assay point +24hpi) treatment indicated 
that 13 transcripts were significantly increased in abundance greater than 2-
fold in the presence of DMSO, whereas 50 transcripts significantly decreased 
in abundance (Figure 4.2). This indicated that out of 62844 surFit transcripts 
that DMSO had a slight effect ( 0.1%) on host cell transcription, but the 
abundance of most transcripts and the corresponding proteins remained 
unchanged (Figure 4.2). 
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Figure 4.2 (A) Volcano plot representing results of the label-free LC-MS/MS 
of mock-infected cells-untreated verses DMSO untreated at 24 hpi. The gray 
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line in the middle shows where p value of 0.05 with points above the line 
having a p value <0.05 and points below the line having a p value >0.05. Two 
cellular proteins increased in abundance and 6 cellular proteins decreased in 
abundance in the presence of DMSO. (B) Showing the match between 
transcript (y-axis) and protein (x-axis) abundance. The log2 fold change 
identified was calculated for both transcript and protein. The corresponding 
values were then plotted on the histogram in similar fashion for each of the 
genes. (C) Venn diagram showing numbers of genes and proteins identified 
in mock-infected, untreated and treated with DMSO. The data indicates for 
the +6hpi (assay point +24hpi), that out of a total of 1716 proteins (identified 
and quantified by 2 or more unique peptides) 2 cellular proteins increased in 
abundance and 6 cellular proteins decreased in abundance in the presence 
of DMSO. Likewise, RNA-seq from 62844 surFit (identified and quantified by 
log2 fold change) 13 significant genes increased in abundance and 51 
significant genes decreased in abundance. 
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The addition of ribavirin at +6hpi (assay point +24hpi) resulted in, based on 
filters that been used, 6 cellular proteins being increased in abundance and 4 
cellular proteins being decreased in abundance (Figure 4.3). Tables 4.1 and 
4.2 show proteins that were significantly decreased and increased in 
abundance, respectively). The proteomic data indicated that UTP14A, 
decreased in abundance by approximately 6-fold in cells treated with DMSO 
and ribavirin compared to cells treated with DMSO only. This protein is 
involved in RNA metabolism and is involved in ribosome biogenesis and 18S 
rRNA synthesis.  From the proteomic data sets, SLC29A1, solute carrier 
family 29, (Equilibrative nucleoside transporter protein), was identified in both 
the analysis of cells treated with DMSO and the analysis of cells treated 
DMSO plus ribavirin, as being increased in abundance. This protein 
increased approximately 2-fold in abundance, in both cases, and may be 
attributed to the potential action of DMSO on cells. 
 
For RNA-seq analysis at this time point and treatment condition, out of 
62,844 surFit transcripts, 389 were shown to have a significant increase 
abundance greater than 2-fold in the presence of ribavirin, whereas 253 
transcripts were decreased more than 2-fold.  For transcripts that increased 
in abundance in the presence of ribavirin, these included connective tissue 
growth factor (CTGF) (8-fold), Cytochrome P450, family 1, subfamily A, 
polypeptide 1 (CYP1A1) (7-fold) (involved in drug metabolism), interleukin-6 
(6 fold), Chemokine (C-X-C motif) ligand 2 (CXCL2) (6-fold) and interleukin-7 
receptor (IL7R) (6-fold) (involved in the development of immune cells). The 
transcript encoding 2'-5' oligoadenylate synthetase (OAS) (OASL) was 
Chapter 4: Investigation the effect of the anti-viral ribavirin on cells infected and un 
 116 
decreased in abundance approximately -5 fold at +6hpi (assay point +24hpi).  
The encoded protein family can bind double stranded RNA and has been 
reported to have anti-viral activity.  Analysis indicated changes in both the 
transcriptome and proteome in the presence of ribavirin (Figure 4.3). In 
addition, the transcriptomic data pointed to activation of the c-fos and c-jun 
and NFKB (p-value of 1.92x1013) transcription pathways in the presence of 
ribavirin. 
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Figure 4.3 (A) Volcano plot demonstrating the analysis of cells treated with 
DMSO and the analysis of cells treated with DMSO plus ribavirin at +6hpi 
(assay point +24hpi) resulted in 6 cellular proteins being increased in 
0 
1 
2 
3 
4 
5 
6 
7 
-6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 
DMSO vs RBV at 24 hpi 
Log2 FC 
-L
o
g
1
0
(p
-v
a
lu
e
) 
P<0.05 
-5.0 
-4.0 
-3.0 
-2.0 
-1.0 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
-4.0 -3.0 -2.0 -1.0 0.0 1.0 2.0 3.0 4.0 
T
ra
n
s
c
ri
p
to
m
ic
s
 (
lo
g
2
 F
C
) 
Proteomics	(log2	FC)	
Proteomics 
1720 proteins identified 
6 significantly increased 
abundance 
4 significantly decreased 
abundance 
Transcriptomics 
62844 surFit identified 
389 significantly 
increased abundance 
253 significantly 
decreased abundance 
A 
B 
C 
Table 4.2 Table 4.1 
Chapter 4: Investigation the effect of the anti-viral ribavirin on cells infected and un 
 118 
abundance and 4 cellular proteins being decreased in abundance. (B) The 
match between transcript (y-axis) and protein (x-axis) abundance and the 
changes in the presence of ribavirin. The log2 fold change identified was 
calculated for both transcript and protein. The corresponding values were 
then plotted on the histogram for the same each gene. (C) Venn diagram 
showing numbers of genes and proteins identified in mock-infected and 
untreated/ treated with DMSO. Analysis indicated changes in both the 
transcriptome and proteome in the presence of ribavirin but no significant 
matched. For RNA-seq analysis at this time point and treatment conditions, 
389 mRNAs were shown to have a significant increase abundance greater 
than 2-fold in the presence of ribavirin, whereas 253 mRNAs were decreased 
more than 2-fold.  
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Table 4.1 Proteins increased in abundance in DMSO vs RBV (top right of 
Figure 4.3). Statistical analysis was based on observed fold change 2 or 
greater, and more than 2 peptides and a p-value less than 0.05. Proteins 
were identified and quantified by LC MS/MS.  
Gene 
name Protein name 
Peptide 
count 
Peptides 
used for 
quantitation Log2 FC 
SLC25
A11 
Mitochondrial 2-
oxoglutarate/malate carrier 
protein 3 3 1.3 
TK1 Thymidine kinase, cytosolic 5 5 1.3 
SLC29
A1 
Equilibrative nucleoside 
transporter 1 2 2 1.2 
AHCTF1 Protein ELYS 2 2 1.2 
KIF11 Kinesin-like protein KIF11 3 2 1.1 
PRPF6 Pre-mRNA-processing factor 6 2 2 1.0 
 
Table 4.2 Proteins decreased in abundance in DMSO vs RBV (top left Figure 
4.3). Statistical analysis was based on observed fold change 2 or greater, 
and more than 2 peptides and a p-value less than 0.05. Proteins were 
identified and quantified by LC MS/MS.  
 Gene 
name Protein name 
Peptide 
count 
Peptides 
used for 
quantitation Log2 FC 
MRFAP1 
MORF4 family-associated 
protein 1 2 2 -1.2 
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UTP14A 
U3 small nucleolar RNA-
associated protein 14 homolog 
A 2 2 -2.9 
RSL1D1 
Ribosomal L1 domain-
containing protein 1 9 8 -1.1 
BYSL Bystin 3 3 -1.1 
 
4.2.2 THE EFFECT OF HRSV WITH DMSO ON THE HOST CELL 
TRANSCRIPTOME AND PROTEOME 
As would be predicted and has been previously characterized by both micro-
array and proteomic analysis (Dave et al., 2014; Hastie et al., 2012; Martínez 
et al., 2007; Munday et al., 2010a; Ternette et al., 2011; van Diepen et al., 
2010; Wu et al., 2011), HRSV infection resulted in a number of changes in 
the abundance of host cell transcripts and proteins (e.g. for +6hpi (assay 
point +24hpi) Figure 4.3), with most changes reflecting an increased 
abundance of both transcripts and proteins. At this time point, out of 62,844 
transcripts, 521 were increased in abundance more than 2-fold and these 
included those that encoded the C-C chemokine receptor-like 2 protein 
(CCRL2), interleukin 6 (IL6) and interferon-induced GTP-binding protein 
MX2. 127 transcripts were significantly decreased in abundance, for 
instance, DNA damage –inducible transcript 4 protein (DDIT4), NDRG4 and 
METTL7A. This transcriptome data was compared to a previously published 
analysis of the cellular transcriptome in HRSV infected cells using micro 
arrays (Martínez et al., 2007). Although different cell types, times post-
infection, viral strains and statistical analysis were used, there was generally 
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good agreement between the different datasets, for example in the increase 
in abundance of mRNAs encoding proteins associated with the immune 
response (data not shown). Taking this data from 24hpi, the transcriptomics 
analysis would suggest that gene expression is increased rather than 
decreased in HRSV-infected cells. 
 
HRSV infection resulted in a number of changes in the abundance of host 
cell proteins at +6hpi (assay point +24hpi) resulted in 30 cellular proteins 
being significantly increased in abundance and 13 cellular proteins that 
significantly decreased in abundance (Figure 4.4). Supplementary tables V 
and VI demonstrated proteins that significantly decreased and increased in 
abundance, respectively. (See appendix). 
 
There were 14 cellular genes that were significantly overlapped with cellular 
proteins in HRSV infected cells with DMSO (Figure 4.4). Interestingly, most 
of these significant overlapped genes and proteins are anti-viral response 
genes; DDX58, OAS3, IFIT1, IFIT2, IFIT3, OASL and ZC3HAV1, and both 
significantly increased abundance. These anti-viral proteins and genes have 
such agreement which all of them were significantly increased in abundance. 
In addition, there are some identified genes that play a key role in the innate 
immune response in viral infection such as ISG15 and KRT16. Overall, all of 
these genes and proteins were increased abundance except UAP1, which 
was significantly increased abundance in transcriptomics and significantly 
decreased abundance in protein (Figure 4.5).   
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Figure 4.4 (A) Volcano plot representing the effect of HRSV on cells plus 
DMSO by proteomics DMSO vs HRSV+DMSO. HRSV infection resulted in 
DMSO vs HRSV+DMSO at 24 hpi 
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increased abundance in viral proteins and in cellular proteins. (B) The match 
between transcript (y-axis) and protein (x-axis) abundance and the changes 
when infected with HRSV at MOI 0.5. The log2 fold change identified was 
calculated for both transcript and protein. The most changes are reflecting an 
increased abundance of both mRNAs and proteins. (C) Venn diagram shows 
numbers of genes and proteins identified in infected cells. Out of a total of 
62844 surFit identified, 555 mRNAs were significantly increased in 
abundance whereas 156 mRNAs were significantly decreased in abundance. 
However, out of a total 1720 proteins identified, 30 proteins were significantly 
increased in abundance and 13 proteins significantly decreased in 
abundance. 14 genes and proteins were significantly overlapped and their 
fold change more than 2. 
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Figure 4.5 Overlap fourteen proteins and genes in infected cells with HRSV 
vs DMSO were significantly increased in abundance. Most of these matched 
genes function as anti-viral response genes. DDX58 is the gene that is 
expressed the highest. 
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Ingenuity Pathway Analysis of the proteomic data sets also highlighted 
several pathways and cellular processes that were affected by HRSV, 
including CXCR4 signalling (data not shown). These identified changes in the 
cellular proteome through virus-infection were in close agreement with 
previous proteomic based approaches to investigate the interaction between 
HRSV and the host cell (Dave et al., 2014; Munday et al., 2010a), placing 
confidence in this analysis. This included activation of interferon, NFKB and 
other pathways such as mitochondrial dysfunction, which has also been 
observed in a targeted analysis (Munday et al., 2014a). Highlighted in the 
proteomic analysis was potential cell cycle disruption at the G2/M phase (p-
value 1.62x10-7). This again, has been observed in HRSV-infected cells (Wu 
et al., 2011), validating the high throughput approach. 
 
There appeared to be little affect of the DMSO on either the cellular and viral 
transcriptome or proteome in HRSV-infected cells either untreated or treated 
with DMSO only ( 0.5) (Figure 4.2). This is evident in the close correlation of 
the mRNA and protein abundance in the untreated-infected cells versus the 
DMSO only treated infected cells ( 3.5) (Figure 4.4). Thus the data indicated 
that DMSO did not have an apparent affect on HRSV biology.  This is 
reflected in the fact that there was no significant difference in HRSV progeny 
virus production between infected cells either untreated or treated with 
DMSO (Chapter 5), and was underlined by no apparent difference in the 
abundance of viral proteins as determined by western blot (data not shown). 
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4.2.3 THE ABUNDANCE OF PROTEOME IS NOT PRESENT AS A LINEAR 
GRADIENT IN VIRUS INFECTED CELLS 
Several studies have previously analysed the abundance of viral proteins in 
HRSV-infected cells using various quantitative approaches (Dave et al., 
2014; Munday et al., 2010a; Munday et al., 2010c). All of these studies found 
that the viral protein abundance did not correspond to a linear gradient as 
would be predicted if the protein abundance matched the predicted viral 
mRNA profile.  The most robust approach, by Dave et al., also used a label 
free quantitative approach (Dave et al., 2014) and found that the abundance 
of viral proteins from highest to lowest abundance was P, N, M, F, M2-1, 
NS1, NS2, G and L, and noted that this profile did not match the expected 
profile (Dave et al., 2014). The authors discussed that deriving relative viral 
protein abundance from mass spectrometry is difficult. As an example they 
noted that the G protein was not very abundant possibly due to its heavy 
glycosylation negatively influencing its ability to be identified and quantified 
by mass spectrometry (Dave et al., 2014). 
 
The proteomics analysis in this study indicated that the abundance of viral 
proteins in HEp-2 cells infected with HRSV at 24hpi from highest to lowest 
was P, M, N, M2-1, F, SH, NS1, G and NS2. The L protein was not detected 
(Figure 4.6). The abundance of viral proteins at 48hpi in HEp-2 cells infected 
with HRSV from highest to lowest was P, M, N, M2-1, SH, F, NS1, G, NS2 
and the L protein (data not shown). Thus taken together with previous 
proteomic studies (Dave et al., 2014; Munday et al., 2010a; Munday et al., 
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2010c) the current data would suggest that the abundance of viral mRNAs 
and proteins does not follow the profile that would be predicted if the 
abundance was related to the order of the gene along the genome. 
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Figure 4.6 Abundance of HRSV proteins after ribavirin treatment. The 
relative abundance of individual viral proteins was measured before and after 
ribavirin treatment with a Hi-N approach using the proteome quantitation 
software Progenesis QI (Nonlinear Dynamics). Briefly, the abundance of the 
top 3 most intense peptides obtained via LC-MS/MS were averaged to 
provide a reading for the protein signal. This reading allows relative 
quantitation of the same protein across LC-MS/MS runs. 
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4.2.4 THE AFFECT OF INFECTED-CELL ON UNTREATED WITH RIBAVIRIN 
BY TRANSCRIPTOME AND PROTEOME  
In order to study the affect of ribavirin on the host cells, it is important to 
study the effect HRSV on cells without treatment with ribavirin and do 
comparison for each sample condition separately. This will allow us to see 
the difference between infected only and infected plus ribavirin treated.  
HRSV infection resulted in a number of changes in the abundance of host 
cell transcripts and proteins (e.g. for +6hpi (assay point +24hpi) Figure 4.7), 
with most changes reflecting an increased abundance of both transcripts and 
proteins. At this time point, out of 62,844 surFit transcripts, 426 were 
increased in abundance more than 2-fold change, whereas, 136 transcripts 
were significantly decreased in abundance more than 2-fold change. This 
data also indicated, for the +6hpi (assay point +24hpi), that out of a total of 
1716 proteins identified and quantified by 2 or more unique peptides, 77 
cellular proteins increased in abundance and 15 cellular proteins decreased 
in abundance in the infected cells (Supplementary Tables VII, VIII) see 
appendix. 
 
There were 21 overlap significant matched genes and proteins in HRSV 
infected cells (Figure 4.8). All of these matched genes and proteins were 
increased abundance and many of them reflect the antiviral response. 
DDX58 had the largest change in abundance and the log2 fold change was 
3.2. However, other anti-viral response genes (IFIT1, OAS1, IFIT3, IFIT2 and 
OAS3) were almost the same fold change 2.7.  
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Figure 4.7 (A) Volcano plot of proteomics data showing the effect of HRSV 
on cells. There were 77 and 15 significant cellular proteins increased and 
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decreased in abundance, respectively. (B) The histogram demonstrated the 
correlation data between proteomics and transcriptomics. Out of 62,844 
surFit transcripts, 426 was increased in abundance more than 2-fold change, 
whereas, 136 transcripts were significantly decreased in abundance. This 
data also indicated that out of a total of 1716 proteins identified and 
quantified by 2 or more unique peptides, 77 cellular proteins increased in 
abundance and 15 cellular proteins decreased in abundance in the infected 
cells. (C) Venn diagram demonstrating the RNA-seq and proteomics 
analysis. At this point, 21 significant overlap proteins and genes which their 
abundance greater than 2-fold. 
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Figure 4.8 Overlap proteins and genes significantly increased in abundance 
in HRSV vs mock at 24 hr post-infection. DDX58 including anti-viral response 
were the largest change in abundance.   
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4.2.5 TREATMENT OF HRSV-INFECTED CELLS WITH RIBAVIRIN 
HRSV infected cells were treated with ribavirin at 6 hr post-infection with 
cellular mRNAs and proteins analyzed at 24 hr post-infection, with 5-fold 
decrease in progeny virus (Chapter 3). The data indicated that for infected 
cells treated at 6 hr post-infection with ribavirin and cellular mRNAs and 
proteins analyzed at 24 hr post-infection there was a reversal in the 
abundance of cellular and viral proteins that had been increased in untreated 
DMSO only infected cells (Figure 4.7). This was also generally reflected in 
the comparison of the cellular transcriptome and proteome (Figure 4.9). As 
an example, in HRSV-infected cells, the DDX58 pathway (anti-viral 
response) contains many proteins that are increased in abundance (Figure 
4.8). In contrast in HRSV-infected cells treated with ribavirin, in this pathway, 
the same proteins were decreased in abundance compared to HRSV-
infected cells only (Figure 4.10). Thus reversing the effects of the virus on 
this host cell pathway. 
At this time point (at 24 hr post-infection), out of 62,844 surFit transcripts, 
480 were increased in abundance more than 2-fold, whereas, 533 transcripts 
were significantly decreased in abundance with more than a 2-fold change. 
This data also indicated, for the +6hpi (assay point +24hpi), that out of a total 
of 1720 proteins identified and quantified by 2 or more unique peptides, 90 
cellular proteins increased in abundance and 23 cellular proteins decreased 
in abundance in the infected cells (Figure 4.9) (Tables 4.3 and 4.4). There 
were 83 genes significantly overlapped with proteins and most of them 
matched with the increased and decreased abundance between genes and 
proteins (Figure 4.10). 
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Figure 4.9 (A) Volcano plot representing the affect of ribavirin on infected 
cells. Decreased abundance in the top left which viral proteins where there, 
-5.0 
-4.0 
-3.0 
-2.0 
-1.0 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
-4.0 -3.0 -2.0 -1.0 0.0 1.0 2.0 3.0 4.0 
T
ra
n
s
c
ri
p
to
m
ic
s
(l
o
g
2
 
F
C
) 
Proteomics (log2 FC) 
HRSV DMSO vs HRSV RBV at 24 hpi 
0	
1	
2	
3	
4	
5	
6	
7	
-6	 -5	 -4	 -3	 -2	 -1	 0	 1	 2	 3	 4	 5	 6	
P<0.05 
-L
o
g
1
0
(p
-v
a
lu
e
) 
Proteomics 
1720 proteins identified 
90 significantly  
increased abundance 
23 significantly  
decreased abundance 
Transcriptomics 
62844 surFit identified 
480 significantly increased 
abundance 
533 significantly  
decreased abundance 
83  
Log2 FC 
Chapter 4: Investigation the effect of the anti-viral ribavirin on cells infected and un 
 135 
whereas, increased abundance in the top right. (B) The histogram shows the 
vibration of RNA-seq and proteomics of each gene. (C) Venn diagram shows 
the significant transcript and proteomics and there are 83 significant 
matched. 
 
Table 4.3 Proteins increased in abundance in HRSV DMSO vs HRSV RBV 
(top right of Figure 4.9). Statistical analysis was based on observed fold 
change 2 or greater, and more than 2 peptides and a p-value less than 0.05. 
These proteins were identified and quantified by LC MS/MS.  
Gene 
name Protein name 
Peptide 
identification  
Peptides 
used for 
quantitation Log2 FC 
MRPL16 
39S ribosomal protein L16, 
mitochondrial 2 2 3.9 
SYNE2 Nesprin-2 2 2 2.6 
HIST1H4
A-L, 
HIST2H4
A,B,HISR
4H4 Histone H4 13 13 2.4 
H2AFY Core histone macro-H2A.1 7 7 2.3 
HMGN2 
Non-histone chromosomal 
protein HMG-17 2 2 2.2 
DFFA 
DNA fragmentation factor 
subunit alpha 3 3 2 
HMGA1 
High mobility group protein 
HMG-I/HMG-Y 2 2 2 
ANXA11 Annexin A11 2 2 2 
CISD1 
CDGSH iron-sulfur domain-
3 3 1.9 
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containing protein 1 
HIST1H2
BM Histone H2B type 1-M 10 2 1.9 
CHD1 
Chromodomain-helicase-DNA-
binding protein 1 2 2 1.9 
C2orf47 
Uncharacterized protein 
C2orf47, mitochondrial 2 2 1.9 
TMPO 
Lamina-associated polypeptide 
2, isoforms beta/gamma 9 3 1.8 
PSIP1 
PC4 and SFRS1-interacting 
protein 5 3 1.8 
TOP2B DNA topoisomerase 2-beta 8 2 1.8 
MDC1 
Mediator of DNA damage 
checkpoint protein 1 4 4 1.8 
RBMX 
RNA-binding motif protein, X 
chromosome 14 4 1.8 
NDUFB10 
NADH dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 10 3 3 1.7 
CCDC86 
Coiled-coil domain-containing 
protein 86 3 3 1.7 
SPCS3 
Signal peptidase complex 
subunit 3 2 2 1.7 
LEPRE1 Prolyl 3-hydroxylase 1 2 2 1.7 
CYB5R1 
NADH-cytochrome b5 
reductase 1 3 3 1.7 
H2AFX Histone H2AX 5 2 1.7 
RPS29 40S ribosomal protein S29 2 2 1.7 
COX6C 
Cytochrome c oxidase subunit 
6C 3 3 1.6 
TOP2A DNA topoisomerase 2-alpha 18 12 1.5 
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MLEC Malectin 2 2 1.5 
HIST1H2
BO Histone H2B type 1-O 10 2 1.5 
TMEM126
A Transmembrane protein 126A 2 2 1.4 
LUC7L3 Luc7-like protein 3 2 2 1.4 
SNRPA 
U1 small nuclear 
ribonucleoprotein A 3 2 1.4 
RECQL 
ATP-dependent DNA helicase 
Q1 4 4 1.4 
PODXL Podocalyxin 2 2 1.4 
ITPR3 
Inositol 1,4,5-trisphosphate 
receptor type 3 5 4 1.3 
SLC25A3 
Phosphate carrier protein, 
mitochondria 11 11 1.3 
SLC25A1
1 
Mitochondrial 2-
oxoglutarate/malate carrier 
protein 3 3 1.3 
NDUFS8 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
8, mitochondrial 3 3 1.3 
CBX5 Chromobox protein homolog 5 3 3 1.3 
CD59 CD59 glycoprotein 3 3 1.3 
DEK Protein DEK 3 3 1.3 
PELP1 
Proline-, glutamic acid- and 
leucine-rich protein 1 2 2 1.3 
CAV1 Caveolin-1 3 2 1.2 
ATP5F1 
ATP synthase F(0) complex 
subunit B1, mitochondrial 4 4 1.2 
ZNF326 
DBIRD complex subunit 
ZNF326 3 3 1.2 
Chapter 4: Investigation the effect of the anti-viral ribavirin on cells infected and un 
 138 
HNRNPM 
Heterogeneous nuclear 
ribonucleoprotein M 30 29 1.2 
RCC1 
Regulator of chromosome 
condensation 6 6 1.2 
NCBP1 
Nuclear cap-binding protein 
subunit 1 4 4 1.2 
S100A10 Protein S100-A10 5 5 1.2 
MTA2 
Metastasis-associated protein 
MTA2 3 3 1.2 
NNT 
NAD(P) transhydrogenase, 
mitochondrial 11 10 1.1 
EGFR 
Epidermal growth factor 
receptor 9 9 1.1 
ANLN Actin-binding protein anillin 3 3 1.1 
LMNA Prelamin-A/C 41 40 1.1 
ATP5C1 
ATP synthase subunit gamma, 
mitochondrial 5 5 1.1 
PTGES Prostaglandin E synthase 2 2 1.1 
NAA10 N-alpha-acetyltransferase 10 6 5 1.1 
SLC25A5 ADP/ATP translocase 2 14 6 1.1 
P20073 Annexin A7 6 6 1.1 
EMD Emerin 6 6 1.1 
MFF Mitochondrial fission factor 4 4 1.1 
SLTM 
SAFB-like transcription 
modulator 3 3 1.1 
SAFB Scaffold attachment factor B1 5 3 1.1 
PDS5A 
Sister chromatid cohesion 
protein PDS5 homolog A 5 5 1.1 
UHRF1 
E3 ubiquitin-protein ligase 
UHRF1 2 2 1.1 
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STT3B 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
subunit STT3B 2 2 1.1 
TFRC Transferrin receptor protein 1 19 19 1 
MT-CO2 
Cytochrome c oxidase subunit 
2 3 3 1 
FUBP3 
Far upstream element-binding 
protein 3 9 6 1 
PARP1 
Poly [ADP-ribose] polymerase 
1 25 25 1 
POR 
NADPH--cytochrome P450 
reductase 4 4 1 
FBL 
rRNA 2'-O-methyltransferase 
fibrillarin 5 5 1 
YBX3 Y-box-binding protein 3 3 2 1 
UQCRC2 
Cytochrome b-c1 complex 
subunit 2, mitochondria 5 5 1 
PHF6 PHD finger protein 6 2 2 1 
LBR Lamin-B receptor 2 2 1 
VDAC2 
Voltage-dependent anion-
selective channel protein 2 11 11 1 
GPRC5A Retinoic acid-induced protein 3 2 2 1 
MPDU1 
Mannose-P-dolichol utilization 
defect 1 protein 2 2 1 
RRP1 
Ribosomal RNA processing 
protein 1 homolog A 2 2 1 
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Table 4.4 Proteins decreased in abundance in Mock vs HRSV (top left of 
Figure 4.9). Statistical analysis was based on observed fold change 2 or 
greater, and more than 2 peptides and a p-value less than 0.05. Proteins 
were identified and quantified by LC MS/MS. Those with a red colour are 
viral proteins. 
Gene name Protein name 
Peptide 
count 
Peptides 
used for 
quantitation 
Log2 
FC 
TUBA1C Tubulin alpha-1C chain 25 2 -1.0 
PMPCA 
Mitochondrial-processing peptidase 
subunit alpha 3 3 -1.1 
CDC123 
Cell division cycle protein 123 
homolog 2 2 -1.1 
CLIC4 
Chloride intracellular channel 
protein 4 2 2 -1.1 
WARS 
Tryptophan--tRNA ligase, 
cytoplasmic 21 21 -1.2 
WNK1 
Serine/threonine-protein kinase 
WNK1 3 3 -1.2 
MRFAP1 MORF4 family-associated protein 1 2 2 -1.3 
RSL1D1 
Ribosomal L1 domain-containing 
protein 1 9 8 -1.5 
SOD2 
Superoxide dismutase [Mn], 
mitochondrial 2 2 -1.6 
KRT1 Keratin, type II cytoskeletal 1 30 24 -1.9 
KRT14 Keratin, type I cytoskeletal 14 23 4 -1.9 
KRT2 
Keratin, type II cytoskeletal 2 
epidermal 17 7 -2.0 
KRT10 Keratin, type I cytoskeletal 10 24 19 -2.2 
Chapter 4: Investigation the effect of the anti-viral ribavirin on cells infected and un 
 141 
HRNR Hornerin 3 3 -2.3 
N Nucleoprotein 18 18 -2.4 
G Major surface glycoprotein G 2 2 -2.6 
M2-1 Matrix M2-1 14 14 -2.7 
F Fusion glycoprotein F0 11 11 -3.0 
NS2 Non-structural protein 2 2 2 -3.5 
P Phosphoprotein 12 12 -3.5 
UTP14A 
U3 small nucleolar RNA-associated 
protein 14 homolog A 2 2 -3.5 
NS1 Non-structural protein 1 3 3 -3.9 
M Matrix protein 17 16 -4.1 
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Figure 4.10 This figure demonstrates 83 genes significantly overlapped with proteins on infected cells verse infected plus treated 
with ribavirin at 24 hr post-infection. Anti-viral ribavirin has a clear effect on infected cells when added after 6 hr post-infection.
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4.2.6. BIOINFORMATIC ANALYSIS OF PROTEOMICS AND 
TRANSCRIPTOMICS DATASET  
Proteomics and RNA-seq data were further analyzed using Ingenuity 
Pathway Analysis (IPA) software (Ingenuity Systems), this helped to build the 
relationships of a large number of proteins and genes and understand their 
potential functions.  In infected cells without treatment with ribavirin (Mock vs 
HRSV), there was significant increased in abundance in proteins and genes 
at 24 hr post-infection. These proteins and genes were classified in terms of 
subcellular localization (Table 4.5). Antimicrobial response, inflammatory 
response and cell signalling were the functional categories containing the 
largest number of 52 significant proteins and 35 significant genes. The 
network of these proteins was analysed using the Core Analysis function on 
IPA (Figure 4.11). It was important to know what the antiviral response and 
viral infection genes that were increased in abundance during infection were, 
as this study focused on the antiviral drug, ribavirin. These genes were 
identified using IPA and a network analysis was made (Figure 4.12 A).  
 
As expected, when samples infected and treated with ribavirin at 6 hr post-
infection (DMSO HRSV vs HRSV RBV), both cellular proteins and genes 
were significantly decreased in abundance (Figure 4.12 B). Interesting, the 
decrease almost was among those proteins and genes that had increased in 
abundance in infected cells without treatment. Data analyses using IPA, 
infectious diseases, cell-to-cell signalling and interaction, and cellular 
movement were the top network function at infection and treated cells with 
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ribavirin. Proteins and genes that were significantly increased and decreased 
in abundance at this condition, were classified in terms of subcellular 
localization (Table 4.5). Moreover, as a big picture for the effect of antiviral 
ribavirin on different condition, heat map and relative clustering (Figure 4.13) 
was created by Gene-E. The analyses indicate that the effect of ribavirin 
when added into infected cells made a significant decreased in abundance.   
 
Table 4.5 Subcellular localization of proteins and genes identified in MOCK 
vs HRSV and HRSV DMSO vs HRSV RBV samples showing a log2 fold or 
greater relative increase or decrease in abundance. The localization was 
determined using Ingenuity Pathway Analysis software. 
Subcellular 
localization 
Number of proteins & genes 
MOCK vs HRSV HRSV DMSO vs HRSV 
RBV 
Proteins Genes Proteins Genes 
Nucleus 38 134 32 220 
Cytoplasm 26 191 14 279 
Plasma 
membrane 
10 96 8 144 
Other 9 141 48 370 
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Figure 4.11 Network pathway analyses of 52 significant genes that function 
as antimicrobial response, inflammatory response and cell signalling using 
IPA. Genes shaded in red corresponded to a 2-fold or greater increase in 
abundance and the colour intensity indicated the degree of gene abundance. 
Genes shaded in green corresponded to a 2-fold or lesser decreased in 
abundance. The shapes donated the molecular class of the gene. 
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Figure 4.12 Network pathway analyses of RNA-seq data on (A) Mock vs 
HRSV. All genes shaded in red corresponded to a 2-fold or greater increased 
in abundance at 6 hr post-infection. All of these genes significantly increased 
abundance during HRSV infection except LDLR and PDE3A. (B) (HRSV 
DMSO  vs HRSV+RBV), viral infection overlapped with antiviral response of 
using IPA. Genes shaded in green corresponded to a 2-fold or greater 
decreased in abundance at 6 hr post-infection.  
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Figure 4.13 Heat map represent genes expression that significantly changed 
in abundance at different conditions. The heat map based on the estimated 
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relative abundance. Colour intensity represents gene abundance with red 
indicating significant increased abundance and blue indicating significant 
decreased abundance. The analyses indicate that the effect of ribavirin when 
added into infected cells made a significant decreased in abundance.  
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4.3 DISCUSSION 
For the first time two high-resolution approaches have been used, RNA-seq 
and quantitative proteomics, to analyse the effect of a widely used and 
reportedly broad spectrum antiviral drug, ribavirin, on the host cell, to 
determine whether the drug causes any effects on host cellular mRNA and 
proteins in the presence and absence of infection. Further, these approaches 
were allowed to simultaneously explore the potential effect of the drug on 
virus biology using HRSV as a model pathogen. Ribavirin is the only licensed 
therapeutic treatment for HRSV infection, yet its mechanism of action 
remains largely uncharacterized and for many viruses, it is thought to 
promote hyper mutation and error catastrophe in the viral genome (Cameron 
& Castro, 2001; Crotty et al., 2002). Thus leading to a decrease in viral load. 
The effect of ribavirin on the host cell was examined, at an active 
concentration that disrupted virus biology, and caused a significant decrease 
in progeny virus production. This study was focused on whether treatment of 
cells with ribavirin resulted in a difference in abundance of either cellular 
mRNAs or proteins using the transcriptomic and proteomic approaches. In 
this case, the transcriptomic approach identified more specific gene products 
than the proteomic approach (Figure 4.3). The data indicated that the 
abundance of several hundred cellular mRNAs was affected by treatment 
with ribavirin and also the abundance of several cellular proteins that were 
detected was altered. This suggests that ribavirin can have a direct effect on 
the host cell, which becomes obvious in terms of the decrease in cell viability 
as the concentration of ribavirin is increased (Chapter 3). A number of 
cellular mRNAs increased in abundance in the presence of ribavirin and 
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these included transcripts associated with the innate immune response and 
also pathways activated as part of anti-viral signalling cascades. This may 
have a direct effect on HRSV-infection, perhaps by activating these 
responses in bystander cells that may be infected during viral spread and 
secondary rounds of infection. 
 
Interestingly, the analysis indicated that there were not many cellular mRNA 
and proteins increased or decreased in the presence and absence of DMSO 
with and without ribavirin (Figures 4.4, 4.5). In terms of viral mRNA and 
proteins, there were a significant increase in infected cells un-treated and 
significant decreased in infected plus treated. Proteomic analysis of cells 
infected with either HRSV or cells infected with HRSV and treated with the 
DMSO, recapitulated many of the previously reported effects of viral infection 
on the host cell (Dave et al., 2014; Munday et al., 2010c). This established 
the robustness and reproducibility of the analysis. The transcriptomic 
approach allowed us not only to examine global gene expression analysis of 
cellular genes in virus-infected cells but also to examine the effect of ribavirin 
treatment on virus RNA by building consensus genomes and mapping minor 
variants (Chapter 5). 
 
What both experimental approaches indicated and agree upon was that the 
mRNA encoding the G gene was the most abundant (Chapter 5), however, 
the P protein was the most abundant. The abundance of the other viral 
mRNAs did not conform to a pattern if their abundance reflected transcription 
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by a linear gradient, at least under the conditions that were used in the 
experiment. Such observations can be supported by the data in this study 
and previous analysis of viral protein abundance using quantitative 
proteomics in different cell types infected with HRSV (Dave et al., 2014; 
Munday et al., 2010b).  Here, the abundance of viral proteins did not 
correspond to a profile if their abundance was solely determined by mRNA 
abundance - assuming a linear gradient expression profile.  As noted by 
Dave et al., 2014, care should be taken when interpreting the relative 
abundance of viral proteins using quantitative proteomics as not all proteins 
may be refractive to the steps used in mass spectrometry identification and 
quantification. This is reflected in the western blot analysis of viral proteins 
(Chapter 3). Taken at face value, the G protein would appear to be more 
abundant, and then the N, P and M proteins. However, this data was 
generated using polyclonal sera raised against viral proteins derived from 
infected cell lysate and several different factors can affect antigen and 
epitope selection.  However, these findings, if correct, do not rule out a model 
in which the abundance of viral transcripts is related to their order and 
position along the viral genome.  Other factors such as mRNA stability may 
play a significant role in determining the relative levels of abundance for 
HRSV transcripts. 
 
These results investigated the effect of ribavirin on HRSV-infected cells using 
a combination of RNA-seq and quantitative label free proteomics. This study 
was able to demonstrate that treatment of cells with ribavirin resulting in 
increase transcription of selected cellular mRNAs including those involved in 
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mediating anti-viral signalling. Additionally, ribavirin treatment caused a 
decrease in the viral mRNA and proteins. Clearly by using IPA that in the 
infected cells the most significant pathway was antiviral response that is a 
natural response to fight the virus that attacking cells (Martínez et al., 2007). 
Therefore, the concentration of ribavirin on HRSV infection has clearly shown 
the reduction of viral proteins and other cellular proteins.  
 
These combined approaches; RNA-seq and label free quantitative 
proteomics, have not been used before to study HRSV biology and can be 
readily applied to the investigation of virus host interactions and the effects of 
therapeutics on the host. This study indicated that ribavirin affected only a 
subset of cellular mRNA and proteins. 
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CHAPTER 5: INVESTIGATING THE INFLUENCE OF RIBAVIRIN 
ON HUMAN RESPIRATORY SYNCYTIAL VIRUS RNA 
SYNTHESIS USING A HIGH-RESOLUTION RNA-SEQ 
APPROACH  
5.1. INTRODUCTION  
Ribavirin can be used in children who are extremely ill to reduce the amount 
of HRSV and lower the burden of disease (Everard et al., 2001; Ventre & 
Randolph, 2007). Ribavirin is also used as an experimental therapy with 
other viruses (Paeshuyse et al., 2011; Sparrelid et al., 1997). However, the 
mechanism of action of ribavirin in HRSV is not well understood, although it 
is thought to increase the mutation rate of the viral polymerase during 
replication (Graci & Cameron, 2006). Previous studies have investigated the 
effect of inosin monophosphate dehydrogenase (IMPDH) inhibition during 
HRSV infection (Leyssen et al., 2005; Smee & Matthews, 1986). Other 
mechanism have been studied; loss of fitness of RNA virus genomes (Crotty 
et al., 2001; Dietz et al., 2013), up-regulation of anti-viral gene products 
(Zhang et al., 2003), Inefficient translation (Tamburini et al., 2009; Volpon et 
al., 2013) and Multiple mechanisms of action  (Day et al., 2005), but the 
effect that ribavirin might have on fidelity of HRSV RNAs, or the stability of 
resulting mRNA transcripts has not previously been examined. To investigate 
the effect of ribavirin on HRSV RNA synthesis, high-resolution RNA-seq was 
used. Minor variant analysis (location of nucleotides mapped along the 
genome of HRSV) helped to assess the effect of ribavirin on the frequency of 
mutations in the HRSV genome. The addition of ribavirin resulted in a 
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decrease in the abundance of viral RNA and a modest increase in the 
frequency of transition, but not transversion, mutations, suggesting direct 
influence on polymerase fidelity. In addition, that been found in both the 
absence and presence of ribavirin, the cumulative abundance of viral mRNA 
at the two time points (24 and 48 hr post-infection) analysed did not follow 
the transcription gradient of mRNA synthesis, contrary to what was 
anticipated. 
 
Various studies have revealed the inhibitory nature of ribavirin on HRSV in 
vitro. For example, addition of ribavirin at -2, 0 and 1 hr post-infection 
resulted in a 95% plaque reduction (Hruska et al., 1980), however the 
mechanism of this inhibition is unclear. In the published literature RNA-seq 
has not been applied at high read depth to study HRSV replication and 
transcription and it provides an ideal approach to study the potential 
mutagenic effect of ribavirin on HRSV genome biology. A recent study 
described a pipeline (based on the Galaxy platform) that was used to 
generate consensus genomes and maps of minor variants to study Ebola 
virus evolution in a guinea pig model (Dowall et al., 2014) and in patient 
samples taken from the 2014-2015 West African outbreak  (Carroll et al., 
2015). These studies indicated that a greater read depth during RNA-seq 
provided more accurate base calling on the consensus genome and provided 
maps of minor variants. 
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To provide sufficient viral RNA for sequencing and to balance this with 
infectivity and cell viability (through both treatment with ribavirin and infection 
with HRSV) several optimization experiments were performed (Chapter 3). 
The concentration of ribavirin used was based on previous literature (Shah et 
al., 2010; Zhang et al., 2003), and an MTT assay was used to establish cell 
viability versus toxicity in HEp-2 cells (Figure 3.1). These analyses, together 
with concentrations previously used in the literature, suggested that a 
concentration of 500 μM would be tolerated by the cells in culture and 
provide anti-viral activity. Also, different optimizations were performed to 
identify the best viral MOI in the absence and presence of 500 μM of ribavirin 
(Chapter 3). The data indicated that at a MOI of 0.5 and in the presence of 
500 μM ribavirin, there was a visible decrease in the number of infected cells 
compared to untreated cells (Figure 3.2). Ribavirin treatment at different time 
points on HRSV infected cells were studied in Chapter 3. The data indicated 
that two time points were chosen for this study; ribavirin added at +6 hr post-
infection and RNA harvested at 24 hr post-infection and ribavirin added at 
+24 hr post-infection and RNA harvested at 48 hr post-infection. The aim of 
this study is to investigate the effect of ribavirin on the HRSV infected cells. 
 
The work described in this chapter has recently been published in the 
Journal of Virology.  Waleed Aljabr, Olivier Touzelet, Georgios Pollakis, 
Weining Wu, Diane C. Munday, Margaret Hughes, Christiane Hertz-Fowler, 
John Kenny, Rachel Fearns, John N. Barr, David A. Matthews and Julian A. 
Hiscox, (2015) Investigating the influence of ribavirin on human respiratory 
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syncytial virus RNA synthesis using a high-resolution RNA-seq approach 
10.1128/JVI.02349-15. (See appendix) 
 
The candidate confirms that the work submitted is his own, except where 
work which has formed part of jointly-authored publications has been 
included. The contribution of the candidate and the other authors to this work 
has been explicitly indicated below. The candidate confirms that appropriate 
credit has been given within the thesis where reference has been made to 
the work of others. 
 
Chapter 5 of this thesis was based on the work from jointly-authored 
publication: 
 
 Waleed Aljabr planned and performed all experiments, prepared 
samples for RNA-seq, western blot, immunofluorescence, data 
analyses, and jointly wrote the manuscript. 
 Rachel Fearns and John Barr provided advice regarding manuscript 
structure. 
 Oliver Touzelet, Weining Wu and Diane Munday provided technical 
support. 
 Georgios Pollakis provided minor variant analysis. 
 John Kenny, Margaret Hughes and Christiane Hertz-Fowler run RNA- 
seq. 
 David Matthews provided viral transcriptomic analysis. 
 Julian Hiscox provided supervision and jointly wrote the manuscript. 
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Also, some of this work in this chapter has been published in Virology. Sarah 
L. Noton, Waleed Aljabr, Julian A. Hiscox, David A. Matthews, Rachel 
Fearns, (2014) Factors affecting de novo RNA synthesis and back-priming by 
the respiratory syncytial virus polymerase. Virology, 462-463:318-327. (See 
appendix) 
 
The candidate confirms that the work submitted is his own, except where 
work which has formed part of jointy-authored publications has been 
included. The contribution of the candidate and the other authors to this work 
has been explicitly indicated below. The candidate confirms that appropriate 
credit has been given within the thesis where reference has been made to 
the work of others. 
Chapter 5 of this thesis was based on the work from jointly-authored 
publication: 
 Sarah Noton and Rachel Fearns planned the experiments, prepared 
figures, performed data analyses and jointly wrote the manuscript.  
 Waleed Aljabr planned and performed all experiments and prepared 
samples for RNA-seq. 
 Julian Hiscox and David Matthews prepared transcriptomics analysis. 
  
Chapter 5: Investigating the influence of ribavirin on hyman respiratory syncytial virus RNA synthesis using 
a high-resolution RNA-seq approach  
 159 
5.2 RESULTS 
5.2.1 DETERMINING THE ABUNDANCE OF VIRAL MRNAS IN HRSV INFECTED 
CELLS USING RNA-SEQ 
RNA-seq was used to measure the abundance of poly A selected viral 
mRNAs under the two different time points in both untreated and ribavirin 
treated HEp-2 cells. RNA-seq analysis of the two different time points 
indicated that in untreated HEp-2 cells at 24 and 48 hr post-infection, 19.8% 
and 10.53% of total reads mapped to HRSV RNA (Table 5.1), corresponding 
to 6,162,832 and 3,810,092 reads at each time point, respectively. HRSV 
transcripts also reached a high level in A549 cells, in this case representing 
34.72% of the total reads (Table 5.1), a total of 14,105,224 reads. 
 
From the RNA-seq data, the relative abundance of each viral mRNA at 24 
and 48 hr post-infection in the absence and presence of ribavirin treatment 
was calculated using the number of reads mapping to each gene. This 
approach was unable to discriminate monocistronic viral mRNA from 
polycistronic RNAs, although the abundances of polycistronic read-through 
products are generally low in HRSV infections (Cartee et al., 2003). The data 
indicated that as a proportion of total reads, the amount of viral RNA 
decreased in the presence of ribavirin (Table 5.1). 
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Table 5.1 Number and proportion of sequence reads mapping to the HRSV 
genome out of the total number of sequence reads. 
Cell lines Conditions Reads 
mapping to 
the HRSV 
genome 
Total 
number of 
reads 
% of 
total 
reads 
 
 
 
HEp-2 
HRSV at 24hpi 6162832 31118416 19.8 
HRSV+RIBAVIRIN 
at 24hpi 
21350 32769666 0.07 
HRSV at 48hpi 3810092 36182362 10.53 
HRSV+RIBAVIRIN 
at 48hpi 
436172 44545058 0.98 
 
A549 
HRSV at 24hpi 14105224 40622791 34.72 
HRSV+17-AAG at 
24hpi 
1549050 37493536 4.13 
 
The accumulation of each viral mRNA in an infected cell, if this follows the 
pattern postulated for other mononegavirales, might be expected to reflect 
the order of genes on the genome, so that the relative abundance of different 
gene transcripts would correlate with gene position relative to the 3’ end (Lim 
& Yin, 2009; Pagán et al., 2012). However, for the two time points examined, 
the data showed that, whilst there was a general trend of abundance 
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correlating with gene order, there were exceptions (Figure 5.1 A). For 
example, as expected the L mRNA was the least abundant transcription 
product (Figure 5.1 A), however, the mRNA encoding the G protein appeared 
to be the most abundant mRNA at both time points in both the absence and 
presence of ribavirin. This observation suggests that factors other than gene 
order may be able to influence HRSV mRNA abundance in cells, in particular 
for the G mRNA. Importantly, the profile of relative viral mRNA abundance 
was equivalent in untreated versus ribavirin treated infected HEp-2 cells, 
suggesting that ribavirin did not impinge upon the overall program of HRSV 
transcription per se. 
 
If viral mRNA transcript levels are governed in part by mRNA stability, the 
profile of relative levels might be different in different cell types. Therefore, 
the abundance of viral mRNA in HRSV infected A549 cells at 24 hr post-
infection was investigated. In this instance 34.72% of the total reads mapped 
to the HRSV mRNA (Table 5.1), a total of 14,105,224 reads. Again, the data 
indicated that the abundance of viral mRNAs at this time point and in this cell 
type did not correspond to the predicated linear gradient (Figure 5.1 A).  
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Figure 5.1 (A) Analysis of the abundance of viral mRNAs HE-p2 or A549 
cells infected with HRSV at different time points and for HEp-2 cells in the 
absence or presence of ribavirin.  The viral mRNA abundance is shown in 
order of the particular gene along the HRSV genome, from 3’ to 5’, and also 
the order in which the particular gene is transcribed. The abundance is 
shown in fragments per kilobase of exon per million fragments mapped 
(FPKM). (B) RNA-seq data from HEp-2 cells at 24 hpi was further processed 
to include only proper mate pair reads, where both reads were mapped and 
correctly orientated with respect to each other.  The seed length was 
increased from 28 to 35. The maximum number of miss matches was 
reduced to 1. The horizontal line traces the average abundance of the 
mapped reads for each gene. 
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To investigate this further, as an exemplar, the RNA-seq data for HRSV in 
HEp-2 cells at 24 hr post-infection was further processed to include only 
proper mate pair reads, where both reads were mapped and correctly 
orientated with respect to each other. The seed length was increased from 
28 to 35. The maximum number of miss matches was reduced to 1. One 
effect of this is to bias the reads to those that match the consensus 
sequence. This data again indicated that the L mRNA was the least 
abundant HRSV transcript (Figure 5.1 B), however the difference in the other 
gene products was less pronounced, with P and G transcripts being almost 
equivalent (Figure 5.1 B). 
 
5.2.2. READ THROUGH AT GENE JUNCTIONS CORRELATES WITH PREVIOUS 
SUBGENOMIC REPLICON DATA 
The data also provided a measurement of read-through, which allowed a 
direct comparison to previously published results, and allowed validation of 
the RNA-seq approach to quantify viral RNA. This was determined by 
comparing the average Fragments Per Kilobase Million (FPKM) in the 
intergenic region to the total virus FPKM (Table 5.2). From this, the % read 
through between adjacent genes was calculated, with those for 
NS1/NS2=30%, NS2/N=13%, N/P=10%, P/M=4%, M/SH=21%, SH/G=4%, 
G/F=8% and F/M2=11%. For the gene junctions examined, this pattern of 
relative read through efficiency correlates with data examining the 
transcription termination efficiency of gene junctions in the context of 
subgenomic replicons (Cartee et al., 2003). For example, in both studies, 
data indicated that the SH/G gene junction terminated transcriptions with the 
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greatest efficiency and produced low levels of read-through transcripts, 
whereas the NS1/NS2 gene junction had the highest level of read through 
(Cartee et al., 2003). 
 
Table 5.2 Percentage read through between adjacent genes along the HRSV 
genome. 
Read-through 
Average 
FPKM 
% Total 
virus FPKM 
% Between 
adjacent 
genes 
Leader 122 0.17 - 
Non-structural protein 1 (NS1) 3578 5.11 - 
Intergenic region 4500 6.43 30 
Non-structural protein 2 (NS2) 6952 9.94 - 
Intergenic region 2070 2.96 13 
Nucleoprotein (N) 6740 9.63 - 
Intergenic region 1838 2.63 11 
Phosphoprotein (P) 8446 12.07 - 
Intergenic region 671 0.96 4 
Matrix protein (M) 6255 8.94 - 
Intergenic region 3098 4.43 21 
Small hydrophobic protein 
(SH) 5072 7.25 - 
Intergenic region 662 0.95 4 
Glycoprotein (G) 9444 13.5 - 
Intergenic region 1177 1.68 8 
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Fusion protein (F) 3544 5.07 - 
Intergenic region 929 1.33 11 
M2 protein 3877 5.54 - 
Large polymerase protein (L) 968 1.38 - 
Trailer 25 0.04 - 
Total 69968 100 - 
 
 
5.2.3 RNA-SEQ ANALYSIS REVEALED AN INCREASE IN THE FREQUENCY OF 
TRANSITION BUT NOT TRANSVERSION MUTATIONS IN THE PRESENCE OF 
RIBAVIRIN 
To access the frequency of potential nucleotide substitution in these different 
populations, the QuasiRecomb algorithm (Töpfer et al., 2013) was used to 
obtain coverage and data on the proportion of each nucleotide used at any 
given location on the genome. The results were further processed by an in-
house script to determine which nucleotide was the most abundant at each 
nucleotide position, and how frequently any of the other three nucleotides 
were used at that position. A similar approach was used to derive consensus 
genomes and examine nucleotide variation that corresponded with increase 
in virulence with Ebola virus in a guinea pig model of infection (Dowall et al., 
2014), to measure Ebola virus evolution during the 2014-2015 West African 
outbreak (Carroll et al., 2015) and to investigate infection of human and bat 
cells with Hendra virus (Wynne et al., 2014). These data were displayed as 
frequency of use of minor nucleotides along the genome (Figure 5.2). For 
example, in the case of HRSV assayed at +24 hr post-infection, there were 
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13 nucleotide positions that had a substitution in 30% or more of the 
sequence reads that mapped across that location (Figure 5.2 A). On first 
inspection, the nucleotide substitution frequency in HRSV RNA isolated from 
cells that had been treated with ribavirin at +6 hr post-infection (assay point 
+24 hr post- infection), seemed large, especially in the L gene sequence 
(Figure 5.2 B). However, further inspection of the data revealed that given 
the 166-fold decrease in mappable reads at this assay point, there were 
relatively few quality reads, and the apparent nucleotide frequency variation 
decreased when lower quality reads were removed (Figure 5.2 C). Also, the 
number of mapped reads obtained without ribavirin was artificially reduced to 
the level seen when examined cells were treated with ribavirin at +6 hr post-
infection (data not shown). This dataset was examined for minor variants and 
a similar pattern of nucleotide variation was seen (data not shown) 
confirming the supposition that compared to the higher number of mappable 
reads (Figure 5.2 D), the low number of mappable reads (Figure 5.2 E) led to 
an apparent increase in variation and this cannot be attributed to be the 
ribavirin treatment.  
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Figure 5.2 Analysis of depth of coverage and minor variation along the 
HRSV genome in the presence or absence of HRSV.  In each part, the 
nucleotide position is indicated along the x axis. Charts illustrating the minor 
variation show the proportion of minor nucleotide calls at each nucleotide as 
a fraction of 1, thus a bar height of 0.4 indicates that at that nucleotide 
position some 40% of the sequence reads indicated an alternate base from 
the consensus. Charts illustrating coverage depth are a simple plot of the 
depth of sequence coverage at each nucleotide position. (A) Shows the 
location of minor variant base calls for HRSV mRNA mapped to the HRSV 
genome at 24 hours post- infection. (B) Shows the location of minor variant 
base calls for HRSV mRNA mapped to the HRSV genome at 24 hours post-
infection when ribavirin has been added to the media at 6 hours post-
infection using the same mapping pipeline as used in part A. (C) Shows an 
analysis of the same raw sequence data as in (B) but with low quality 
sequence reads removed (e.g. all reads with MAPQ less than 11 and 
mapped read length less than 50 bases). (D) Depth of coverage of sequence 
data for HRSV mRNA mapped to the HRSV genome at 24 hours post-
infection with the location of HRSV genes indicated. (E) Depth of coverage of 
sequence data for HRSV mRNA mapped to the HRSV genome at 24 hours 
post-infection with ribavirin added at 6 hours post- infection, note the change 
in scale on the Y axis. (F) Shows the location of minor variant base calls for 
HRSV mRNA mapped to the HRSV genome at 48 hours post-infection. (G) 
Shows the location of minor variant base calls for HRSV mRNA mapped to 
the HRSV genome at 48 hours post-infection when ribavirin has been added 
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to the media at 24 hours post-infection using the same mapping pipeline as 
used in (A). 
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Analysis of the sequence data when ribavirin was added at +24 hr post-
infection and viral RNA analysed at 48 hr post-infection provided higher 
quality reads. For the control untreated HRSV infection there were 8 
nucleotide positions that had a substitution in 30% or more of the sequence 
reads that mapped across that location (Figure 5.2 F). For HRSV infection in 
which ribavirin was added at +24 hr post-infection and nucleotide sequence 
analysed at 48 hr post-infection there were 5 nucleotide substitutions that 
were present in 30% or more of the sequence reads that mapped across that 
location (Figure 5.2 G). 
 
As described in the introduction, ribavirin treatment might be expected to 
result in an increase in transition mutations specifically. To distinguish this 
effect, analysis of mutations was performed using the Bioedit Textpad and 
Excel software. Initially all transitions and transversions were scored and 
given a binary identification. Transversions were also analysed as an internal 
control to investigate whether the frequency of any mutation increased in the 
presence of ribavirin. Subsequently a sliding window of 500 nucleotides, was 
arbitrarily chosen, and was moved across the full length of the reference 
sequence by increments of 500 nucleotides. In each step, the number of 
transversion and transitions was determined among the minor sequence 
quasispecies (Figure 5.3). The data indicated that transition mutations 
significantly increased in the presence of ribavirin compared to the untreated 
control. The frequency of transversions was not significantly different. 
Reflecting this, the ratio of transitions to transversions was significantly 
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higher in ribavirin treated infected cells compared to untreated infected cells. 
There was greater experimental noise associated with the analysis of 
transitions in cells treated with ribavirin at +6 hr post-infection (assay point 24 
hr post-infection) compared to ribavirin added at +24 hr post-infection (assay 
point 48 hr post-infection). This was attributed to the lower quality sequence 
reads, and the comparative data shown in Figure 5.3 is based on sequence 
reads obtained with the more abundant transcripts produced from the first 
half of the genome. 
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Figure 5.3 Transition and transversion analyses for each of the culture 
conditions. The analysis was implemented, using a 500 hundred nucleotide 
sliding window across the genome. The area coding for the polymerase gene 
was not included in the analysis since the sequencing depth for this genomic 
region was much lower. The box-plot indicates the mean value, the 25 and 
75 percentiles and the 95% CI of mean.  For comparisons the paired t-test 
was implemented using the Prism software package 
(http://www.graphpad.com/scientific-software/prism.htm). (A) Shows the 
purine/pyrimidine transversions (B) the purine/purine and 
pyrimidine/pyrimidine transitions (C) shows transitions and tranversions (D) 
shows the G to A (E) the A to G and (F) the C to U permutations.  The 
analysis was also performed using a 100 hundred nucleotide sliding window 
(data not shown) and results were similar. 
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These results were also compared to data obtained from cells treated with 
17-AAG as a control. Treatment of infected cells with 17-AAG inhibits the 
chaperone activity of HSP90, and results in destabilization of the HRSV L 
protein and concomitant reduction in viral mRNA and protein levels (Munday 
et al., 2014b). Thus, 17-AAG acts indirectly as an inhibitor of RdRp 
accumulation (rather than activity) and has been shown to have an antiviral 
affect for HRSV (Geller et al., 2013; Munday et al., 2014b; Radhakrishnan et 
al., 2010) and other negative strand RNA viruses (Connor et al., 2007). Here, 
nucleotide substitution frequency was analysed at 24 hr post-infection. At this 
time, there were 8 nucleotide positions that had a substitution in 30% or more 
of the sequence reads that mapped across that location in the untreated 
control (Figure 5.4). For HRSV infection treated with 17-AAG at +6 hr post-
infection and HRSV sequence analysed at 24 hr post-infection, this resulted 
in a 9-fold decrease in mappable reads to the HRSV genome (Table 5.1). 
There were 9 nucleotide positions that had a substitution in 30% or more of 
the sequence reads that mapped across that location (Figure 5.4). There was 
no evidence that 17-AAG caused an increase in the frequency of transition or 
transversions in HRSV-infected cells (Figure 5.3). 
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Figure 5.4 Analysis of minor variation along the HRSV genome in the presence or absence of 17-AAG.  In each part, the nucleotide 
position is indicated along the x axis. As before, the minor variation shows the proportion of minor nucleotide calls at each 
nucleotide as a fraction of 1, thus a bar height of 0.4 indicates that at that nucleotide position some 40% of the sequence reads 
indicated an alternate base from the consensus. (A) Shows the location of minor variant base calls for HRSV mRNA mapped to the 
HRSV genome at 24 hours post-infection in A549 cells. (B) Shows the location of minor variant base calls for HRSV mRNA mapped 
to the HRSV genome at 24 hours post-infection when 17-AAG has been added to the media at 6 hours post-infection in A549 cells 
using the same mapping pipeline as used in part A. Both data sets were generated independently of those analysed in Figure 5.2.
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5.2.4 TRANSITION AND TRANSVERSION SUBSTITUTIONS POTENTIALLY OCCUR IN 
CLUSTERS ALONG THE HRSV RNA GENOME 
Interestingly, analysis of the position and frequency of the transition and 
transversion mutations along the HRSV genome, either untreated or treated 
with ribavirin suggested that these background substitutions did not occur 
with an even distribution and instead clustered in discrete hotspots (e.g. 
Figure 5.5). These hotspots were equivalent for HRSV grown in either HEp-2 
or A549 cells, indicating that this observation was not dependent in these two 
cell types. Some of these hotspots are located at the intergenic regions but 
were also found in coding regions. There was no significant increase in 
transition or transversion substitutions in HRSV-infected cells treated with 
DMSO (e.g. Figure 5.3), which was the ribavirin solvent. However, there was 
an increase in transition mutations between (and within) hotspots with 
ribavirin treatment. From this analysis, it is clear that nucleotide changes in 
the viral genome due to the action of ribavirin then occur both in these 
clusters and between these clusters (Figure 5.5). The data also indicated 
that, in general, there was a greater frequency of transition and transversion 
substitutions within non-coding regions compared to coding regions (Figure 
5.6).
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Figure 5.5 Representative analysis of transitions (full circle) and 
transversions (open rombe) resulting the minor nucleotide variants at each 
position of HRSV genome with the different treatment regimes. For each 
condition, the consensus sequence is shown on the first line. The following 
four lines represent each of the four nucleotides found as a minor variant. 
The cut off value was 0.5% and the region of the genome shown is indicated 
by the bold numbers on top. 
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Figure 5.6 Analysis of transitions and transversions in coding and non-coding regions of the HRSV genome with the different 
treatment regimes. 
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5.3 DISCUSSION   
For the first time, RNA-seq at high-resolution has been used to investigate 
HRSV RNA synthesis and to analyse the effect of a widely used and 
reportedly broad spectrum antiviral drug, ribavirin, on infected cell RNA 
accumulation and viral RNA mutation frequency. In the absence of ribavirin, 
RNA-seq analysis revealed that HRSV-specific RNAs formed up to one third 
of all RNA reads, suggesting a remarkable domination of the cellular RNA 
pool, at least in cell culture models. Indeed the analysis of sequencing data 
to generate minor variants was capped at 1 million reads mapping to the 
HRSV genome. 
 
Ribavirin treatment of HRSV-infected cells resulted in decreases in progeny 
virus and overall levels of viral RNA as determined by the number of 
sequence reads that mapped to the HRSV genome (Table 5.1). Whilst this 
reduction in reads mapping to the HRSV genome in proportion to the total of 
reads obtained could be explained by an increase in cellular mRNA levels 
caused by ribavirin treatment, the data available does not support this 
conclusion. This would require a significant (~10 fold) and across the board 
increase (and in just the same genes detected in the ribavirin only control 
samples) in the total amount of mRNA in the cell. This would be unusual for 
either ribavirin treatment or HRSV infection. In addition, no evidence of 
increases in total RNA extracted from the cells treated solely with ribavirin 
was seen.  
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The analysis indicated that the frequency of transitions but not transversions 
in the HRSV genome were significantly different between infected cells 
treated with ribavirin versus untreated infected cells. No increase in 
nucleotide transitions or transversions in HRSV sequence was associated 
with treatment of infected cells with 17-AAG, an inhibitor of HSP90 (Figure 
5.3) and HRSV polymerase accumulation and function (Munday et al., 
2014b). There was an approximately 1.5-fold increase in the recorded 
frequency of transitions on HRSV RNA in infected cells treated with ribavirin 
at 24 hr post-infection compared to the untreated control (Figure 5.3). This is 
less than the 4.4-fold increase in the frequency of transitions associated with 
the treatment of poliovirus-infected cells with 400 μM ribavirin (Crotty et al., 
2001), and the reasons for this are unclear. In the poliovirus study, cells were 
pretreated with ribavirin and the drug was maintained throughout the six-hour 
infection, whereas in this study, ribavirin was not added to the HRSV infected 
cells until either 6 or 24 hr post-infection. Alternatively, or in addition, it might 
be that the HRSV RdRp is more stringent than that of poliovirus, possibly due 
to the two-fold longer length of the HRSV genome. In this scenario, the 
HRSV RdRp might better discriminate against ribavirin triphosphate, resulting 
in reduced incorporation and thus a lower mutation rate. Regardless, 
elevations in mutation frequencies by as low as two-fold have been proposed 
to lead to fitness losses and extinctions of large RNA virus populations in cell 
culture and animal models of infection (Anderson et al., 2004), and so the 
1.5-fold increase in mutation frequency observed here could explain why 
ribavirin treatment resulted in reduced HRSV-specific RNA levels and 
progeny virus (Figures 3.8 and 3.11). While these results strongly suggest 
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the anti-HRSV action of ribavirin is through direct incorporation into nascent 
RNA by the viral polymerase, it cannot exclude the possibility that other 
proposed activities such as reduction of the GTP pool also contribute to 
reduced viral growth and HRSV-specific RNAs, although ribavirin did not 
affect the overall levels of cellular mRNA (Table 5.1). 
 
As noted, the read depth of viral RNA was much lower when infected cells 
were treated with ribavirin at +6 hr post-infection compared to when infected 
cells were treated with ribavirin at +24 hr post-infection. In order to compare 
the nucleotide substitution frequency between these two experimental 
conditions, data from 3’ proximal portion half of the HRSV genome was used. 
This is because the majority of the 5’ proximal portion of the genome 
encodes the L mRNA, and this is the least abundant transcript, and 
subsequently has even fewer sequence reads mapping to it. The error rate of 
viral RdRp is estimated to be between 1.5×10-3 bp-1 (bacteriophage Q β) and 
7.2×10-5bp-1 (influenza virus) (Drake, 1993). This relaxed fidelity of RdRp 
activity is an important feature of RNA virus biology, providing a source of 
sequence diversity that can allow virus quasispecies to form, enabling the 
virus to adapt successfully to changing environments.  However, this inherent 
RdRp error rate can also be detrimental to virus biology and lead to the 
generation of non-viable templates that reduce overall viral fitness. The term 
rate ‘error catastrophe’ has been used to describe the outcome of a RdRp 
error rate at which too many non-viable templates are generated and a virus 
population becomes unsustainable, and it is believed that many viral RdRps 
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operate close to this threshold (Crotty & Andino, 2002; Crotty et al., 2002). 
Although the length of the HRSV genome is only ~1.5 x longer than HCV or 
poliovirus, a 50% increase in the frequency of transition mutations appears to 
be sufficient to cause a loss in viable virus. 
 
Interestingly the analysis indicated that transitions and transversions 
occurred in clusters along the HRSV RNA genome (Figure 5.5), and this was 
the same for viruses grown in different cell lines (e.g. HEp-2 and A549) and 
under a variety of different treatment conditions (e.g. in the presence of 17-
AAG). Some of these clusters localized to the intergenic regions, and one 
possibility for this is the known tolerance for sequence changes within this 
region of the HRSV genome, and this is reflected in the difference between 
transition and transversion events between the coding and non-coding 
sequence (Figure 5.6). It is worth noting that these are the positions where 
such minor variants can occur, but these do not reflect the average 
consensus sequence. Analysis indicated that treatment with ribavirin 
increased the frequency of transition mutations in both the coding and non-
coding regions (Figure 5.6). 
 
The data also indicated a preponderance of A to G changes in the minor 
variants, which is a characteristic of adenosine deaminases acting on RNA 
(ADAR) modification, which depending on the virus, has been reported to 
have both anti-viral and pro-viral activity (Samuel, 2011). Genome wide 
association studies have shown an increase in ADAR transcripts during 
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HRSV infection in a mouse model (Stark et al., 2010). Escape mutant 
analysis with antibodies specific for the G protein suggested that the G gene 
could potentially be modified by ADAR activity (Martínez & Melero, 2002). 
 
Analysis of the abundance of HRSV mRNA, at the two time points analysed, 
indicated that they did not reflect a linear gradient that is predicated by the 
generally accepted and long-standing model for polar and sequential 
transcription of negative stranded RNA viruses (Figure 5.1). Several different 
algorithms were used to analyse the RNA-seq data and each of these 
indicated that the abundance of viral mRNAs in the cell at these specific time 
points did not follow a precise linear gradient. For the final data analysis 
shown in Figure 5.1, fragments per kilobase of gene per million bases 
mapped were manually calculated. Even a very conservative analysis of the 
RNA-seq data indicated a non-polar abundance of viral transcripts (Figure 
5.1B). Given that there are very strong data to show that the HRSV RdRp 
cannot enter the template internally (Dickens et al., 1984) and that in an in 
vitro transcription assay the amount of each transcript reflects the position of 
the gene on the genome (Barik, 1992), this result indicates that while gene 
order is a principle determinant of transcript abundance, it is not the only 
factor, with mRNA stability likely making an important contribution to relative 
mRNA levels. Importantly with respect to this study, ribavirin had no effect on 
the relative abundance of the ten sequentially transcribed HRSV transcripts 
(Figure 5.1). This current finding also suggests ribavirin has no detectable 
influence on RNA synthesis processes that could affect transcript stability. 
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These include RNA processing events such as 5’ capping and poly (A) tail 
addition. The RNA-seq approach may provide a bias towards the recording of 
different mRNA abundances, although the data indicated that the % read 
through of HRSV transcripts followed the same pattern as that described 
using alternative approaches (Cartee et al., 2003). 
 
Using RNA-seq to measure viral mRNA abundance, a similar result has been 
recently described in the analysis of Hendra virus mRNA in infected human 
or bat cells (Wynne et al., 2014). Similar to HRSV, Hendra virus is a member 
of the Paramyxoviridae family and both viruses share a similar genome 
architecture, replication and expression strategy. The order of genes along 
the Hendra virus genome (3’ to 5’) is N, P, M, F, G and L. In the analysis of 
either human or bat cells infected Hendra virus, there was a steep decline in 
the abundance of transcripts at the M-F gene boundary and the mRNA 
encoding the G protein was more abundant than the preceding mRNA 
encoding the F protein (Wynne et al., 2014).      
 
In summary, RNA-seq analysis was used to investigate HRSV RNA 
synthesis in infected cells and cells treated with ribavirin. This indicated that 
both transition and transversion mutations occurred in clusters along the 
HRSV genome. The frequency of transitions was increased in HRSV-infected 
cells treated with ribavirin and correlated with a reduction in the abundance of 
viral RNA and progeny virus, consistent with a loss of viral fitness. 
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CHAPTER 6: GENERAL DISCUSSION AND FUTURE WORK  
HRSV is mainly a paediatric infection and one of the major lower respiratory 
tract pathogens in infants - which are usually infected at least once within the 
first two years of life (Collins & Graham, 2008). Elderly patients, patients with 
chronic heart and lung conditions and immunocompromised patients are also 
at risk (Falsey et al., 2005). There is no vaccine for HRSV or general anti-
viral therapy. In acute cases, HRSV infection is treated therapeutically with 
ribavirin whose mechanism of action is not clearly understood. Ribavirin is 
the only therapeutic approved by the Food and Drug Administration (FDA) for 
the treatment of HRSV (Chu & Englund, 2013). In addition, ribavirin may also 
be used in immune-compromised and/or transplant and acute high-risk 
groups infected with HRSV. However, one postulated mechanism of action is 
to cause hyper-mutation of the target viral genome, which leads to error 
catastrophe during virus replication. Other mechanisms may include effects 
on host cell biology such as capping of mRNAs and activation of anti-viral 
gene expression. Therefore, studies in this field are necessary for a better 
understanding the action of ribavirin in HRSV infection and its wider 
application as anti-viral for the treatment of Crimean Congo Haemorrhagic 
fever virus and hepatitis C virus.  
 
This thesis focused on the investigation of the effect of the antiviral, ribavirin 
on the cell biology of infected and un-infected cells and virus biology in an in 
vitro cell culture model using a combined high-resolution RNA-seq and deep 
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discovery label free quantitative proteomics approach.  These approaches 
had not been applied before to investigate the effect of ribavirin as an anti-
viral.  Three aspects were studied, involving optimising the conditions for 
ribavirin treatment and viral infection in the cell culture model (Chapter 3), 
investigating the effect of ribavirin on host cells infected and uninfected with 
HRSV (Chapter 4) and analysis of the effect of ribavirin on HRSV infection 
(Chapter 5).  Thus investigating both host cell biology and virus biology.  The 
mechanisms of ribavirin on HRSV and infection of other viruses have been 
studied previously, however they are conflicting and may reflect different 
experimental conditions and viruses. To investigate the potential mechanism 
of action on HRSV, a combined high-resolution RNA-seq and deep discovery 
label free quantitative proteomics approach was used in this thesis. These 
combined approaches have not been used before to study HRSV biology and 
provides an opportunity to capture the maximum amount of data concerning 
the mechanism of action of this therapeutic.  This includes investigating 
potential mechanisms of action of viral mutation rate, activation of host gene 
expression in anti-viral pathways and a reduction in the stability of mRNAs in 
general. In addition, several time points and treatment conditions were 
examined and these focused on early and late events during virus infection.  
This was to investigate and potentially model when ribavirin is used during 
infection in vivo.  In general, ribavirin is not given as prophylactic and if 
treatment is giving too late in infection, then it is ineffective.  This is also 
similar to influenza virus, when antivirals have to be given within the first 48 
hr of infection, or viral loads become to high for the anti-viral to be effective 
(Monto et al., 1999; Whitley et al., 2001). 
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The effect of ribavirin on the host cell was examined and caused a significant 
decrease in progeny virus production. This study was focused on whether 
treatment of cells with ribavirin resulted in a difference in abundance of either 
cellular mRNAs or proteins. The transcriptomic approach identified more 
specific gene products than the proteomic approach, probably due to its 
higher sensitivity for detecting low abundance products.  Potentially the mass 
spectrometry could be conducted under more sensitive conditions by 
increasing both sample run time and also pre-fractionation of the sample by 
gel electrophoresis to reduce the complexity of the sample being analysed. 
 
The data indicated that the abundance of several hundred cellular mRNAs 
was affected by treatment with ribavirin and also the abundance of several 
cellular proteins were altered. This suggests that ribavirin can have a direct 
effect on the host cell.  A number of cellular mRNAs increased in abundance 
in the presence of ribavirin and these included transcripts associated with the 
innate immune response and also pathways activated as part of anti-viral 
signalling cascades, confirming that ribavirin can directly activate host anti-
viral gene transcripts – in the absence of viral infection. This may have a 
direct effect on HRSV-infection, perhaps by activating these responses in 
bystander cells that may subsequently be infected during viral spread and 
secondary rounds of infection.  This has previously been observed before for 
HRSV in cell culture using microarrays to quantify host cell mRNAs (Martínez 
et al., 2007; Zhang et al., 2003).  The RNA-seq based approach had the 
greater advantage of identifying many more transcripts – both in terms of 
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mRNA species that were unchanged and also those that were altered in 
abundance. 
 
Additionally, ribavirin treatment caused a dramatic decrease in the viral 
mRNA abundance which then affected viral protein abundance (detected in 
the mass spectrometry) and also viral load (assayed by plaque assay).  Most 
interestingly the data indicated that the transcription/abundance profile of 
viral mRNAs inside the infected cells did not conform to established literature. 
The potential of negative strand RNA virus mRNA transcription or at least 
mRNA abundance not to follow a linear gradient was also recently described 
for Hendra virus (Wynne et al., 2014) and follows unpublished data from our 
own laboratory examining the replication of Ebola virus.  Overall, the data 
suggested that both virological and cell factors (affecting RNA stability) 
influence the relative abundance of viral mRNA. 
 
The analysis indicated that the frequency of transitions but not transversions 
in the HRSV genome were significantly different between infected cells 
treated with ribavirin versus untreated infected cells. There was an 
approximately 1.5-fold increase in the recorded frequency of transitions on 
HRSV RNA in infected cells treated with ribavirin at 24 hr post-infection 
compared to the untreated control. This is less than the 4.4-fold increase in 
the frequency of transitions associated with the treatment of poliovirus-
infected cells with 400 μM ribavirin (Crotty et al., 2001), and the reasons for 
this are unclear. Alternatively, or in addition, it might be that the HRSV RdRp 
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is more stringent than that of poliovirus, possibly due to the two-fold longer 
length of the HRSV genome. In this scenario, the HRSV RdRp might better 
discriminate against ribavirin triphosphate, resulting in reduced incorporation 
and thus a lower mutation rate. Regardless, elevations in mutation 
frequencies by as low as two-fold have been proposed to lead to fitness 
losses and extinctions of large RNA virus populations in cell culture and 
animal models of infection (Anderson et al., 2004), and so the 1.5-fold 
increase in mutation frequency observed here could explain why ribavirin 
treatment resulted in reduced HRSV-specific RNA levels and progeny virus. 
While these results strongly suggest the anti-HRSV action of ribavirin is 
through direct incorporation into nascent RNA by the viral polymerase, it 
cannot exclude the possibility that other proposed activities such as reduction 
of the GTP pool also contribute to reduced viral growth and HRSV-specific 
RNAs, although ribavirin did not affect the overall levels of cellular mRNA.  It 
would be interesting to use these datasets to analyse whether there are any 
potential errors in cellular mRNA transcripts e.g. the mutational frequency 
increases.  However, this might be predicted to adversely affect cellular 
protein synthesis or abundance either due to incomplete translation or protein 
mis-folding.  However, in general no overall decrease in the levels of cellular 
proteins were observed. 
 
From five primary mechanisms of action suggested for ribavirin; inhibition of 
the viral polymerase, inhibition of RNA capping activity, loss of fitness of RNA 
virus genomes, immunomodulation effect and inhibition of IMPDH activity; 
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the novel data in this thesis strongly supports two out of these five potential 
mechanisms of action.  These are the loss of fitness of viral RNA genomes 
and activation of innate/intrinsic anti-viral genes.  Together these factors are 
likely to promote an anti-viral in both infected and bystander cells – that 
mediates the mechanism of action of ribavirin.  There was no evidence in the 
RNAseq and proteomic data that overall levels of cellular mRNAs or cellular 
proteins were affected by ribavirin thus eliminating other mechanisms such 
as disruption of RNA capping as a potential route by which ribavirin works.  
However, these maybe viral specific as disruption of human parainfluenza 
virus acitivity in vitro is based on inhibition of IMPDH activity (Leyssen et al., 
2005).  One of the future implementation plans from this study is to perform 
high-resolution approaches on human primary cells infected with HRSV and 
do some experiments to investigate whether the nucleotide mutations can 
cause amino acid changes and this causes redaction in viral biology.  Such 
as the use of replicon or reverse genetic systems to evaluate the function of 
the polymerase under higher mutational frequency. Additionally, nasal 
aspirates from patients infected with and hospitalized due to HRSV could be 
analysed using deep sequencing – particularly if the patients have been 
treated with ribavirin and longitudinal samples taken.         
 
In future, as the application of RNA-seq and label free proteomics provided 
powerful tools for investigating the mechanism of action of ribavirin and for 
better understanding of mutation in HRSV infection, this will allow further 
studies into the effect of ribavirin on other viruses as mechanisms differ from 
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virus to virus (Crotty et al., 2002). Further studies could then compare the in 
vitro and in vivo data and study transcripts that are up/down-regulated in the 
presence of antiviral ribavirin. This general combined approach of RNAseq 
and proteomics could be used to rapidly study and characterize new viruses 
and measure the effect of therapeutics.  For example, to study Middle East 
Respiratory Syndrome coronavirus MERS-CoV, which is a new strain of a 
coronavirus that was discovered in late 2012.  This would also identifying 
biomarkers within a patient that will act as predictors of disease severity and 
inform treatment options.  Also, potential cellular targets that the virus uses to 
enhance infection will be identified.  These potentially could be targeted with 
repurposed therapeutics to reduce viral load and clinical symptoms by using 
high-resolution approaches; RNA-seq and proteomics to study MERS-CoV in 
respiratory epithelial cells. 
 
In conclusion, this thesis and resulting publications have given a new insight 
into the action of the antiviral ribavirin with/without HRSV by using high-
resolution approaches RNA-seq and label free proteomics. The data analysis 
indicated that ribavirin had a direct mutagenic effect on the HRSV genome 
and the frequency of transition mutations were increased in HRSV-infected 
cells treated with ribavirin and correlated with a reduction in the abundance of 
viral RNA and progeny virus, consistent with a loss of viral fitness. The 
findings of this study have increased our understanding of mechanism of 
ribavirin for HRSV supporting its direct role in increasing the mutation rate in 
the viral genome and activation of intrinsic/innate anti-viral signalling.  
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CHAPTER 8: APPENDIX 
 
Table I Proteins increased in abundance in untreated verses DMSO (top 
right of Figure 4.1) identified and quantified by LC MS/MS. Statistical analysis 
was based on observed fold change 2 or greater, and more than 2 peptides 
and a p-value less than 0.05. 
Gene name 
Protein name 
Peptide 
count 
Peptides 
used for 
quantitation Log2 FC 
HIST1H3A-
J 
Histone H3.1 5 2 2.1 
TMEM126A 
Transmembrane protein 126A 2 2 1.7 
CBX1 
Chromobox protein homolog 1 4 3 1.4 
TOR1AIP1 
Torsin-1A-interacting protein 1 4 3 1.1 
SLC29A1 
Equilibrative nucleoside transporter 
1 2 2 1.1 
RIF1 
Telomere-associated protein RIF1 2 2 1.0 
 
Table II Proteins decreased in abundance in untreated verses DMSO (top 
left of Figure 4.1) identified and quantified by LC MS/MS. Statistical analysis 
was based on observed fold change 2 or greater, and more than 2 peptides 
and a p-value less than 0.05. 
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Gene 
name Protein name 
Peptide 
count 
Peptides 
used for 
quantitation 
Log2 
FC 
SNAP29 Synaptosomal-associated protein 29 2 2 -1.1 
S100A7 Protein S100-A7 3 3 -1.3 
 
Table III Genes increased in abundance in untreated vs DMSO  (Figure 4.1 
C). Statistical analysis was based on observed fold change 2 or greater, and 
more than 2 peptides and a p-value less than 0.05. Genes were identified 
and quantified by RNA-seq.  
gene_id Gene log2 FC p_value q_value 
ENSG00000171858 RPS21 1.0 0.0109 0.561336 
ENSG00000159335 PTMS 1.0 0.01815 0.712119 
ENSG00000184831 APOO 1.1 0.0396 0.976553 
ENSG00000226958 RNA28S5 1.1 0.0222 0.784769 
ENSG00000228974 AC006483.5 1.2 0.0071 0.456032 
ENSG00000227034 RP11-234N17.1 1.2 0.0429 0.99965 
ENSG00000188243 COMMD6 1.2 0.03615 0.943075 
ENSG00000230679 ENO1-AS1 1.3 0.0202 0.750345 
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ENSG00000149499 EML3 1.3 0.0495 0.99965 
ENSG00000256167 ATF4P4 1.6 0.03545 0.935561 
ENSG00000140931 CMTM3 1.8 0.0386 0.968004 
ENSG00000166922 SCG5 3.9 0.03115 0.892923 
ENSG00000230259 AC008738.1 10.5 0.0465 0.99965 
 
Table IV Genes decreased in abundance in untreated vs DMSO (Figure 4.1 
C) identified and quantified by RNA-seq. Statistical analysis was based on 
observed fold change 2 or greater, and more than 2 peptides and a p-value 
less than 0.05. 
Gene_id Gene log2 FC p_value q_value 
ENSG00000269922 
DKFZP547B0
914 -12.3 0.009 0.511812 
ENSG00000189157 FAM47E -3.5 0.02575 0.82978 
ENSG00000134121 CHL1 -3.4 0.0184 0.71603 
ENSG00000130822 PNCK -3.2 0.04285 0.99965 
ENSG00000155465 SLC7A7 -2.8 0.0061 0.42248 
ENSG00000196876 SCN8A -2.5 0.02265 0.789101 
ENSG00000253686 CTB-43E15.3 -2.4 0.04305 0.99965 
ENSG00000136895 GARNL3 -2.3 0.00915 0.516982 
ENSG00000233280 CRYBG3 -2.1 0.00745 0.46535 
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ENSG00000163596 ICA1L -2.1 0.0137 0.626684 
ENSG00000018236 CNTN1 -2 0.0468 0.99965 
ENSG00000198265 HELZ -1.8 0.01785 0.708638 
ENSG00000118596 SLC16A7 -1.7 0.0009 0.137934 
ENSG00000198315 ZKSCAN8 -1.7 0.00195 0.220881 
ENSG00000008086 CDKL5 -1.6 0.0219 0.780472 
ENSG00000109756 RAPGEF2 -1.6 0.0262 0.836745 
ENSG00000226121 AHCTF1P1 -1.6 0.0039 0.330727 
ENSG00000176994 SMCR8 -1.6 0.0059 0.414956 
ENSG00000248109 
CTC-
295J13.3 -1.5 0.0499 0.99965 
ENSG00000240618 
RP11-
206L10.5 -1.4 0.02275 0.790719 
ENSG00000135913 USP37 -1.4 0.02815 0.861175 
ENSG00000105855 ITGB8 -1.4 0.0229 0.791738 
ENSG00000177888 ZBTB41 -1.4 0.02265 0.789101 
ENSG00000196159 FAT4 -1.3 0.02965 0.875645 
ENSG00000157106 SMG1 -1.3 0.0147 0.644706 
ENSG00000103222 ABCC1 -1.3 0.0465 0.99965 
ENSG00000158987 RAPGEF6 -1.3 0.03895 0.970352 
ENSG00000090857 PDPR -1.3 0.04225 0.99965 
ENSG00000188211 NCR3LG1 -1.2 0.041 0.989687 
ENSG00000106692 FKTN -1.2 0.04685 0.99965 
ENSG00000177034 MTX3 -1.2 0.0478 0.99965 
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ENSG00000144460 NYAP2 -1.1 0.04295 0.99965 
ENSG00000165895 ARHGAP42 -1.1 0.0477 0.99965 
ENSG00000170153 RNF150 -1.1 0.0307 0.886371 
ENSG00000174197 MGA -1.1 0.01045 0.550158 
ENSG00000114127 XRN1 -1.1 0.03105 0.891679 
ENSG00000168143 FAM83B -1.1 0.04625 0.99965 
ENSG00000103994 ZNF106 -1.1 0.0321 0.902411 
ENSG00000100697 DICER1 -1.1 0.04 0.981294 
ENSG00000111371 SLC38A1 -1.1 0.0202 0.750345 
ENSG00000152104 PTPN14 -1.1 0.0201 0.748632 
ENSG00000095564 BTAF1 -1.1 0.02215 0.784528 
ENSG00000160551 TAOK1 -1 0.0107 0.556374 
ENSG00000166128 RAB8B -1 0.03325 0.914493 
ENSG00000116984 MTR -1 0.03375 0.918511 
ENSG00000157540 DYRK1A -1 0.04675 0.99965 
ENSG00000076770 MBNL3 -1 0.0334 0.915952 
ENSG00000138829 FBN2 -1 0.0119 0.586857 
ENSG00000139496 NUPL1 -1 0.0269 0.843251 
ENSG00000140563 MCTP2 -1 0.0458 0.99965 
ENSG00000145495 Mar-06 -1 0.02345 0.801484 
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Table V Proteins increased in abundance in DMSO vs HRSV+DMSO (top 
right of Figure 4.3). Statistical analysis was based on observed fold change 2 
or greater, and more than 2 peptides and a p-value less than 0.05. Proteins 
were identified and quantified by LC MS/MS. Those with a red color are viral 
proteins. 
Gene 
name Protein name 
Peptide 
count 
Peptides used for 
quantitation 
Log2 
FC 
NS1 Non-structural protein 1 3 3 4.7 
P Phosphoprotein 12 12 4.3 
M Matrix protein 17 16 4.3 
NS2 Non-structural protein 2 2 2 3.3 
N Nucleoprotein 18 18 3.2 
F Fusion glycoprotein F0 11 11 3.2 
M2-1 Matrix M2-1 14 14 3.1 
G 
Major surface glycoprotein 
G 2 2 2.9 
EPHA2 Ephrin type-A receptor 2 2 2 2.6 
SOD2 
Superoxide dismutase 
[Mn], mitochondrial 2 2 2.2 
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IFIT1 
Interferon-induced protein 
with tetratricopeptide 
repeats 1 9 9 2.2 
ISG15 
Ubiquitin-like protein 
ISG15 9 8 2.1 
OASL 
2'-5'-oligoadenylate 
synthase-like protein 6 6 2.0 
SAMD9 
Sterile alpha motif domain-
containing protein 9 6 5 1.9 
IFIT3 
Interferon-induced protein 
with tetratricopeptide 
repeats 3 13 13 1.9 
DDX58 
Probable ATP-dependent 
RNA helicase DDX58 4 4 1.8 
S100A7 Protein S100-A7 3 3 1.6 
IFIT2 
Interferon-induced protein 
with tetratricopeptide 
repeats 2 3 3 1.4 
 
Trypsin 5 5 1.3 
APOL2 Apolipoprotein L2 4 3 1.3 
Chapter 8: Appendix 
224 
 
OAS3 
2'-5'-oligoadenylate 
synthase 3 2 2 1.3 
WARS 
Tryptophan—tRNA ligase, 
cytoplasmic 21 21 1.2 
CYP51A1 
Lanosterol 14-alpha 
demethylase 2 2 1.1 
BAZ1B 
Tyrosine-protein kinase 
BAZ1B 5 4 1.1 
KPNA4 Importin subunit alpha-3 4 3 1.0 
PITRM1 
Preseq 
uence protease, 
mitochondria 2 2 1.0 
NUP62 
Nuclear pore glycoprotein 
p62 2 2 1.0 
GLRX Glutaredoxin-1 3 3 1.0 
RRS1 
Ribosome biogenesis 
regulatory protein homolog 2 2 1.0 
NHP2L1 NHP2-like protein 1 2 2 1.0 
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Table VI Proteins decreased in abundance in DMSO vs HRSV DMSO (top 
left of Figure 4.3) identified and quantified by LC MS/MS. Statistical analysis 
was based on observed fold change 2 or greater, and more than 2 peptides 
and a p-value less than 0.05. 
Gene 
name Protein name Peptide count 
Peptides 
used for 
quantitation 
Log2 
FC 
BLMH Bleomycin hydrolase 4 4 -1.0 
GSS Glutathione synthetase 2 2 -1.1 
TRAFD1 
TRAF-type zinc finger 
domain-containing protein 1 3 3 -1.1 
SNCG Gamma-synuclein 3 3 -1.1 
UAP1 
UDP-N-acetylhexosamine 
pyrophosphorylase 7 7 -1.2 
YBX3 Y-box-binding protein 3 3 2 -1.3 
PFKL 
6-phosphofructokinase, liver 
type 4 3 -1.3 
HDAC2 Histone deacetylase 2 3 2 -1.3 
ACACA Acetyl-CoA carboxylase 1 4 3 -1.6 
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DTYMK Thymidylate kinase 2 2 -1.6 
LEPRE1 Prolyl 3-hydroxylase 1 2 2 -1.7 
DFFA 
DNA fragmentation factor 
subunit alpha 3 3 -1.7 
MRPL16 
39S ribosomal protein L16, 
mitochondrial 2 2 -2.4 
 
Table VII Proteins increased in abundance in DMSO vs HRSV+DMSO (top 
right of Figure 4.6) identified and quantified by LC MS/MS. Statistical analysis 
was based on observed fold change 2 or greater, and more than 2 peptides 
and a p-value less than 0.05. 
Gene 
name Protein name 
Peptide 
identification  
Peptides 
used for 
quantitation 
Log2 
FC 
P 
Phosphoprotein 
12 12 4.2 
M 
Matrix protein 
17 16 4.1 
RPL7L1 
60S ribosomal protein L7-like 1 
2 2 3.5 
NS1 
Non-structural protein 1 
3 3 3.2 
HIST1H
3A,B,C, Histone H3.1 
5 2 3.1 
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D,E,F,G,
F,H,I,J 
N 
Nucleoprotein 
18 18 3.1 
M2-1 
Matrix M2-1 
14 14 2.9 
F 
Fusion glycoprotein F0 
11 11 2.6 
G 
Major surface glycoprotein G 
2 2 2.6 
EPHA2 
Ephrin type-A receptor 2 
2 2 2.5 
DDX58 Probable ATP-dependent RNA 
helicase DDX58 
4 4 2.4 
TAP1 
Antigen peptide transporter 1 
2 2 2.4 
SAMD9 Sterile alpha motif domain-
containing protein 9 
6 5 2.2 
NS2 
Non-structural protein 2 
2 2 2.2 
SYNE2 
Nesprin-2 
2 2 2.1 
TOR1AI
P1 
Torsin-1A-interacting protein 1 
4 3 2 
IFIT1 Interferon-induced protein with 
tetratricopeptide repeats 1 
9 9 2 
IFIT2 Interferon-induced protein with 
tetratricopeptide repeats 2 
3 3 1.9 
IFIT3 Interferon-induced protein with 
tetratricopeptide repeats 3 
13 13 1.9 
Chapter 8: Appendix 
228 
 
APOL2 
Apolipoprotein L2 
4 3 1.9 
SLC29A
1 Equilibrative nucleoside 
transporter 1 
2 2 1.8 
CBX1 
Chromobox protein homolog 1 
4 3 1.8 
C19orf4
3 Uncharacterized protein 
C19orf43 
2 2 1.8 
ISG15 
Ubiquitin-like protein ISG15 
9 8 1.8 
OASL 2'-5'-oligoadenylate synthase-
like protein 
6 6 1.8 
TMEM1
26A 
Transmembrane protein 126A 
2 2 1.8 
HIST1H
4A-L, 
HIST2H
4A,B, 
HIST4H
4 
Histone H4 
13 13 1.7 
HEATR1 HEAT repeat-containing protein 
1 
8 8 1.6 
GTPBP4 Nucleolar GTP-binding protein 
1 
3 3 1.6 
HIST2H Histone H3.2 
5 2 1.6 
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3A,C,D  
H2AFX 
Histone H2AX 
5 2 1.6 
WDR36 WD repeat-containing protein 
36 
2 2 1.6 
OAS3 
2'-5'-oligoadenylate synthase 3 
2 2 1.5 
ANXA11 
Annexin A11 
2 2 1.5 
FHL2 Four and a half LIM domains 
protein 2 
3 3 1.5 
HIST1H
2BM 
Histone H2B type 1-M 
10 2 1.4 
CYP51A
1 Lanosterol 14-alpha 
demethylase 
2 2 1.4 
TCERG
1 Transcription elongation 
regulator 1 
3 3 1.4 
TMPO Lamina-associated polypeptide 
2, isoforms beta/gamma 
9 3 1.3 
 
EIF2AK2 
Interferon-induced, double-
stranded RNA-activated protein 
kinase 
6 6 1.3 
RIF1 Telomere-associated protein 
RIF1 
2 2 1.3 
PELP1 Proline-, glutamic acid- and 
leucine-rich protein 1 
2 2 1.3 
SMCHD Structural maintenance of 
chromosomes flexible hinge 
2 2 1.3 
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1 domain-containing protein 1 
AHCTF1 
Protein ELYS 
2 2 1.3 
COMTD
1 Catechol O-methyltransferase 
domain-containing protein 1 
2 2 1.2 
NOLC1 Nucleolar and coiled-body 
phosphoprotein 1 
8 8 1.2 
ATAD1 ATPase family AAA domain-
containing protein 1 
3 3 1.2 
H2AFY 
Core histone macro-H2A.1 
7 7 1.2 
ANXA2 
Annexin A2 
26 26 1.2 
FBL rRNA 2'-O-methyltransferase 
fibrillarin 
5 5 1.2 
PML 
Protein PML 
2 2 1.2 
EXOSC
10 
Exosome component 1 
2 2 1.2 
BST2 
Bone marrow stromal antigen 2 
3 3 1.2 
DR1 
Protein Dr1 
2 2 1.2 
MDC1 Mediator of DNA damage 
checkpoint protein 1 
4 4 1.2 
CISD1 CDGSH iron-sulfur domain-
containing protein 1 
3 3 1.2 
SLC25A
Mitochondrial 2-
oxoglutarate/malate carrier 
protein 
3 3 1.2 
Chapter 8: Appendix 
231 
 
11 
MYO1B 
Unconventional myosin-Ib 
5 5 1.1 
HIST1H
2BO 
Histone H2B type 1-O 
10 2 1.1 
NOL6 
Nucleolar protein 6 
3 3 1.1 
BMS1 Ribosome biogenesis protein 
BMS1 homolog 
2 2 1.1 
CELF1 CUGBP Elav-like family 
member 1 
2 2 1.1 
NKRF 
NF-kappa-B-repressing factor 
2 2 1.1 
TSPO 
Translocator protein 
2 2 1.1 
FTSJ3 pre-rRNA processing protein 
FTSJ3 
5 5 1.1 
PHF5A PHD finger-like domain-
containing protein 5A 
4 4 1.1 
WDR12 Ribosome biogenesis protein 
WDR12 
4 4 1.1 
NHP2 H/ACA ribonucleoprotein 
complex subunit 2 
2 2 1.1 
GPRC5
A 
Retinoic acid-induced protein 3 
2 2 1.1 
HIST2H
2AA3 
Histone H2A type 2-A 
7 2 1.1 
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GNAI3 Guanine nucleotide-binding 
protein G(k) subunit alpha 
4 2 1.1 
ANXA4 
Annexin A4 
5 4 1.1 
MLEC 
Malectin 
2 2 1.1 
ANXA1 
Annexin A1 
21 21 1.1 
RRP9 U3 small nucleolar RNA-
interacting protein 2 
4 4 1.1 
BOP1 Ribosome biogenesis protein 
BOP1 
3 3 1 
NOP58 
Nucleolar protein 58 
7 7 1 
 
Table VIII Proteins decreased in abundance in Mock vs HRSV  (top left of 
Figure 4.6) identified and quantified by LC MS/MS. Statistical analysis was 
based on observed fold change 2 or greater, and more than 2 peptides and a 
p-value less than 0.05. 
Gene 
name Protein name 
Peptide 
identification  
Peptides used 
for 
quantitation 
Log2 
FC 
HSBP1 
Heat shock factor-binding 
protein 1 3 3 -1.0 
PTPN1
1 
Tyrosine-protein 
phosphatase non-receptor 
2 2 -1.1 
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type 11 
SKP1 
S-phase kinase-associated 
protein 1 8 7 -1.1 
CAP2 
Adenylyl cyclase-associated 
protein 2 3 3 -1.1 
ADI1 
1,2-dihydroxy-3-keto-5-
methylthiopentene 
dioxygenase 3 3 -1.1 
TRAFD
1 
TRAF-type zinc finger 
domain-containing protein 1 3 3 -1.2 
CKB Creatine kinase B-type 9 8 -1.2 
YBX3 Y-box-binding protein 3 3 2 -1.4 
CLPP 
Putative ATP-dependent Clp 
protease proteolytic subunit, 
mitochondrial 2 2 -1.4 
MRFA
P1 
MORF4 family-associated 
protein 1 2 2 -1.5 
PPP1R
2 
Protein phosphatase 
inhibitor 2 3 3 -1.5 
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PEX19 
Peroxisomal biogenesis 
factor 19 2 2 -1.6 
PREP Prolyl endopeptidase 2 2 -1.7 
SNAP2
9 
Synaptosomal-associated 
protein 29 2 2 -1.8 
NT5C2 
Cytosolic purine 5'-
nucleotidase 5 5 -2.3 
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